



安克生醫股份有限公司
AmCad BioMed Corporation

股票代碼：4188

2024 Annual Report



安克呼止偵™

十分鐘睡眠呼吸中止症檢測



安克甲狀偵™

甲狀腺超音波 AI



安克乳安偵™

乳房超音波 AI



Notice to readers

This English-version annual report is a summary translation of the Chinese version and is not an official document of the shareholders' meeting. If there is any discrepancy between the English and Chinese versions, the Chinese version shall prevail.

Printed and Published on March 31, 2025

Annual report inquiry URL: <https://mops.twse.com.tw>

Company website: <https://www.amcad.com.tw/>

I. Spokesperson :

Name : Lee,Yili
Job Title : Chairman and General Manager
Telephone : 02-2713-6227
E-mail : yili@amcad.com.tw

Deputy Spokesperson :

Name : Ann Chen
Job Title : Financial Officer
Telephone : 02-2713-6227
E-mail : ann.chen@amcad.com.tw

II. Headquarters, Branches and Plant :

Corporate Headquarters

Address : 5F, No.167, Fuxing N. Rd., Songshan Dist., Taipei City 105, Taiwan (R.O.C.)
Telephone : 02-2713-6227
Factory Address : 3F, No. 58, Ln. 188, Ruiguang Rd., Neihu Dist., Taipei City 114062, Taiwan (R.O.C.)
Website : <https://www.amcad.com.tw>

III. Stock Transfer Agent :

Name of Stock Transfer Agency : Grand Fortune Securities Co.,Ltd.
Address : 6F, No.6, Sec. 1, Zhongxiao W. Rd., Zhongzheng Dist.,Taipei City, Taiwan.
Telephone : 02-2371-1658
Website : <https://www.gfortune.com.tw>

IV. Contact Information of the Certified Public Accountants for the Latest Financial Report :

Name of CPA : Yu Chien-ju , Chang Chiao-Ying
Name of Firm : Ernst & Young
Address : 9F, No. 333, Section 1, Keelung Road, Xinyi Dist., Taipei, Taiwan
Telephone : 02- 2725 - 8888
Website : https://www.ey.com/zh_tw

V. Overseas Trade Places for Listed Negotiable Securities and Method to Inquire for Such Overseas Negotiable Securities : None °**VI. Company website : <https://www.amcad.com.tw>**

Table of Contents

Page

1. Letter to Shareholders.....	1
2. Corporate Governance Report	
2.1 Information on Directors, General Manager, Vice President and Assistant Vice President and Heads of Departments and Branches.....	9
2.2 Remuneration to Directors, Supervisors, General Manager, and Vice Presidents.....	22
2.3 The operating status of corporate governance	28
2.4 Information on the public fees for certified public accountants for visa applications.....	87
2.5 Information on changing the accounting firm.....	88
2.6 There is no information to be disclosed regarding the Chairman, General Manager, Manager responsible for finance or accounting affairs who have worked for the accounting firm or its related enterprises within the past year	88
2.7 Transfer of Stock Options and Changes in Equity Pledge of Directors, Supervisors, Managers and Shareholders Holding More Than 10%.....	88
2.8 Information of Relationship among Top 10 Shareholders.....	90
2.9 Shares Held by Company, Directors, Managers of Company, and Businesses Controlled Directly or Indirectly by Company of Same Reinvestment Business and Consolidated Calculation of Comprehensive Shareholding Ratio.....	90
3. Capital Overview	
3.1 Capital and shares.....	92
3.2 Corporate bonds.....	95
3.3 Preferred shares.....	95
3.4 Global depository receipts.....	95
3.5 Employee share subscription warrants and new restricted employee shares... ..	96
3.6 Restrictions on employee rights related to the issuance of new shares.....	99
3.7 Mergers or acquisitions involving the issuance of new shares to acquire or transfer the shares of other companies.....	99
3.8 Capital Utilization Plan and Execution Status.....	99
4. Operational Overview	
4.1 Business activities.....	113
4.2 Market and Sales Overview.....	118
4.3 Information on employees for the past two years and up to the date of publication of the annual report.....	122
4.4 Environmental Expenditure Information.....	123

4.5 Labor-Management Relations.....	123
4.6 Cyber security management.....	127
4.7 Important Contract.....	130
5. Review and analysis of financial condition and financial performance, as well as risk factors	
5.1 Financial condition	131
5.2 Financial performance.....	132
5.3 Cash Flow.....	133
5.4 Impact of significant capital expenditures on financial operations in the recent year.....	133
5.5 The investment policy of the latest year 、the main reason of the operating result and the improvement plans and the investment plans for the coming year.....	133
5.6 Risk Analysis and Assessment During the Most Recent Fiscal Year and as they Stood on the Date of Publication of the Annual Report.....	134
5.7 Other significant matters.....	137
6. Special Notes	
6.1 Information on affiliates.....	13
6.2 The situation regarding private placement of securities up to and including the date of printing of the latest annual report.....	138
6.3 Additional necessary explanatory items.....	138
7. Any significant events as defined in Article 36, Paragraph 3, Subparagraph 2 of the Securities and Exchange Act that have had a significant impact on shareholder equity or securities prices, up to and including the date of printing of the latest annual report.....	138

1 、 Letter to Shareholders

Dear Shareholders,

In 2024, the global healthcare market showed steady recovery, accompanied by advances in AI applications in medical imaging diagnostics. AmCAD-UO[®] experienced steady domestic growth. Following the approval of its self-pay procedure code in Taichung, the product also received approvals from the health bureaus of Taipei City and New Taipei City, further expanding its clinical applications and market penetration. The company signed collaborative research agreements with the School of Dentistry at the University of the Pacific in the U.S. and Stanford University to explore product applications in the dental market. In addition, a procurement agreement was signed with a premium AI-powered diabetes care clinic in Dubai to support the product's clinical use in weight loss therapy. A clinical study conducted at the University of Bern in Switzerland was successfully completed and is being prepared for submission to an international journal, further enhancing the company's international academic presence and product credibility.

In 2024, AmCAD-UT[®] successfully entered several medical institutions, including China Medical University Hospital (Hsinchu) and Tainan Hospital (Ministry of Health and Welfare). The product is now in use at over 30 medical facilities across Taiwan, and it is expected to be included in the National Health Insurance (NHI) program in 2025, marking a key milestone in the company's development of innovative medical devices.

As a leading company in AI-driven innovative medical devices in Taiwan, AmCad BioMed possesses advanced AI technology and a comprehensive patent portfolio. Looking ahead, the company will continue to enhance its AI diagnostic capabilities and expand the application of products such as AmCAD-UT[®], AmCAD-UO[®], and AmCAD-UB[®] across various medical fields. By engaging in co-development discussions with major ultrasound manufacturers, the company aims to strengthen international partnerships. Leveraging its existing AI scanning technology and real-time medical image analysis—combined with point-of-care ultrasound (POCUS)—AmCad BioMed seeks to enhance market accessibility and further facilitate international market entry.

We are pleased to report our business achievements for the year 2024 and provide an overview of our business plan for the year 2025.

I. Business Results for the Year 2024

(I).Results of Business Plan Execution

1. AmCAD-UT[®] :

- (1) Successfully established a presence in multiple medical institutions, including China Medical University Hsinchu Hospital and Tainan Hospital under the Ministry of Health and Welfare.
- (2) Entered the "Proposed New NHI Reimbursement Items"; submitted in the first half of 2024, with provisional payment anticipated in 2025 to further enhance market acceptance.
- (3) Signed an MOU with Dubai's Meridian Healthcare (MHC) to launch business collaboration in the Middle Eastern market.
- (4) Continuously optimizing AmCAD-UT[®] deep learning model to enhance diagnostic performance and developing automated application of scan planes detected by the deep learning model.
- (5) Developing AmCAD-UT[®] LiveScan to enhance real-time scanning guidance, seize POCUS and AI business opportunities, and support telemedicine in remote areas.

2. AmCAD-UO[®] :

- (1) Collaborated with the University of the Pacific School of Dentistry and Stanford to

expand product applications in the dental market while continuing post-market clinical research.

- (2) Swiss clinical research confirms that the Backscatter technology of AmCAD-UO[®] can improve the success rate of HNS treatment and has been presented at international conferences, with submissions to international journals.
- (3) Signed a procurement contract with a high-end AI diabetes care clinic in Dubai to promote the application of products in the weight loss treatment market.
- (4) Collaborated with Myluxvitae for corporate screenings, integrating the sale of therapeutic products, and successfully developed a new business model.
- (5) Continuing clinical collaborations with National Taiwan University Hospital, Chang Gung Memorial Hospital, and Tzu Chi Hospital to enhance the value of product usage.

(II).Budget Execution Status

According to the "Regulations Governing the Publication of Financial Forecasts of Public Companies," financial forecast information for 2024 has not been disclosed, so this item is not applicable.

(III).Financial Revenue and Profitability Analysis

Unit: NT\$ thousands

Year		2024	2023	Increase (decrease)%
Items				
Financials	Revenue	53,105	65,256	(19)
	Gross Profit	32,934	41,024	(20)
	Operating Loss	(64,664)	(53,985)	-
	Non-Operating Income (Expense)	11,788	10,836	9
	Net Income (Loss)	(52,876)	(43,149)	-
Profitability	Return on Assets (%)	(8.73)	(8.07)	-
	Return on Equity (%)	(9.26)	(8.65)	-
	Net Profit Margin (%)	(99.57)	(66.12)	-
	EPS(Loss) (NTD)	(0.88)	(0.85)	

(IV).Research and Development Status.

1. Research and development expenses.

Year	2024	2023
Item		
Operating Revenue (A)	53,105 (in thousands)	65,256 (in thousands)
R&D expenditure (B)	43,783 (in thousands)	44,122 (in thousands)
Total employees (C)	74 people	76 people
R&D staff (D)	19 people	19 people
R&D expenditure ratio B/A	83%	68%
R&D personnel ratio D/C	26%	25%

2. Research and development results

Research and development results	
1. AmCAD-UT [®]	– Optimizing the AI deep learning model to improve diagnostic accuracy. – Developing Android and iOS versions that integrate AI detection features. – Launched the UT LiveScan version, supporting multiple ultrasound systems.
2. AmCAD-UO [®]	– Continuously developing customized reports. – Optimizing deep learning and diagnostic models. – Clinical research published by the University of Bern, Switzerland, verifying product efficacy. – Continuing patient enrollment and analysis in clinical studies at National Taiwan University Dental School, Chang Gung Memorial Hospital, and pediatric clinics.
3. AmCAD-US	– Software optimization and cybersecurity enhancement.
4. AmCAD-UB [®]	– Developing the Android version and integrating AI detection features. – Launched the UB Live feature and integrated it with ultrasound systems.
Regulations and patents :	
– S1000 KFDA certification completed. – QMS certification passed. – UT/UO TFDA site change and certificate extension have been completed. – The entire product line has completed QMS and ISO 13485 documentation, with zero deficiencies in the SGS audit. – UO patents (United States, Taiwan, Europe) are undergoing opinion examination and responses.	

II. The business plan for 2025 is summarized as follows:

(I). Business Strategy and Objectives

Project Items	Planned Execution Objectives
AmCAD-UT [®]	1. Optimize Android UI/UX experience and prepare for regulatory application. 2. Develop an iOS version. 3. Continue Windows version development, integrating health insurance requirements and customized functions. 4. Develop an automated thyroid scan position recognition deep learning model, and continuously accelerate and optimize segmentation and diagnostic deep learning models. 5. Expand partnerships: Establish collaborations with medical and health screening centers, global ultrasound equipment manufacturers, enterprise imaging platform providers, and distributors to broaden market coverage and enhance product penetration.

AmCAD-UO®	1. Continue optimizing deep learning models to accelerate scanning processes. 2. Complete user interface (UI/UX) optimization and software functionality upgrades. 3. Complete the regulatory pre-submission and application for the advanced version of the software. 4. Build on existing collaborations with renowned medical centers such as the Stanford Sleep Center and National Taiwan University Hospital by seeking additional clinical partners—both domestically and internationally—in otolaryngology and dentistry, to deepen and expand clinical applications. 5. Completed clinical collaborations and research publications in Europe and the United States to pursue insurance code adoption and support market expansion in these regions, and formally introduced the product into the UAE to strengthen the company's presence and international footprint in the Middle East.
AmCAD-US	1. Software functionality upgrades and computational acceleration. 2. Respond to EU MDR TD review.
AmCAD-UB	1. Conducting consultations for clinical physician feedback. 2. Develop proprietary feature algorithms to enhance product uniqueness. 3. Develop Windows UB Live feature visualization and reporting system integration. 4. Develop Android UB Live structured reporting and reporting system, optimizing UI/UX. 5. Expand deep learning models for breast tumor detection, optimizing segmentation and BIRADS diagnostic models. 6. Plan clinical study enrollment for regulatory submission.
Medical Conference and Healthcare Expo	1. Arab Health 2025 – Dubai, UAE 2. World Sleep 2025 – International Congress on Sleep Medicine 3. Medical Fair Thailand 2025 – Bangkok, Thailand 4. MEDICA 2025 – Düsseldorf, Germany 5. RSNA 2025 – Radiological Society of North America Annual Meeting, Chicago, USA
Statute	1. Three products are CE MDR certified to maintain the EU listing qualification. 2. AmCAD-US obtained the TFDA inspection and registration license. 3. Laser Alignment Tool TFDA market approval by cooperating with MISC. 4. AmCAD-UT applies for a new feature change for TFDA deep learning. 5. Obtained Taiwan QMS certification, established and controlled the product regulation update compliance system, and successfully implemented and maintained.

(II).Expected sales quantity and its basis

In 2025, the Company will focus on expanding clinical applications and accelerating international market deployment to drive sales growth. AmCAD-UT® is expected to be included in the National Health Insurance's provisional reimbursement scheme, significantly increasing

its adoption by medical institutions, while simultaneously advancing technology licensing collaborations in Europe and the United States to expand into international markets. Meanwhile, AmCAD-UO[®] will continue to steadily grow in the domestic self-pay market, extend into fields such as dentistry and weight management, and explore market opportunities in Europe and the Middle East. The Company will remain committed to innovation, evidence-based development, and regulatory advancement as its core strategies to steadily promote market sales and drive revenue growth.

(III). Important Production and Sales Policies

1. Production Policies:

At the end of 2023, the Company established a new facility in Neihu, which successfully obtained certification for Taiwan's Quality Management System (QMS) and the international quality management standard ISO 13485:2016. All production processes for related products are carried out in compliance with QMS and ISO 13485:2016 procedures to ensure that manufacturing and quality standards meet the requirements of QMS, ISO 13485:2016, and regulatory approvals for market authorization. To support a diversified product line, the Company also outsources certain quality assurance, manufacturing, packaging, and distribution operations to qualified medical device manufacturers.

2. Sales Policies

(I). AmCAD-UT[®]:

Domestic Market Sales: Leverage past promotional experience to gain physician recognition of the diagnostic accuracy and efficiency of AmCAD-UT[®], thereby expanding into major hospitals and health screening channels. Existing customers are encouraged to switch to a subscription model to increase usage.

International Business Development: Continue negotiations for technology licensing with medical imaging platform providers and ultrasound equipment manufacturers.

(II). AmCAD-UO[®]:

Domestically, the sales team conducts product presentations and hosts medical seminars at major hospitals. The Company also collaborates with ventilator therapy providers and health screening centers to promote group health checkups, thereby increasing product awareness. Internationally, the business development team actively participates in global trade shows and engages with distributors possessing established market channels to negotiate distribution and licensing agreements.

III. Company's Development Strategies in the future:

Amid the global trend toward precision health and smart healthcare, the Taiwanese government is actively promoting the "Taiwan Precision Health Policy" with a vision of "Holistic Health for All by 2030." The policy aims to strengthen integration across academia, research, industry, and clinical practice, foster the convergence of artificial intelligence, big data, and clinical applications, and encourage the adoption of innovative medical technologies by enterprises to accelerate international alignment of the healthcare industry. The Company has long focused on AI-based medical imaging applications and clinical integration, aligning closely with national policy objectives. In 2025, the Company will continue to focus on four core strategies: advancing National Health Insurance inclusion, obtaining regulatory approvals, fostering international partnerships, and clinical evidence-based applications. These efforts aim to steadily drive business growth and technological implementation, further strengthening the Company's global presence.

In terms of product strategy, AmCAD-UT[®] is expected to be included in National Health Insurance coverage by the end of the year. Leveraging AI-assisted diagnostic technology, the product aims to enhance diagnostic efficiency and consistency, thereby conserving medical resources and enabling precision medicine to achieve a win-win outcome for both patients and

healthcare providers. The product's applications are also being extended to breast. Furthermore, the Company seeks to collaborate with leading international ultrasound manufacturers through technology licensing agreements to promote AI software-hardware integration, thereby increasing market penetration and broadening clinical applications.

Meanwhile, AmCAD-UO[®] continues to expand its applicability under Taiwan's self-pay medical coding system and is extending into promising clinical areas such as dentistry and weight management, fostering diverse and cross-disciplinary applications.

In terms of regulatory and quality strategies, the products have obtained medical device certifications from the U.S. FDA, EU CE, and Taiwan TFDA. Additionally, the Company has successfully passed the EU MDR certification, becoming the first smart medical software company in Taiwan to receive this designation. These achievements ensure compliance with the latest international standards, supporting future global market expansion and regulatory alignment.

AmCad BioMed also prioritizes user experience by incorporating clinical feedback into UI/UX design, and is developing AI solutions integrated with handheld ultrasound devices to meet the needs of primary, mobile, and telemedicine settings.

Looking ahead, the company will continue to advance through regulatory progress, clinical validation, technological innovation, and global collaboration—laying a solid foundation for long-term international growth.

IV. Impact of External Competitive, Regulatory, and Overall economy Environment

(I). External Competitive Environment:

As AI applications in medical imaging continue to deepen, ultrasound computer-aided diagnosis (CAD) has become a key industry trend. Major medical device companies such as GE, Siemens, and Philips are actively incorporating AI features into their ultrasound systems to enhance diagnostic automation and standardization. At the same time, emerging technology companies are targeting specific disease areas, accelerating market diversification and competition.

While many current solutions still face limitations in real-time image processing and clinical integration, AmCad BioMed's products provide real-time analysis, automated detection, and anatomical visualization. Backed by FDA and TFDA approvals and strong clinical validation, these capabilities reflect the company's technological maturity and clear market differentiation.

However, global expansion continues to face challenges, including stricter regulatory reviews, varying evidence requirements, and different commercialization timelines across regions. AmCad BioMed remains committed to regulatory readiness and localized clinical studies to ensure effective market entry and product acceptance.

The growing demand for handheld ultrasound (POCUS) and telemedicine also drives the company to accelerate integration of its AI solutions with portable devices—expanding accessibility, flexibility, and clinical applicability in frontline, mobile, and remote care settings.

In a rapidly evolving environment, AmCad BioMed will continue to strengthen its core technologies, regulatory compliance, and strategic execution to enhance its competitiveness in the smart ultrasound diagnostics market.

(II). Regulatory Environment:

Due to the increasingly stringent regulatory audits of various countries, in order to comply with the new law, it is necessary to introduce relevant standards to ensure that product development and manufacturing can meet the standards, which will undoubtedly increase the product development and regulatory costs of medical device manufacturers.

The company will continue to innovate product technology, obtain regulatory certifications, make good use of local agent resources, and extend compliance with national laws and regulations, so as to successfully obtain sales licenses.

(III).Overall business environment:

In 2024, the global economy remained under pressure from geopolitical tensions, inflation, and ongoing supply chain adjustments, making industry recovery challenging. However, with the easing of the pandemic, medical demand gradually returned to normal. Given its inelastic nature, the medical device industry continued to demonstrate steady overall growth.




圖 2-3 全球醫療器材市場規模分布

資料來源：BMi Research，2024 年；財團法人工業技術研究院產業科技國際策略發展所，2024 年 5 月。

According to the latest edition of the Biotechnology Industry White Paper published by the Industrial Development Bureau, Ministry of Economic Affairs, the global medical device market was valued at \$517.34 billion in 2023, representing a 7.3% increase from 2022. It is estimated to grow to \$617.528 billion by 2026, with a compound annual growth rate (CAGR) of approximately 6.08% from 2023 to 2026.

According to the subcategory classification of medical device products by BMI Research, medical devices can be divided into six major categories: Consumables, Diagnostic Imaging, Dental Products, Orthopaedic and Prosthetic, Patient Aids, and Others. Among these, diagnostic imaging products accounted for the largest share at 23.8%.

Meanwhile, the widespread adoption of AI and digital technologies in healthcare is accelerating the development of diagnostic support, telemedicine, and primary care applications. This trend is driving medical devices toward greater intelligence, real-time capabilities, and portability—bringing new momentum and efficiency potential to healthcare systems.

In response to a rapidly evolving environment and emerging technological

opportunities, AmCad BioMed will continue to monitor policy developments and clinical needs, focusing on deepening product applications and expanding use scenarios. The company remains committed to steadily advancing its smart healthcare strategy and reinforcing its long-term value and position within the global medical industry ecosystem.

Thank you to all the shareholders for your support of the company. Our team will continue to work hard to create value for all shareholders. Wishing you all good health and success in everything.

Chairman and General Manager: Lee Yi-li



2. Corporate Governance Report

2.1 Information on Directors, General Manager, Vice President and Assistant Vice President and Heads of Departments and Branches:

2.1.1 Information on Directors :

April 5, 2025 (stock closing date)

Job title	Nationality or place of registration	Name	Gender , age	Date of election / appointment to current term	Term of office	Commencement date of first term	No. of shares held at time of election		No. of shares currently held		Shares currently held by spouse and minor children		Shares held through nominees		Principal work experience and academic qualifications	Positions held concurrently in the company and/or in any other company	Directors with which the person has a relationship of spouse or relative within the second degree			Remarks(Note:1)
Chairman	R.O.C.	Lee Yi-Li	F 41~50	05/18/2023	3 years	05/06/2011	369,872	0.69%	582,327	0.92%	0	0.00%	0	0.00%	➤ MBA, Rutgers University ➤ BBA In Finance, National Taiwan University ➤ Director, PhytoHealth Corp. ➤ Director, AmCad BioMed Corp. ➤ Supervisor, Taiwan Bio Industry Organization. ➤ 2016 Top 10 Female Heads of The Biomedical Industry ➤ Vice President, International Global Corporate, Standard Chartered Bank ➤ Vice President, Credit Agricole Corporate and Investment Bank ➤ Manager, Corporate Banking Group, Citibank, N.A.	➤ Chairman/General Manager, AmCad BioMed Corp. ➤ Chairman, PhytoHealth Corp. ➤ Vice Chairman, Maywufa Company Ltd. ➤ Chairman, Broadsound Corporation ➤ Director, Maywufa Cosmetics (Shanghai) Co., Ltd. ➤ Director, Taiwan Incubator SME Development Corporation ➤ Independent Director, Sinyi Realty Inc.	Director	Lee Chen-Chia	Father and daughter	None
																Vice Chairman	Lee I-Lin	Sisters		
Vice Chairman	R.O.C.	PhytoHealth Corp. Representative : Lee I-Lin	F 41~50	05/18/2023	3 years	05/06/2011	18,937,948	35.58%	22,155,049	34.98%	0	0.00%	0	0.00%	➤ MBA, Carnegie Mellon University ➤ B.Acc., National Taiwan University ➤ Product Manager (Sales and Marketing), Janssen Pharmaceutical Factory of Johnson & Johnson ➤ Auditor/Risk Assessment Consultant, Deloitte Taiwan	➤ Vice Chairman, AmCad BioMed Corp. ➤ Vice Chairman / General Manager, PhytoHealth Corp. ➤ Executive Director, Maywufa Company Ltd. ➤ Vice Chairman, Broadsound Corporation ➤ Supervisor, Maywufa Cosmetics (Shanghai) Co., Ltd. ➤ Supervisor, Taiwan Bio Industry Organization.	Director	Lee Chen-Chia	Father and daughter	None
				05/18/2023					100,000	0.16%						Chairman	Lee Yi-Li	Sisters		
Director	R.O.C.	PhytoHealth Corp. Representative : Lee Chen-Chia	M 71~80	05/18/2023	3 years	05/06/2011	18,937,948	35.58%	22,155,049	34.98%	0	0.00%	0	0.00%	➤ Honorary Ph.D. , National Taipei University of Technology ➤ EMBA, National Chengchi University ➤ B.Pharma., School of Pharmacy, Kaohsiung Medical University ➤ Founder / Chairman, PhytoHealth Corp. ➤ Founder / Chairman, AmCad BioMed Corp. ➤ Chairman, Broadsound Corporation ➤ National Policy Consultants, Presidential Palace ➤ Director, Central Bank of the Republic of China (Taiwan) ➤ Representatives of the National Assembly ➤ Director, Straits Exchange Foundation ➤ Chairman, Taiwan Federation of Industry ➤ Chairman, Taiwan Province Industry Association	➤ Director, AmCad BioMed Corp. ➤ Chairman, Maywufa Company Ltd. ➤ Director, PhytoHealth Corp. ➤ Chairman, Taiwan Incubator SME Development Corporation.	Chairman	Lee Yi-Li	Father and daughter	None
				05/18/2023					595,375	0.94%						Vice Chairman	Lee I-Lin	Father and daughter		

Job title	Nationality or place of registration	Name	Gender, age	Date of election / appointment to current term	Term of office	Commencement date of first term	No. of shares held at time of election		No. of shares currently held		Shares currently held by spouse and minor children		Shares held through nominees		Principal work experience and academic qualifications	Positions held concurrently in the company and/or in any other company	Directors with which the person has a relationship of spouse or relative within the second degree			Remarks(Note:1)
Director	R.O.C.	Chang King-Jen	M 71~80	05/18/2023	3 years	06/27/2014	2,902,000	5.45%	2,902,000	4.58%	0	0.00%	0	0.00%	➢ Researcher at Memorial Sloan-Kettering Cancer Center, N.Y. (U.S.A.) ➢ Ph.D. in Clinical Medicine, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University ➢ Director of the Department of Surgery, National Taiwan University Hospital ➢ Superintendent of Taoyuan General Hospital, Department of Health ➢ Superintendent of Taichung Cheng Ching Hospital	➢ Director, AmCad BioMed Corp. ➢ Director, SynCore Biotechnology Co., Ltd. ➢ Supervisor, GeneTex International Corporation. ➢ Director, Knowledge Freeway Co., Ltd Development Corporation ➢ Honorary Professor of Surgery, College of Medicine, National Taiwan University, and Attending Physician. ➢ Chairman of the Breast Cancer Foundation. ➢ Independent Director, HONG HO PRECISION TEXTILE CO., LTD.	None	None	None	None
Director	R.O.C.	Maywufa Company Limited. Representative : Sheu Jin-Chuan	M 71~80	05/18/2023 05/18/2023	3 years	06/27/2014	3,473,783	6.53%	3,994,996	6.31%	0	0.00%	0	0.00%	➢ Ph.D. in Clinical Medicine, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University ➢ Professor of Internal Medicine, College of Medicine, National Taiwan University ➢ Director of the Department of Internal Medicine, Gastroenterology and Hepatology, National Taiwan University Hospital. ➢ Visiting Researcher at the National Cancer Institute, National Institutes of Health, USA	➢ Director, AmCad BioMed Corp. ➢ Honorary Professor, College of Medicine, National Taiwan University. ➢ Chairman, Liver Disease Prevention & Treatment Research Foundation. ➢ Chairman, Taiwan Health Foundation. ➢ Chairman, Good Liver Foundation. ➢ Director, ASMEDIA TECHNOLOGY INC..	None	None	None	None
Director	R.O.C.	PhytoHealth Corp. Representative : Chen Wal-Ter	M 71~80	05/18/2023 05/18/2023	3 years	05/24/2019	18,937,948	35.58%	22,155,049	34.98%	0	0.00%	0	0.00%	➢ Master of Science in Human Nutrition, Columbia University, USA. ➢ Vice President (Acting President) of China Medical University.Director, . ➢ Director of Beigang Hospital, China Medical University. ➢ Outstanding Alumni of China Medical University..	➢ Director, AmCad BioMed Corp. ➢ Advisor and Chair Professor of the Department of Medicine, College of Medicine, China Medical University. ➢ Consultant for Beigang Hospital and Children's Hospital, China Medical University.	None	None	None	None
Director	R.O.C.	Jen Yu Ltd. Representative : Chiou Shu-Ti	F 61~70	05/18/2023 05/18/2023	3 years	05/22/2020	46,000	0.09%	46,000	0.07%	0	0.00%	0	0.00%	➢ Ph.D. in Epidemiology, National Taiwan University. ➢ Director-General of the National Health Service, Ministry of Health and Welfare. ➢ Director of the Bureau of National Health, Department of Health. ➢ Director of the Department of Health, Taipei City Government. ➢ Director of the Health Bureau, Yilan County. ➢ Adjunct Associate Professor, College of Medicine, National Yang-Ming University. ➢ Chairperson/Vice Chairperson of the International Network of Health Promoting Hospitals. ➢ Co-Chair of the International Health Promotion Evaluation Council. ➢ Global Vice President (Training Affairs, Partnerships) of the International Alliance for Health Promotion and Education. ➢ President of the Outstanding Young Women Association of the Republic of China (Taiwan). ➢ Committee Member, 23rd IUHPE World Conference on Health Promotion ➢ Chairperson of the International Environmentally Friendly Health Care Committee. ➢ Consulting Physician at Taoyuan Hospital, Ministry of Health and Welfare. ➢ Resident Physician in Family Medicine at Taipei Veterans General Hospital.	➢ Director, AmCad BioMed Corp. ➢ Chairman, Health and Sustainable Development Foundation. ➢ Consultant, Cheng Hsin General Hospital ➢ Global Executive Committee Member of the International Alliance for Health Promotion and Education. ➢ Chairperson of the International Age-Friendly Health Care Committee. ➢ Deputy Editor of the Global Health Promotion Journal Editorial Board. ➢ Adjunct Professor, College of Medicine, National Yang Ming Chiao Tung University.	None	None	None	None

Job title	Nationality or place of registration	Name	Gender, age	Date of election / appointment to current term	Term of office	Commencement date of first term	No. of shares held at time of election		No. of shares currently held		Shares currently held by spouse and minor children		Shares held through nominees		Principal work experience and academic qualifications	Positions held concurrently in the company and/or in any other company	Directors with which the person has a relationship of spouse or relative within the second degree			Remarks(Note:1)
Director	R.O.C.	Maywufa Company Limited. Representative : Wang Tsay-Ping	M 71~80	05/18/2023 05/18/2023	3 years	05/18/2023	3,473,783	6.53%	3,994,996	6.31%	0	0.00%	0	0.00%	➤ Bachelor of Science in Pharmacy, National Taiwan University ➤ Director, MAYWUFA COMPANY LTD. ➤ General Manager, Pharmaceutical Division, MAYWUFA COMPANY LTD. ➤ Executive Director, Kaisers Medical Corporation ➤ Chairman, Ching-Kang Foundation for Pharmacy Promotion ➤ President, National Taiwan University Pharmacy Alumni Association	➤ Director, AmCad BioMed Corporation ➤ Honorary Chairman, Ching-Kang Foundation for Pharmacy Promotion ➤ Advisor, Taipei Pharmacists Association ➤ Consultant, Federation of Taiwan Pharmacists Association ➤ Supervisor, ImmunAdd Inc.	None	None	None	None
Director	R.O.C.	Jen Yu Ltd. Representative : Tseng Gary T	M 61~70	05/18/2023 05/18/2023	3 years	05/06/2021	46,000	0.09%	46,000	0.07%	0	0.00%	0	0.00%	➤ Master's Degree, Graduate Institute of Diplomacy and International Law, National Chengchi University ➤ Vice Chairman, Taiwan External Trade Development Council (TAITRA) ➤ Secretary, Office of the President, Republic of China (Taiwan) ➤ Director, Special Affairs Office, Office of the President, Republic of China (Taiwan) ➤ Passed the Special Examination for Diplomatic and Consular Personnel, Republic of China (Taiwan) ➤ Lecturer, Shih Hsin University	➤ Director, AmCad BioMed Corporation ➤ Advisor, TTY Biopharm Company Limited ➤ Responsible Person, Charlotte Investment & Service Inc. ➤ Vice Chairman and General Manager, BlackWood Capital Co., Limited ➤ Director, Weigao Panion Biotech Holding Company Limited (Hong Kong) ➤ Chairman, Wisteria Trade Co., Ltd. ➤ Director, Glory Hong International Co., Ltd. (Hong Kong) ➤ Director, Great Novel Therapeutics Biotech & Medicals Corporation	None	None	None	None
Independent Director	R.O.C.	Chang Ching-Tian	M 71~80	05/18/2023	3 years	06/07/2017	0	0.00%	0	0.00%	0	0.00%	0	0.00%	➤ Master's Degree, Graduate Institute of Business Administration, Chang Gung University ➤ Special Assistant to the President, General Management Office of the Formosa Plastics Group, concurrently General Manager of Formosa Plastics Environmental Technology Corporation ➤ Assistant Vice President, General Management Office of the Formosa Plastics Group, concurrently General Manager of Huaya Campus Management Consultant Corporation ➤ Supervisor, BIOTRUST INTERNATIONAL CORPORATION	➤ Independent Director, AmCad BioMed Corporation	None	None	None	None
Independent Director	R.O.C.	Huang Weng-Foung	M 71~80	05/18/2023	3 years	05/22/2020	0	0.00%	0	0.00%	0	0.00%	0	0.00%	➤ Ph.D. in Philosophy (Major in Social and Administrative Pharmacy), University of Minnesota, USA ➤ Associate Professor and Professor, Institute of Health and Welfare Policy, National Yang-Ming University ➤ Director, Bureau of Pharmaceutical Affairs and Food Sanitation, Department of Health, Executive Yuan ➤ Director, Pharmaceutical Affairs Division, Department of Health, Executive Yuan ➤ Deputy Director, Pharmaceutical Affairs Division, Department of Health, Executive Yuan	➤ Independent Director, AmCad BioMed Corporation ➤ Independent Director, TaiGen Biopharmaceuticals Holdings Limited ➤ Independent Director, EUSOL BIOTECH CO., LTD. ➤ Corporate Representative Director, ORIENT PHARMA CO., LTD. ➤ Director, Panion & BF Biotech Inc. ➤ Director, Bowlin Holding Co., Ltd. (Seychelles) ➤ Director, Bowlin Holding Co., Ltd. (Cayman) ➤ Director, CHENG FONG CHEMICAL CO., LTD. ➤ Senior Advisor, YFY Biotech Management Co., Ltd. ➤ Corporate Representative Director, Aadi Biosciences, Inc. ➤ Corporate Representative Director, Caravel Oculus INC.	None	None	None	None
Independent Director	R.O.C.	Li Hsueh-Yu	M 61~70	05/18/2023	3 years	05/18/2023	0	0.00%	0	0.00%	0	0.00%	0	0.00%	➤ Bachelor of Medicine, China Medical University ➤ Vice Chair, International Medical Services,	➤ Independent Director, AmCad BioMed Corporation	None	None	None	None

Job title	Nationality or place of registration	Name	Gender, age	Date of election / appointment to current term	Term of office	Commencement date of first term	No. of shares held at time of election		No. of shares currently held		Shares currently held by spouse and minor children		Shares held through nominees		Principal work experience and academic qualifications	Positions held concurrently in the company and/or in any other company	Directors with which the person has a relationship of spouse or relative within the second degree			Remarks(Note:1)
															Linkou Chang Gung Memorial Hospital ➤ Director, International Affairs Center, Linkou Chang Gung Memorial Hospital ➤ Chair, Department of Otolaryngology, Linkou Chang Gung Memorial Hospital ➤ Executive Director, Taiwan Society of Otorhinolaryngology ➤ President, Taiwan Society of Sleep Medicine ➤ President, Taiwan Association of Voice Medicine	➤ Professor-level Attending Physician, Linkou Chang Gung Memorial Hospital ➤ Professor, School of Medicine, Chang Gung University				
Independent Director	R.O.C.	Lin She-Yi	F 51~60	05/18/2023	3 years	05/18/2023	0	0.00%	0	0.00%	0	0.00%	0	0.00%	➤ Master's Degree in Pharmacy, Taipei Medical University ➤ Senior Director, Novartis (Taiwan) Co., Ltd. ➤ Director, Taiwan Heart Foundation ➤ Supervisor, HoneyBear Biosciences, Inc.	➤ Independent Director, AmCad BioMed Corporation ➤ Executive Director and CEO, T.M.U. Pharmacy Foundation For Culture and Education ➤ Supervisor, Shu Rong Co., Ltd. ➤ Vice Chairman, HoneyBear Biosciences, Inc.	None	None	None	None

Note: Where the General Manager or an equivalent position (the most senior executive) is the same person as the Chairperson, or where the two are spouses or first-degree relatives, the reason, reasonableness, necessity, and response measures must be disclosed.

In the Company, the Chairperson and General Manager positions are held by the same person. This is due to the Group's second-generation succession plan initiated in recent years. Former Chairperson Mr. Lee Chen-Chia resigned from his position on November 5, 2020. In the 2023 shareholders' meeting, following a full re-election of directors, the Board elected Ms. Lee Yi-Li as Chairperson on the same day. Ms. Lee Yi-Li has served concurrently as Chairperson and General Manager for many years. With a background in finance and international banking, she has introduced a strong sense of risk control to the Company and has actively led development in AI technologies. Several of the Company's products have received international certifications and are globally unique.

In addition, Ms. Lee maintains close communication with all directors regarding the Company's operations and strategic direction to ensure sound corporate governance. In the 2023 Annual General Meeting, the Company appointed four independent directors to further enhance board functionality and strengthen its supervisory role.

The Company has adopted the following specific measures:

1. Current independent director Mr. Chang Ching-Tian has expertise in finance and accounting, contributing effectively to the Company's oversight. Independent directors Mr. Huang Weng-Foung, Ms. Li Hsueh-Yu, and Mr. Lin She-Yi are distinguished figures in the biomedical industry and provide valuable support to the Company's management.
2. Independent directors actively participate in all functional committees, engaging in thorough discussions and offering suggestions for the Board's consideration, thereby reinforcing corporate governance.
3. The majority of board members are not concurrently employees or managers of the Company and are professionals and scholars from various fields of expertise.

1. Major Shareholders of Corporate Shareholders

April 5, 2025 (stock closing date)

Name of corporate shareholder	Major shareholders of the corporate shareholder (Note)
PhytoHealth Corp.	Maywufa Company Ltd.(17.69%)、Yun Cheng Investment Corporation (0.90%)、Chen Qing-Tang(0.60%)、Zheng An-Hang(0.58%)、Wu Yu-Kun(0.53%)、Wu Li-Hua(0.51%)、Wu Zhao-Xiong(0.50%)、Lu Xue-Chang(0.48%)、Lu Xue-Chang(0.48%)、National Defense Education Foundation Research Foundation(0.48%)
Maywufa Company Ltd.	Cheng Yi Investment Company Ltd.(17.75%)、PhytoHealth Corp.(12.59%)、Li Ling Investment Company Ltd.(11.25%)、Chen Wen-Hwa (2.71%)、Cheng Hsin Investment Company Ltd.(2.36%)、Lee Chen-Chia (2.03%)、Lee Yi-Li(1.05%)、Yi Xin International Company Ltd.(1.04%)、Tsai Mao-Chen(1.03%)、Lin Ting-Chi(0.81%)
Jen Yu Ltd.	Wu Pei-Ling (100%)

Note: The name of the main shareholder of the legal person shareholder (whose shareholding ratio accounts for the top ten) and the shareholding ratio.

2. If any Major Shareholder Listed in Form 1 is a Corporate/Juristic Person, List its Major Shareholders in this Form

April 5, 2025 (stock closing date)

Name of corporate/juristic person	Major shareholders of the corporate/juristic person (Note)
Maywufa Company Ltd.	Cheng Yi Investment Company Ltd.(17.75%)、PhytoHealth Corp.(12.59%)、Li Ling Investment Company Ltd.(11.25%)、Chen Wen-Hwa (2.71%)、Cheng Hsin Investment Company Ltd.(2.36%)、Lee Chen-Chia (2.03%)、Lee Yi-Li(1.05%)、Yi Xin International Company Ltd.(1.04%)、Tsai Mao-Chen(1.03%)、Lin Ting-Chi(0.81%)
Yun Cheng Investment Corporation	International CSRC Investment Holdings Co.(94.68 %)、CS Development & Investment Co.(0.33%)
National Defense Education Foundation Research Foundation	It is a foundation and does not have shareholders.
Cheng Yi Investment Company Ltd.	Lee Chen-Chia(33.42%)、Lee Yi-Li(43.25%)、Lee I-Lin(9.04%)、Tsai Yu-Yun(14.28%)
PhytoHealth Corp.	Maywufa Company Ltd.(17.69%)、Yun Cheng Investment Corporation (0.90%)、Chen Qing-Tang(0.60%)、Zheng An-Hang(0.58%)、Wu Yu-Kun(0.53%)、Wu Li-Hua(0.51%)、Wu Zhao-Xiong(0.50%)、Lu Xue-Chang(0.48%)、Lu Xue-Chang(0.48%)、National Defense Education Foundation Research Foundation(0.48%)
Li Ling Investment Company Ltd.	Lee Chen-Chia(41.41%)、Lee I-Lin(21.82%)、Lee Yi-Li (0.34%)、Tsai Yu-Yun (37.43%)
Cheng Hsin Investment Company Ltd.	Lee I-Lin (81.03%)、Tsai Yu-Yun (11.73%)
Yi Xin International Company Ltd.	Lee Yu-Chia(35.00%)、Lee Yong-Rui(7.5%)、Lee Yin-Rui(7.5%)、Lee Bi-Jen (50.00%)

Note: Fill in the names of the major shareholders of the legal person (whose shareholding ratio accounts for the top ten) and their shareholding ratio.

3. Information on Directors and Supervisors

(1) Disclosure of Information Regarding the Professional Qualifications and Experience of Directors and Supervisors and the Independence of Independent Directors :

Qualification Name	Professional qualifications and experience (Note 1)	Independence analysis	No. of other public companies at which the person concurrently serves as an independent director
Chairman Lee Yi-Li	1. Chairman/General Manager, AmCad BioMed Corp. 2. Chairman, PhytoHealth Corp. 3. Vice Chairman, Maywufa Company Ltd. 4. Independent Director, Audit Committee Member, and Compensation Committee Member, Sinyi Realty Inc. 5. Vice President, International Global Corporate, Standard Chartered Bank 6. Vice President, Credit Agricole Corporate and Investment Bank 7. Over 20 years of experience in the biotech and healthcare industry, financial management, and capital markets.	There are no circumstances as specified in Article 30 of the Company Act.	1
Vice Chairman Lee I-Lin	1. Vice Chairman/General Manager, PhytoHealth Corp. 2. Executive Director, Maywufa Company Ltd. 3. Product Manager (Sales and Marketing), Janssen Pharmaceutical Factory of Johnson & Johnson 4. Auditor/Risk Assessment Consultant, Deloitte Taiwan 5. Over 15 years of experience in the biotech and healthcare industry, as well as in risk management and financial auditing at accounting firms.		0
Director Lee Chen-Chia	1. Founder/Chairman, Maywufa Company Ltd. 2. Founder / Chairman, PhytoHealth Corp. & AmCad BioMed Corp. 3. National Policy Consultants, Presidential Palace 4. Director, Central Bank of the Republic of China (Taiwan). 5. Director, Straits Exchange Foundation 6. Chairman of the Taiwan Provincial Industrial Association and Chairman of the National Association of Small and Medium Enterprises, R.O.C. 7. Over 45 years of experience in leadership roles at listed companies and related industry associations, government agencies, and in the biotech and healthcare industry.		0
Director Chang King-Jen	1. Chairman, Taiwan Breast Cancer Foundation. 2. Director, PharmaEssentia Corporation and iXensor Co., Ltd. 3. Supervisor, EirGenix, Inc. 4. Independent Director, Honghwa International Co., Ltd. 5. Former Director of the Department of Surgery, National Taiwan University Hospital; former Superintendent of Taoyuan General Hospital (Department of Health) and Cheng Ching General Hospital, Taichung. 6. Over 45 years of experience in hospital administration, university teaching, and management in the biotech and healthcare industry.		1
Director Sheu Jin-Chuan	1. Chairman of the Liver Disease Prevention & Treatment Research Foundation, the John Tung Foundation, and the Health for All Foundation. 2. Director, ASMedia Technology Inc. 3. Former Professor of Internal Medicine and Director of the Division of Gastroenterology and Hepatology, National Taiwan University College of 4. Renowned physician, university professor, with over 45 years of experience in management within the biotech and healthcare industry.		0

Qualification Name	Professional qualifications and experience (Note 1)	Independence analysis	No. of other public companies at which the person concurrently serves as an independent director
Director Chen Wal- Ter	1. Advisor and Chair Professor, School of Medicine, China Medical University 2. Former Vice President (Acting President), China Medical University; Former Superintendent, CMU Beigang Hospital 3. Renowned physician and university professor with over 45 years of experience in biotech and healthcare industry management.		1
Director Chiou Shu-Ti	1. Chairman, Health and Sustainable Development Foundation. 2. Global Executive Committee Member, International Alliance for Health Promotion and Education. 3. Chairperson, International Age-Friendly Health Care Committee. 4. Adjunct Professor, College of Medicine, National Yang Ming Chiao Tung University 5. Former Director-General of the Health Promotion Administration, Ministry of Health and Welfare, and former Director of the Taipei City Department of Health and the Yilan County Public Health Bureau. 6. Former government health official, medical doctor, and university professor with over 30 years of experience in the biotech and healthcare industry.		0
Director Wang Tsay-Ping	1. Honorary Chairman, Ching-Kang Foundation for Pharmacy Promotion. 2. Advisor, Taipei Pharmacists Association. 3. Consultant, Federation of Taiwan Pharmacists Association. 4. Former Director and General Manager of the Pharmaceutical Division, MAYWUFA COMPANY LTD. 5. Over 40 years of experience in the biotech and healthcare industry, as well as in business management.	There are no circumstances as specified in Article 30 of the Company Act.	0
Director Tseng Gary T	1. Responsible Person, SHF Biotechnology Co., Ltd. 2. Chairman, Sunyoung Trading Co., Ltd. 3. Former Vice Chairman of the Taiwan External Trade Development Council and Secretary to the Office of the President. 4. Over 40 years of experience in government agencies, university lecturing, and the biotech and healthcare industry.		0
Independent Director Chang Ching-Tian	1. Former Special Assistant to the President of the General Management Office, Formosa Plastics Group, concurrently General Manager of Formosa Plastics Environmental Technology Corporation, and Supervisor of SciVision Biotech Inc. 2. Over 40 years of experience as an executive and manager in the biotech and healthcare industry, public company management, and financial accounting-related roles.	1. There are no circumstances as specified in Article 30 of the Company Act. 2. Note 2.	0

Qualification Name	Professional qualifications and experience (Note 1)	Independence analysis	No. of other public companies at which the person concurrently serves as an independent director
Independent Director Huang Weng-Foung	1. Independent Director, TaiGen Biopharmaceuticals Holdings Limited and Eusol Biotech Co., Ltd. 2. Director, Panion & BF Biotech Inc., Bowlin Holding Co., Ltd. (Seychelles), Cheng Fong Chemical Co., Ltd., TaiRx, Inc., and New Eye Biotech Co., Ltd. 3. Former Director of the Bureau of Pharmaceutical Affairs and Food Sanitation, Department of Health, Executive Yuan; Former Director of the Pharmaceutical Affairs Division, Department of Health, Executive Yuan; Professor at the Institute of Health and Welfare Policy, National Yang-Ming University 4. Over 45 years of experience as a senior official in government health agencies, university professor, and in pharmaceutical and biotech industry management, pharmacy practice, and pharmaceutical administration.	1. There are no circumstances as specified in Article 30 of the Company Act. 2. Note 2.	2
Independent Director Li Hsueh-Yu	1. Professor-level Attending Physician, Linkou Chang Gung Memorial Hospital. 2. Professor, School of Medicine, Chang Gung University. 3. Former Vice Chair of International Medical Services and Director of the International Affairs Center at Linkou Chang Gung Memorial Hospital; Former Executive Director of the Taiwan Society of Otorhinolaryngology; Former President of the Taiwan Society of Sleep Medicine; Former President of the Taiwan Association of Voice Medicine. 4. Renowned physician and university professor with over 40 years of experience in the biotech and healthcare industry		0
Independent Director Lin She-Yi	1. Executive Director and CEO, T.M.U. Pharmacy Foundation for Culture and Education. 2. Vice Chairman, HoneyBear Biosciences, Inc. 3. Former Director, Taiwan Heart Foundation; Former Senior Director, Novartis (Taiwan) Co., Ltd. 4. Over 30 years of experience in the biotech and healthcare industry, as well as in pharmacy and pharmaceutical management.		0

Note1 : Professional qualifications and experience: Specify the professional qualifications and experience of each director and supervisor. If a member of the Audit Committee, specify their accounting or finance background and work experience. Additionally, specify whether any circumstance under any subparagraph of Article 30 of the Company Act exists with respect to a director or supervisor.

Note2 : Describe the status of independence of each independent director, including but not limited to the following: did they or their spouse or any relative within the second degree serve as a director, supervisor, or employee of the Company or any of its affiliates? ; specify the number and ratio of shares of the Company held by the independent director and their spouse and relatives within the second degree (or through nominees); do they serve as a director, supervisor, or employee of any company having a specified relationship with the Company (see Article 3, paragraph 1, subparagraphs 5 to 8 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies)?; specify the amount(s) of any pay received by the independent director for any services such as business, legal, financial, or accounting services provided to the Company or any affiliate thereof within the past 2 years.

Meets the Independence Criteria	Includes but is not limited to whether oneself, spouse, or first-degree relatives serve as directors,	The number and proportion of shares held by oneself, spouse, and first- degree relatives (or	Whether serving as a director, supervisor, or employee of companies with specific relationships	The amount of compensation received for providing business, legal, financial, accounting, or other
---------------------------------------	---	--	---	--

Name and Title	supervisors, or employees of the company or its affiliated enterprises.	held under others' names).	with the company (referring to provisions 5-8 of Article 3, Paragraph 1 of the Measures for the Appointment of Independent Directors of Publicly Traded Companies).	services to the company or its affiliated enterprises in the past 2 years.
Chang Ching-Tian Independent Director	No	0 stocks 0%	No	\$0
Huang Weng-Fong Independent Director	No	0 stocks 0%	No	\$0
Li Hsueh-Yu Independent Director	No	0 stocks 0%	No	\$0
Lin She-Yi Independent Director	No	0 stocks 0%	No	\$0

(2)Board diversity and independence :

A. Board diversity :

The company has established "Corporate Governance Best Practice Guidelines", which stipulate that the composition of the board of directors should consider diversity and formulate a diversity policy for basic criteria and professional knowledge and skills based on its own operations, operating style, and development needs. When appointing directors, the company not only considers their professional background, but also diversity as an important factor. According to Article 20, Paragraph 3 of the "Corporate Governance Best Practice Guidelines", board members should generally have the knowledge, skills, and qualities necessary to perform their duties. To achieve the ideal goal of corporate governance, the board of directors as a whole should have the following abilities :

- (A)Operational judgment capability.
- (B)Accounting and financial analysis capability.
- (C) Business management capability.
- (D)Crisis management capability.
- (E)Industry knowledge.
- (F)International market perspective.
- (G) Leadership capability.
- (H) Decision-making capability.

The Company has a total of 13 directors, including 4 independent directors, of whom 4 are female. The board members possess professional backgrounds across various fields such as management, medicine, pharmacy, finance, accounting, and are composed of experts including physicians and pharmacists. With diverse industry and academic experience, the Board brings multifaceted perspectives and professional insights that significantly contribute to enhancing the Company's operational and managerial performance. Furthermore, the Company places great emphasis on gender equality in board composition, with a target of maintaining at least 20% female representation. Currently, the percentage of female directors (including independent directors) has reached 31%.

Explanation for Not Reaching One-Third Female Board Representation and Measures to Promote Gender Diversity :

1. Reason : At the Company's shareholders' meeting held on May 18, 2023, 13 directors

were elected, including 4 female directors. While this meets the legal requirements at the time of election, it does not reach the one-third threshold. The main reason is the nature of the industry, which makes it challenging to identify suitable female candidates within a short period.

2. Measures : Prior to the next board re-election, the Company will actively seek candidate recommendations through various channels, including industry and academic institutions, in order to enhance corporate governance effectiveness and implement the policy of board diversity.

The implementation of board diversity is shown in the following table :

Core elements of diversity. Director Name	Nationality	Gender	Employed by the company.	Age				Length of tenure as an independent director			Industry experience			Professional expertise			
				41 to 50	51 to 60	61 to 70	71 to 80	Less than 3 years.	3 to 9 years	9 years or more	Biotech and Healthcare	Finance and Capital Markets	Business Management	Doctor	Pharmacist	Financial Accounting	Risk Management
Chairman Lee Yi-Li	R.O.C	F	✓	✓							✓	✓	✓			✓	✓
Vice Chairman Lee I-Lin		F	✓	✓							✓	✓	✓			✓	✓
Director Lee Chen-Chia		M					✓				✓		✓				✓
Director Chang King-Jen		M					✓				✓		✓	✓			✓
Director Sheu Jin-Chuan		M					✓				✓		✓	✓			✓
Director Chen Wal-Ter		M					✓				✓		✓	✓			✓
Director Chiou Shu-Ti		F			✓						✓		✓	✓			✓
Director Wang Tsay-Ping		M					✓				✓		✓		✓		✓
Director Tseng Gary T		M			✓						✓		✓			✓	✓
Independent Director Chang Ching-Tian		M					✓		✓		✓	✓	✓			✓	✓
Independent Director Huang Weng-Foung		M					✓		✓		✓		✓		✓		✓
Independent Director Li Hsueh-Yu		M			✓			✓			✓		✓	✓			✓
Independent Director Lin She-Yi		F		✓				✓			✓		✓		✓		✓

B.Independence of the Board of Directors :

- (A)Our company currently has 13 directors, of which 4 are Independent Directors, accounting for 30.77% of the total board members.
- (B)The Company has three directors who are related within the second degree of kinship, as follows: Chairperson Lee Yi-Li and Vice Chairperson Lee I-Lin are daughters of Director Lee Chen-Chia, and Chairperson Lee Yi-Li and Vice Chairperson Lee I-Lin are sisters. These related directors account for only 23.08% of the entire board, which is below the 50% threshold; therefore, the circumstances specified in Paragraphs 3 and 4 of Article 26-3 of the Securities and Exchange Act do not apply.

2.1.2 Information of General Manager, Deputy General Manager, Assistant General Manager, Department Heads, and Branch Managers :

April 5, 2025 (stock closing date)

Job title	Nationality or place of registration	Name	Gender, age	Commencement date of first term	No. of shares held at time of election		Shares currently held by spouse and minor children		Shares held through nominees		Principal work experience and academic qualifications	Positions held concurrently in the company and/or in any other company	Directors with which the person has a relationship of spouse or relative within the second degree			Remarks (Note)
					Shares	%	Shares	%	Shares	%			Job title	Name	Relation	
General Manager	R.O.C	Lee Yi-Li	F 41~50	2018.04.20	582,327	0.92%	0	0.00%	0	0.00%	➤ MBA, Rutgers University ➤ BBA In Finance, National Taiwan University ➤ Director, PhytoHealth Corp. ➤ Director, AmCad BioMed Corp. ➤ Supervisor, Taiwan Bio Industry Organization. ➤ 2016 Top 10 Female Heads of The Biomedical Industry ➤ Vice President, International Global Corporate, Standard Chartered Bank ➤ Vice President, Credit Agricole Corporate and Investment Bank ➤ Manager, Corporate Banking Group, Citibank, N.A.	➤ Chairman, PhytoHealth Corp. ➤ Vice Chairman, Maywufa Company Ltd. ➤ Chairman, Broadsound Corporation ➤ Director, Maywufa Cosmetics (Shanghai) Co., Ltd. ➤ Director, Taiwan Incubator SME Development Corporation ➤ Independent Director, Sinyi Realty Inc.	None	None	None	None
Deputy General Manager of Business Development	R.O.C	Ning Hong-Yuan	F 41~50	2022.01.18	2,000	0.00%	0	0.00%	0	0.00%	➤ Bachelor's Degree in Foreign Languages and Literature, National Taiwan University ➤ Associate Vice President of Marketing, PlexBio Co., Ltd. ➤ Head of Marketing and Sales & Special Assistant to the General Manager, GeneReach Biotechnology Corp. ➤ Head and Vice President of Sales and Marketing, ConVida Healthcare (USA) ➤ Associate Vice President of International Business, TopQ Corporation	NA	None	None	None	None
Chief Financial	R.O.C	Chen Chao-	F 41~50	2024.10.31	0	0.00%	0	0.00%	0	0.00%	➤ Bachelor's Degree in Accounting, National Chung Hsing University	NA	None	None	None	None

2.2 Remuneration to Directors, Supervisors, General Manager, and Vice Presidents

2.2.1 Remuneration of general directors and independent directors (disclosing individual names and remuneration methods).

Dec. 31, 2024 Unit: NTD thousands

Dec. 31, 2024 Unit: NTD thousands

Job title	Name	Remuneration to directors								Sum of A+B+C+D and ratio to net income		Remuneration received by directors for concurrent service as an employee								Sum of A+B+C+D+E+F+G and ratio to net income		Remuneration from Invested Businesses Other than Subsidiaries or Parent Company
		Remunerations (A)		Retirement pension (B)		Directors Compensation (C)		Allowances (D)				Salary, rewards, and special disbursements (E)		Retirement pay and pension (F) (Note 1)		Employee profit-sharing compensation (G)						
		The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company		All consolidated entities				
																Cash	Stock	Cash	Stock			
Chairman	Lee Yi-Li	0	0	0	0	0	0	505	510	505 (1.00)	510 (1.01)	4,627	4,627	0	0	0	0	0	0	5,132 (10.15)	5,137 (10.16)	0
Vice Chairman	Phytohealth Corp. Representative : Lee I-Lin	0	0	0	0	0	0	260	264	260 (0.51)	264 (0.52)	1,168	1,168	66	66	0	0	0	0	1,494 (2.95)	1,498 (2.96)	0
Director	Phytohealth Corp. Representative : Lee Chen-Chia	0	0	0	0	0	0	265	265	265 (0.52)	265 (0.52)	0	0	0	0	0	0	0	0	265 (0.52)	265 (0.52)	0
Director.	Phytohealth Corp. Representative : Chen Wal-ter	0	0	0	0	0	0	265	265	265 (0.52)	265 (0.52)	0	0	0	0	0	0	0	0	265 (0.52)	265 (0.52)	0
Director.	Maywufa Company Ltd.. Representative : Sheu Jin-Chuan	0	0	0	0	0	0	245	245	245 (0.48)	245 (0.48)	0	0	0	0	0	0	0	0	245 (0.48)	245 (0.48)	0
Director.	Maywufa Company Ltd.. Representative : Wang Tsay-Ping	0	0	0	0	0	0	265	265	265 (0.52)	265 (0.52)	0	0	0	0	0	0	0	0	265 (0.52)	265 (0.52)	0
Director.	Jen Yu Ltd. Representative : Tseng Gary T	0	0	0	0	0	0	265	265	265 (0.52)	265 (0.52)	0	0	0	0	0	0	0	0	265 (0.52)	265 (0.52)	0
Director.	Jen Yu Ltd. Representative : Chiou Shu-Ti	0	0	0	0	0	0	260	260	260 (0.51)	260 (0.51)	0	0	0	0	0	0	0	0	260 (0.51)	260 (0.51)	0
Director.	Chang King-Jen	0	0	0	0	0	0	265	265	265 (0.52)	265 (0.52)	0	0	0	0	0	0	0	0	265 (0.52)	265 (0.52)	0
Independent director.	Chang Ching-Tian	0	0	0	0	0	0	300	300	300 (0.59)	300 (0.59)	0	0	0	0	0	0	0	0	300 (0.59)	300 (0.59)	0
Independent	Huang Weng-Foung	0	0	0	0	0	0	300	300	300 (0.59)	300 (0.59)	0	0	0	0	0	0	0	0	300 (0.59)	300 (0.59)	0

Job title	Name	Remuneration to directors								Sum of A+B+C+D and ratio to net income		Remuneration received by directors for concurrent service as an employee								Sum of A+B+C+D+E+F+G and ratio to net income		Remuneration from Invested Businesses Other than Subsidiaries or Parent Company
		Remunerations (A)		Retirement pension (B)		Directors Compensation (C)		Allowances (D)				Salary, rewards, and special disbursements (E)		Retirement pay and pension (F) (Note 1)		Employee profit-sharing compensation (G)						
		The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company		The Company				
																Cash	Stock	Cash	Stock			
director.																						
Independent director.	Li Hsueh-Yu							270	270	270 (0.53)	270 (0.53)	0	0	0	0	0	0	0	0	270 (0.53)	270 (0.53)	0
Independent director.	Lin She-Yi							300	300	300 (0.59)	300 (0.59)	0	0	0	0	0	0	0	0	300 (0.59)	300 (0.59)	0
1.The policy, system, standards, and structure of remuneration for independent directors, as well as the correlation between their remuneration amount and factors such as their responsibilities, risks, and time input, are stated as follows: According to Article 25 of the Company's Articles of Association, the remuneration of all directors is authorized by the Board of Directors. It shall be paid at the same level as that of the industry, regardless of the operating profit or loss. In addition, the "Director Remuneration Payment Method" was formulated and approved by the Remuneration and Compensation Committee and the Board of Directors on February 18, 2022, and the relevant provisions for the remuneration of independent directors are implemented in accordance with this method. 2. In addition to the disclosure in the table above, the remuneration received by the company's directors for providing services to all companies in the financial report (such as serving as non-employee consultants, etc.) in the recent fiscal year amounted to 1,200NT thousand																						

Note 1: The actual amount of retirement benefits paid in the 2024 fiscal year was NTD 0, with NTD 66,000 recorded as an expense for retirement benefits.

2.2.2 Remuneration of Supervisors: The company has established an Audit Committee to replace the supervisors; therefore, this is not applicable.

2.2.3 Remuneration of General Manager and Vice Presidents:

Dec. 31, 2023 Unit: NTD thousands

Job title	Name	salary (A)		salary (A)		Retirement pay and pension (B) (Note 1)		Rewards and special disbursements. (C)				Employee profit- sharing compensation (D)		Sum of A+B+C+D and ratio to net income (%) All consolidated entities
		The Company	The Company	The Company	All consolidated entities	The Company	All consolidated entities	The Company		All consolidated entities		All consolidated entities	The Company	
								cash	stock	cash	stock			
General manager	Lee Yi-Li	5,682	5,682	96	96	960	960	0	0	0	0	6,738 (13.32)	6,738 (13.32)	0
Vice President, Business Development.	Evelyn Ning													

Note 1: The actual amount of retirement benefits paid in the 2024 fiscal year was NTD 0, with NTD 96,000 recorded as an expense for retirement benefits.

Remuneration Range Table

Remuneration Range for Each of the Company's Director	Name of Directors	
	The Company	All consolidated entities (Note)
Under NTD 1,000,000		
NTD 1,000,000 (inclusive)		
NTD 2,000,000 (inclusive)	Evelyn Ning	Evelyn Ning
NTD 3,500,000 (inclusive)		
NTD 5,000,000 (inclusive)	Lee Yi-Li	Lee Yi-Li
NTD 10,000,000 (inclusive)		
NTD 15,000,000 (inclusive)		
NTD 30,000,000 (inclusive)		
NTD 50,000,000 (inclusive)		
Over NTD 100,000,000		
Total	2	2

Note: Parent company and all affiliated invested businesses.

The top five highest-paid executives and their remuneration (disclosed by name and remuneration method).

Job title	Name	salary (A)		Retirement pay and pension (B)		Rewards and special disbursements. (C)		Employee profit-sharing compensation (D)				Sum of A+B+C+D and ratio to net income (%)		Remuneration received from investee enterprises other than subsidiaries or from the parent company
		The Company	All consolidated entities	The Company	All consolidated entities	The Company	All consolidated entities	The Company		All consolidat ed entities		The Company	All consolidated entities	
								cash	stock	cash	stock			
Manager	A	4,080	4,080	0	0	608	608	0	0	0	0	4,688 (9.27)	4,688 (9.27)	0
Manager	B	1,183	1,183	95	95	356	356	0	0	0	0	1,634 (3.23)	1,634 (3.23)	0
Manager	C(Note 1)	443	443	28	28	0	0	0	0	0	0	471 (0.93)	471 (0.93)	0
Manager	D(Note 2)	336	336	20	20	30	30	0	0	0	0	386 (0.76)	386 (0.76)	0

Note 1: 2024.08 Dismissed.

Note 2: 2024.10 Assumed office.

2.2.4Name(s) of manager(s) who received employee remuneration and the allocation situation: Our company has no surplus yet; therefore, there has been no distribution of employee compensation.

2.2.5Comparison and analysis of the total remuneration paid to the directors, general managers, and deputy general managers of the Company and all companies in the consolidated financial statements in the past two years, as a percentage of the post-tax net profit of the individual financial statements. The policy, standards, and composition of remuneration, the procedures for determining remuneration, and their relationship with business performance should also be explained.

Explanation:

- 1.The percentage of the total remuneration paid to the directors, general managers, and deputy general managers of the Company and all companies in the consolidated financial statements in the past two years, as a percentage of the post-tax (loss) profit of the individual financial statements.

Ratio of total remuneration paid to directors, supervisors, general manager and vice presidents to net income (%)			
Year	The Company	Companies in the consolidated financial statements	Explanation of Differences
2024	-23.21%	-23.22%	The proportion increased in 2024; however, the absolute amount difference is not significant.
2023	-25.01%	-25.02%	

- 2.Policies, standards, and composition of remuneration, procedures for determining remuneration, and their relationship with business performance and future risks:

To establish a sound compensation and remuneration system for the Company's directors and managerial officers, the Board of Directors has established the Compensation Committee in accordance with the "Regulations Governing the Establishment and Exercise of Powers of Compensation Committees of Companies Whose Stock Is Listed on the Stock Exchange or Traded at the Business Premises of Securities Firms." The Compensation Committee, in a professional and objective capacity, formulates the Company's director and managerial compensation policies and systems. In determining remuneration, the Committee considers industry standards, individual factors such as time commitment, responsibilities undertaken, and goal achievement, as well as the Company's historical compensation practices for equivalent positions. Additionally, the Committee takes into account the achievement of short-term and long-term business objectives, the Company's financial status, and future risks to ensure that directors and managerial officers do not engage in activities beyond the Company's risk appetite solely to pursue compensation benefits.

Furthermore, the remuneration of managerial officers is evaluated in accordance with the "Managerial Officer Compensation and Remuneration Payment Regulations" of the Company. The evaluation criteria include not only the salary level of the position in the industry, the scope of responsibilities within the Company, and contributions to corporate operational goals but also financial and non-financial indicators. Financial indicators include metrics such as revenue and pre-tax and post-tax net profit achievement rates, while non-financial indicators encompass factors such as the planning and execution of various projects and the severity of regulatory compliance and operational risk deficiencies within the respective departments.

The annual remuneration of directors and managers is determined in accordance with Article 30 of the Company's Articles of Association. If the Company has profits for the year (meaning pre-tax profit minus employee and director remuneration), after reserving for accumulated losses, a portion ranging from 3% to 6% is allocated for employee remuneration and no more than 4% is allocated for director remuneration.

The above-mentioned remuneration for directors and managers must be approved by the Remuneration Committee and submitted to the Board of Directors for resolution.

2.3 The operating status of corporate governance.

2.3.1 Operation of the Board of Directors

In the most recent fiscal year, the Board of Directors convened 5 meetings (A). The attendance of directors is summarized as follows :

Title	Name	No. of meetings attended in person (B)	No. of meetings attended by proxy	In-person attendance rate (%) (B/A)	Remarks
Chairman	Lee Yi-Li	5	0	100%	-
Vice Chairman	PhytoHealth Corp. Representative : Lee I-Lin	4	1	80%	-
Director	PhytoHealth Corp. Representative : Lee Chen-Chia	5	0	100%	-
Director	Chang King-Jen	5	0	100%	-
Director	Maywufa Company Limited. Representative : Sheu Jin-Chuan	1	4	20%	-
Director	PhytoHealth Corp. Representative : Chen Wal-Ter	5	0	100%	-
Director	Jen Yu Ltd. Representative : Chiou Shu-Ti	4	1	80%	-
Director	Maywufa Company Limited. Representative : Wang Tsay-Ping	5	0	100%	-
Director	Jen Yu Ltd. Representative : Tseng Gary T	5	0	100%	-
Independent Director	Chang Ching-Tian	5	0	100%	-
Independent Director	Huang Weng-Foung	4	1	80%	-
Independent Director	Li Hsueh-Yu	2	3	40%	-
Independent Director	Lin She-Yi	5	0	100%	-

Other information required to be disclosed :

I. If any of the following circumstances exists, specify the board meeting date, meeting session number, content of the motion(s), the opinions of all the independent directors, and the measures taken by the Company based on the opinions of the independent directors :

(I) Any matter under Article 14-3 of the Securities and Exchange Act(All independent directors had no objections to the resolutions of the board meetings of the Company for the year 2024 and the first quarter of 2025, and therefore, the Company did not need to address any opinions from independent directors.) :

Board of Directors Date/Term	Agenda items and follow-up actions
2024.02.23 6h 4th	1.Proposal for discussion : To lift the restriction on directors from engaging in competitive conduct.
	2.Proposal for discussion : To amend the “Board Meeting Rules of Procedure.”
	Resolutions : Approved as proposed without objection by all attending directors upon the Chairperson’s inquiry.
2024.06.24. 6h 6th	1.Proposal for discussion : To determine the issuance price and related matters for the Company’s 2024 cash capital increase.
	Resolution : Upon the Chairperson’s inquiry, all attending directors raised no objections. It was resolved that the reference price shall be NT\$27.78, calculated as the simple arithmetic average of the closing prices of the common shares for the five business days prior. The issuance price shall not be lower than 70% of the reference price; therefore, the issuance price is set at NT\$23 per share, issued at a premium. The proposal was approved as presented.
	2.Proposal for discussion : Allocation of employee stock subscription rights for the 2024 cash capital increase to managerial officers and directors with employee status.
	Resolution : Except for interested directors—Chairperson Lee Yi-Li, Vice Chairperson Lee I-Lin, and Director Lee Chen-Chia—who recused themselves from discussion and voting due to conflicts of interest, the remaining attending directors, upon inquiry by the Acting Chairperson, raised no objections. The proposal was approved as presented.
2024.08.08 6h 7th	Proposal for approval : Appointment of the Corporate Governance Officer.
	Resolution : Upon the Chairperson’s inquiry, all attending directors raised no objections. The proposal was approved as presented.
2024.10.31 6h 8th	Proposal for discussion : Adoption of the “Risk Management Policy and Procedures.”
	Resolution : Upon the Chairperson’s inquiry, all attending directors raised no objections. The proposal was approved as presented.
2025.02.25 6h 9th	Proposal for discussion : Amendment to the “Articles of Incorporation.”
	Resolution : Upon the Chairperson’s inquiry, all attending directors raised no objections. The proposal was approved as presented.

(II) In addition to the matters referred to above, any dissenting or qualified opinion of an

independent directory that is on record or stated in writing with respect to any board resolution : None.

II. The status of implementation of recusals of directors with respect to any motions with which they may have a conflict of interest: specify the director's name, the content of the motion, the cause for recusal, and whether and how the director voted :

2024.6.24 6h 9th Board Meeting :

Proposal : Discussion on the allocation of employee stock subscription rights in the 2024 cash capital increase to managerial officers and directors with employee status.

Resolution : Except for interested directors—Chairperson Lee Yi-Li, Vice Chairperson Lee I-Lin, and Director Lee Chen-Chia—who recused themselves from discussion and voting due to conflicts of interest, the remaining attending directors raised no objections upon inquiry by the Acting Chairperson. The proposal was approved as presented.

III. Implementation of Evaluations of the Board of Directors :

Assessment cycle	The evaluation period	Evaluation Scope	Assessment methods	Evaluation Content
Once a year	January 1st, 2024 to December 31st, 2024	Board of Directors, individual directors, and functional committees	Overall board of directors, individual board members, and functional committees performance evaluation.	Note

Note : The evaluation content shall include at least the following based on the scope of the evaluation:

- (1)Evaluation of the performance of the board should include at least the following: degree of the board's participation in the operation of the company; the quality of the board's decision making; composition and structure of the board; election and continuing education of the directors; internal control.
- (2)Evaluation of the performance of individual directors should include at least the following: familiarity with the goals and missions of the company; awareness of the duties of a director; participation in the operation of the company; management of internal relationships and communication; the director's professionalism and continuing education; internal control.
- (3)Evaluation of the performance of the functional committees: degree of participation in the operation of the company; awareness of the duties of the functional committee; quality of decisions made by the functional committee; makeup of the functional committee and election of its members; internal control.

IV. Give an evaluation of the targets that were adopted for strengthening of the functions of the board during the current and immediately preceding fiscal years (e.g., establishing an audit committee, increasing information transparency, etc.) and the measures taken toward achievement there of :


- (1) The operation of the board of directors of our company is exercised in accordance with the law, the company's articles of association, and resolutions of the shareholders' meeting. All directors not only possess the necessary professional knowledge, skills and qualities required for performing their duties, but also act in good faith and exercise due care to create the maximum benefits for all shareholders.
- (2) The company appointed four independent directors during the 2023 shareholders' meeting. In order to establish a sound corporate governance system, strengthen supervisory functions

and enhance management capabilities, our company has established a board meeting protocol in accordance with the regulations of the securities regulator. The protocol includes the main content of the agenda, operating procedures, matters to be recorded in the minutes, announcements and other requirements to be followed.

- (3) Our company has established a board of directors performance evaluation system, and the board has passed the board performance evaluation method, which is reviewed and summarized by self-assessment and peer assessment questionnaires every year. At least once every three years, an external professional independent agency or team of experts and scholars will be commissioned to conduct an evaluation as needed to encourage self-discipline among board members and improve the sound operation of the board of directors.
- (4) In addition to conducting regular self-inspections of the operation of the board of directors and strengthening its functions, the internal audit staff also prepares an audit report on the operation of the board of directors, and the monthly audit report is submitted to each independent director for review by the end of the following month, in compliance with the regulations of the securities regulator.
- (5) In accordance with the regulations of the securities regulatory authority, the Company established a Compensation Committee as resolved by the Board of Directors on November 29, 2013. In 2024, the Committee convened two meetings as required to review the compensation policies for directors and managerial officers, as well as employee stock subscription matters, thereby reinforcing corporate governance.
- (6) To comply with the regulations of the securities regulatory authority, the Company resolved to establish an Audit Committee in place of supervisors, as approved by the Board of Directors on February 21, 2014. In 2024, the Audit Committee convened four meetings, with resolutions submitted to the Board for approval, thereby enhancing corporate governance.

V. Attendance of independent directors at each board meeting in the current and recent fiscal year :

(◎ : Personally attended ★ : Proxy Attendance ◆ : Absent)

2024	1st	2nd	3rd	4th
Chang Ching-Tian	◎	◎	◎	◎
Huang Weng-Foung	◎	◎	◎	◎
Li Hsueh-Yu	★	◎	★	◎
Lin She-Yi	◎	◎	◎	◎
2025	1st			
Chang Ching-Tian	◎			
Huang Weng-Foung	★			
Li Hsueh-Yu	★			
Lin She-Yi	◎			

2.3.2 Operation of the Audit Committee :

The Company currently has four independent directors, who also form the Audit Committee. The Committee holds meetings at least once per quarter. Its purpose is to assist the Board of Directors in overseeing the quality and integrity of the Company's accounting, auditing, financial reporting processes, and internal controls.

The matters reviewed by the Audit Committee mainly include :

1. First quarter, second quarter, third quarter, and annual financial reports.
2. Audit of financial statements and accounting policies and procedures.
3. Internal control system and related policies and procedures.
4. Assessment of the effectiveness of the internal control system.
5. Significant asset or derivative transactions.
6. Significant loans, endorsements, or guarantees.
7. The issuance or offering of securities.
8. Appointment, removal, or compensation of the certifying accountant.
9. Appointment or removal of financial, accounting, or internal audit executives.
10. Self-evaluation questionnaire of the Audit Committee's performance assessment.

In the most recent fiscal year, the Audit Committee convened 4 meetings (A). The attendance of independent directors is as follows :

Title	Name	No. of meetings attended in person (B)	No. of meetings attended by proxy	In-person attendance rate (%) (B/A)	Remarks
Chairperson	Chang Ching-Tian	4	0	100%	-
Member	Huang Weng-Foung	4	0	100%	-
Member	Li Hsueh-Yu	2	2	50%	-
Member	Lin She-Yi	4	0	100%	-

Other information required to be disclosed :

I. If any of the following circumstances exists, specify the audit committee meeting date, meeting session number, content of the motion(s), the content of any dissenting or qualified opinion or significant recommendation of the independent directors, the outcomes of audit committee resolutions, and the measures taken by the Company based on the opinions of the audit committee :

1. Any matter under Article 14-5 of the Securities and Exchange Act :

Board of Directors Date/Term	Audit Committee Date/Term	Agenda items and follow-up actions
2024.02.23 6th 4th	2024.02.23 4th 3th	1. Proposal for approval of the 2023 financial statements and business report.
		2. Proposal for discussion on conducting a private placement of common shares through capital increase.
		3. Proposal for approval of the 2023 assessment of the effectiveness of the internal control system and the internal control system declaration.
		4. Proposal for discussion on amendments to the "Internal Control System" and the "Self-Assessment Procedures for Internal Control."
		5. Proposal for discussion on amendments to the "Audit Committee Charter."
		6. Proposal for discussion on the remuneration of the certifying CPA and the evaluation of their independence.
		7. Proposal for discussion on reconfirming the procedures and general policy for prior approval of non-assurance services by EY Taiwan and its affiliates, as well as the list of such non-assurance services.
		Audit Committee Resolution: All proposals were approved without objection by the attending committee members upon inquiry by the Chairperson and were submitted to the Board of Directors for further discussion.
		Board Response to Audit Committee Recommendations: All attending directors agreed to approve the proposals.
2024.05.02 6th 5th	2024.05.02 4th 4th	1. Proposal for approval of the consolidated financial statements for the first quarter of 2024.
		2. Proposal for discussion on the planned cash capital increase through the issuance of common shares.
		Audit Committee Resolution: All proposals were approved without objection by the attending committee members upon inquiry by the Chairperson and were submitted to the Board of Directors for further discussion.
		Board Response to Audit Committee Recommendations: All attending directors agreed to approve the proposals.
2024.08.08 6th 7th	2024.08.08 4th 5th	Proposal for approval of the consolidated financial statements for the second quarter of 2024.
		Audit Committee Resolution:

		All proposals were approved without objection by the attending committee members upon inquiry by the Chairperson and were submitted to the Board of Directors for further discussion. Board Response to Audit Committee Recommendations: All attending directors agreed to approve the proposals.
2024.10.31 6th 8th	2024.10.31 4th 6th	1. Proposal for approval of the appointment of the Chief Financial Officer. 2. Proposal for approval of the consolidated financial statements for the third quarter of 2024. 3. Proposal for discussion on the adoption of the “Procedures for the Preparation and Verification of the Sustainability Report.” 4. Proposal for discussion on the adoption of the internal control system for Management of Sustainability Information.” 5. Proposal for discussion on the 2025 internal audit plan. 6. Proposal for discussion on investing in financial sector stocks of domestic listed companies. Audit Committee Resolution: All proposals were approved without objection by the attending committee members upon inquiry by the Chairperson and were submitted to the Board of Directors for further discussion. Board Response to Audit Committee Recommendations: All attending directors agreed to approve the proposals.
2025.02.25 6th 9th	2025.02.25 4th 7th	1. Proposal for approval of the 2024 financial statements and business report. 2. Proposal for discussion on conducting a private placement of common shares through a cash capital increase. 3. Proposal for approval of the 2024 assessment of the effectiveness of the internal control system and the internal control system declaration. 4. Proposal for discussion on amendments to the “Internal Control System.” 5. Proposal for discussion on the remuneration of the certifying CPA and the evaluation of their independence. 6. Proposal for discussion on reconfirming the procedures and general policy for prior approval of non-assurance services by Ernst & Young and its affiliates, as well as the list of such non-assurance services. Audit Committee Resolution: All proposals were approved without objection by the attending committee members upon inquiry by the Chairperson and were submitted to the Board of Directors for further discussion. Board Response to Audit Committee Recommendations: All attending directors agreed to approve the proposals.

2. In addition to the matters referred to above, any matter that was not approved by the audit committee but was approved by a two-thirds or greater majority resolution of the board of directors : None ◦

II. Implementation of recusals of independent directors with respect to any motions with which they may have a conflict of interest: specify the independent director’s name, the content of the motion, the cause for recusal, and whether and how the independent director voted : None.

III. Communication between the independent directors and the chief internal audit officer and the CPAs that serve as external auditor (including any significant matters communicated about with respect to the state of the company’s finances and business and the method(s) and outcomes of the communication.) :

1. The company’s internal audit manager regularly communicates the results of audit reports and their follow-up execution with the Independent Director on a monthly basis, and has fully communicated the implementation and effectiveness of the audit business.
2. The company’s internal audit manager regularly communicates the results of audit reports and their follow-up execution with the Independent Director before each quarterly audit committee meeting, and has fully communicated the implementation and effectiveness of the audit business.

3. Prior to the Audit Committee meeting on February 25, 2025, the auditor communicated and fully discussed the results of the annual financial statement audit and other related legal requirements with the Independent Director.
4. The audit manager and the auditor maintain open communication channels and are in direct contact with the Independent Director as needed.

2.3.3 Corporate Governance – Implementation Status and Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies and the Reasons :



Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies and the reasons
	Yes	No	Summary description	
1. Has the Company established and disclosed its Corporate Governance Best-Practice Principles based on the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies?	✓		1. The Company adopted its “Corporate Governance Best Practice Principles” as approved by the Board of Directors on February 21, 2014. In line with amendments issued by the competent authority and to reflect the Company’s operational needs, the Principles were subsequently revised and approved by the Board on April 24, 2015, August 9, 2019, and February 22, 2023, with each revision duly reported at the respective Annual General Meeting of Shareholders. 2. The company has disclosed the Corporate Governance Best Practice Guidelines on its website.	No difference.
2. Shareholding Structure and Shareholders’ Rights (1) Does the Company have Internal Operation Procedures for handling shareholders’ suggestions, concerns, disputes and litigation matters. If yes, have these procedures been implemented accordingly?	✓		The company has established a spokesperson and proxy spokesperson system in accordance with regulations, and has published their contact telephone numbers and email addresses on the official website for shareholders to contact. The spokesperson and proxy spokesperson use these channels to understand and assist shareholders in resolving their issues.	No difference.
(2) Does the Company know the identity of its major shareholders and the parties with ultimate control of the major shareholders?	✓		The company has commissioned the stock transfer agent, "Grand Fortune Securities Co., Ltd. Share Transfer Agency Department," to regularly update the shareholder and major shareholder rosters, in order to fully understand the ultimate controllers of the company's equity, and to comply with legal requirements for internal personnel to report changes in their shareholding status to the company on a monthly basis. This enables the company to effectively maintain the list of major shareholders.	No difference.
(3) Has the Company built and implemented a risk management system and a firewall between the Company and its affiliates?	✓		The company has established relevant systems in its internal control system in compliance with legal requirements, such as the "Regulations for Supervision and Management of Subsidiaries," "Management Procedures for Related Party Transactions," and "Operating procedures for financial transactions among related	No difference.

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and the reasons
	Yes	No	Summary description	
			parties."	
(4)Has the Company established internal rules prohibiting insider trading of securities based on undisclosed information?	✓		The company has established relevant systems in its internal control system in compliance with legal requirements, such as the "Management Procedures for Preventing Insider Trading."	No difference.
3. Composition and responsibilities of the board of directors (1)Have a diversity policy and specific management objectives been adopted for the board and have they been fully implemented?	✓		The company has established the "Corporate Governance Best Practice Guidelines," which stipulate that the composition of the board of directors should take into account diversity, and that the company should develop a diversity policy for basic conditions and professional knowledge and skills based on its own operations, business models, and development needs. When appointing directors, the company considers not only their professional background but also their diversity as an important factor. In accordance with Article 20, Paragraph 3 of the Corporate Governance Best Practice Guidelines, members of the board of directors should possess the knowledge, skills, and competencies necessary to perform their duties. To achieve the ideal goal of corporate governance, the overall capabilities that the board of directors should possess are as follows : 1. Operational judgment capability. 2. Accounting and financial analysis capability. 3. Business management capability. 4. Crisis management capability. 5. Industry knowledge. 6. International market perspective. 7. Leadership capability. 8. Decision-making capability. The Company has a total of 13 directors, including 4 independent directors. Among them, 3 directors and 1 independent director are female. The board members possess professional expertise across various fields, including management, medicine, pharmacy, financial accounting, risk management, and	No difference.

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and the reasons
	Yes	No	Summary description	
			include licensed physicians and pharmacists. The board is composed of individuals with diverse industry, academic, and knowledge backgrounds, enabling them to provide professional insights from multiple perspectives, which greatly contributes to enhancing the Company's operational and managerial performance. Furthermore, the Company places strong emphasis on gender equality in board composition, with a target of maintaining female representation at 20% or above. Currently, the percentage of female directors (including independent directors) stands at 31%. For information on the implementation of the board of directors' diversity policy, please refer to page 17-19 of this year's annual report.	
(2)Has the Company voluntarily established other functional committees in addition to the remuneration committee and the audit committee	✓		The Company has duly established an Audit Committee and a Compensation Committee in accordance with applicable laws, and on October 31, 2024, the Board of Directors approved the establishment of a Sustainability Development Committee.	Other types of functional committees will be considered for establishment in the future based on actual needs.
(3)Has the Company established rules and methodology for evaluating the performance of its Board of Directors, implemented the performance evaluations on an annual basis, and submitted the results of performance evaluations to the board of directors and used them as reference in determining salary/compensation for individual directors and their nomination and additional office terms?	✓		The Company adopted the “Board Performance Evaluation Measures and Assessment Methods” on February 24, 2016. On August 9, 2019, and August 7, 2020, the Board further approved the inclusion of performance evaluations for functional committees and the revision of evaluation procedures. Annual performance evaluations are conducted at the end of each fiscal year, and at least once every three years, evaluations shall be conducted by an external independent professional institution or a team of external experts and scholars, as needed. The scope of evaluation includes the overall performance of the Board, individual directors, and functional committees. The measurement items for the performance evaluation of the Board of Directors of our company include the following five aspects : 1. Participation in the company's operations. 2. Improving the quality of the Board's decisions. 3. Composition and structure of the Board of Directors.	No difference.

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies and the reasons
	Yes	No	Summary description	
			4. Selection and continuous education of directors. 5. Internal control. The measurement items for the performance evaluation of individual directors should include at least the following six aspects : 1. Understanding of the company's goals and mission. 2. Awareness of the duties of a director. 3. Participation in the company's operations. 4. Management of internal relationships and communication. 5. Professionalism and continuous education of directors. 6. Internal control. The measurement items for the performance evaluation of functional committees should include at least the following five aspects : 1. Participation in the company's operations. 2. Awareness of the duties of the functional committee. 3. Improving the quality of the functional committee's decisions. 4. Composition and member selection of the functional committee. 5. Internal control. Scoring method: 1 point is given for full compliance, 0.75 points for mostly compliance, 0.5 points for partial compliance, 0.25 points for minor compliance, and 0 points for non-compliance. The final score is obtained by summing up the points and dividing by the total number of items * 100. The secretariat of the Board of Directors reports the evaluation results during the Board meeting and provides recommendations on areas that need improvement. In accordance with the aforementioned procedures, the evaluation results for 2024 were reported to the Board of Directors on February 25, 2025, as follows:	

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and the reasons																										
	Yes	No	Summary description																											
			Performance Evaluation of the Board and Individual Directors - Based on the self-assessment results, the average scores from valid questionnaires, calculated on a weighted basis, ranged from 91.67 to 100. Upon analysis, the relatively lower scoring areas were “Level of participation in company operations” and “Continuous education of directors.” Areas identified for improvement include “Whether more than half of all directors attend the shareholders' meeting” and “Enhancing knowledge and skills through continuous education courses.” - Going forward, the Company will continue to comply with regulatory requirements by encouraging director participation in shareholders’ meetings and providing relevant training programs to strengthen their knowledge and competencies. Board of Directors <table><caption>Board of Directors Scores</caption><thead><tr><th>Category</th><th>Score</th></tr></thead><tbody><tr><td>Level of involvement in company operations</td><td>91.67</td></tr><tr><td>Enhance the quality of board decision-making</td><td>96.67</td></tr><tr><td>Board composition and structure</td><td>100.00</td></tr><tr><td>Director selection and ongoing training</td><td>91.67</td></tr><tr><td>Internal control</td><td>100.00</td></tr></tbody></table> Board members <table><caption>Board members Scores</caption><thead><tr><th>Category</th><th>Score</th></tr></thead><tbody><tr><td>Understanding of the company's goals and mission</td><td>98.33</td></tr><tr><td>Awareness of directors' duties</td><td>100.00</td></tr><tr><td>Level of participation in company operations</td><td>95.00</td></tr><tr><td>Internal relationship management and communication</td><td>100.00</td></tr><tr><td>Director professionalization and ongoing training</td><td>98.33</td></tr><tr><td>Internal controls</td><td>100.00</td></tr></tbody></table>	Category	Score	Level of involvement in company operations	91.67	Enhance the quality of board decision-making	96.67	Board composition and structure	100.00	Director selection and ongoing training	91.67	Internal control	100.00	Category	Score	Understanding of the company's goals and mission	98.33	Awareness of directors' duties	100.00	Level of participation in company operations	95.00	Internal relationship management and communication	100.00	Director professionalization and ongoing training	98.33	Internal controls	100.00	
Category	Score																													
Level of involvement in company operations	91.67																													
Enhance the quality of board decision-making	96.67																													
Board composition and structure	100.00																													
Director selection and ongoing training	91.67																													
Internal control	100.00																													
Category	Score																													
Understanding of the company's goals and mission	98.33																													
Awareness of directors' duties	100.00																													
Level of participation in company operations	95.00																													
Internal relationship management and communication	100.00																													
Director professionalization and ongoing training	98.33																													
Internal controls	100.00																													

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies and the reasons																						
	Yes	No	Summary description																							
			Performance Evaluation of Functional Committees - Based on the self-assessment results, the average scores from valid questionnaires, calculated on a weighted basis, ranged from 87.5 to 100. Analysis indicated that the relatively lower scoring aspect was “Level of participation in company operations,” with the main area for improvement being “Lower average attendance by some committee members.” - Moving forward, the Company will encourage committee members to attend meetings in person as much as possible. Audit Committee <table><caption>Audit Committee Performance Data</caption><thead><tr><th>Category</th><th>Score</th></tr></thead><tbody><tr><td>Degree of involvement in company operations</td><td>87.5</td></tr><tr><td>Awareness of Audit Committee responsibilities</td><td>100</td></tr><tr><td>Enhancing the quality of Audit Committee decision-making</td><td>100</td></tr><tr><td>Audit Committee composition</td><td>100</td></tr><tr><td>Internal control</td><td>100</td></tr></tbody></table> Compensation Committee <table><caption>Compensation Committee Performance Data</caption><thead><tr><th>Category</th><th>Score</th></tr></thead><tbody><tr><td>Degree of involvement in company operations</td><td>87.5</td></tr><tr><td>Awareness of Compensation Committee responsibilities</td><td>100</td></tr><tr><td>Enhancing the quality of Compensation Committee decision-making</td><td>100</td></tr><tr><td>Composition of the Compensation Committee and selection of its members</td><td>100</td></tr></tbody></table>	Category	Score	Degree of involvement in company operations	87.5	Awareness of Audit Committee responsibilities	100	Enhancing the quality of Audit Committee decision-making	100	Audit Committee composition	100	Internal control	100	Category	Score	Degree of involvement in company operations	87.5	Awareness of Compensation Committee responsibilities	100	Enhancing the quality of Compensation Committee decision-making	100	Composition of the Compensation Committee and selection of its members	100	
Category	Score																									
Degree of involvement in company operations	87.5																									
Awareness of Audit Committee responsibilities	100																									
Enhancing the quality of Audit Committee decision-making	100																									
Audit Committee composition	100																									
Internal control	100																									
Category	Score																									
Degree of involvement in company operations	87.5																									
Awareness of Compensation Committee responsibilities	100																									
Enhancing the quality of Compensation Committee decision-making	100																									
Composition of the Compensation Committee and selection of its members	100																									
(4)Does the Company regularly evaluate its external auditors’ independence?	✓		On February 25, 2025, the Audit Committee and the Board of Directors approved the remuneration for the certifying accountants and assessed their independence. The current certifying accountants engaged by the Company are Ms. Yu Chien-Ju and Ms. Chang Chiao-Ying, who have been serving since the first quarter of 2022 and the first quarter of 2023, respectively. Neither has yet reached the seven-year rotation threshold. According to Taiwan’s Statements of Auditing Standards, auditors are required to provide a declaration to the governance body affirming that the personnel of the audit firm, including its affiliates and associated entities, have complied with the independence requirements outlined in the Code of Professional Ethics. Auditors must also communicate all relationships and matters that may reasonably be considered to affect their independence, including related safeguards. The Company has received the AQI (Audit Quality Indicators) information and independence declaration from the certifying accountants. No issues were																							

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies and the reasons
	Yes	No	Summary description	
			identified that would impair the independence of Ernst & Young, the audit firm engaged by the Company. Furthermore, based on the Company's internal assessment, the certifying accountants are not directors, shareholders, or salaried employees of the Company, nor are they related parties, and therefore are deemed to comply with applicable independence requirements.	
4.Does the TWSE/TPEX listed company have in place an adequate number of qualified corporate governance officers and has it appointed a chief corporate governance officer with responsibility corporate governance practices (including but not limited to providing information necessary for directors and supervisors to perform their duties, aiding directors and supervisors in complying with laws and regulations, organizing board meetings and annual general meetings of shareholders as required by law, and compiling minutes of board meetings and annual general meetings)?	✓		Currently, the Corporate Governance Officer of the parent company also serves as the Corporate Governance Officer of the Company. This individual has more than three years of experience in managing finance, shareholder services, and meeting affairs for a public company. Responsibilities include planning corporate governance affairs, safeguarding shareholder rights, and strengthening the Board's functions. Key duties involve providing necessary information to directors and independent directors to perform their duties, updating them on relevant regulatory developments, and assisting them in complying with applicable laws and regulations. The implementation of corporate governance in 2024 was reported to the Board of Directors on February 25, 2025, with the following key actions: 1. Board members were promptly notified after material information disclosures, ensuring they remained informed of important Company matters. 2. Directors were kept up to date with the latest amendments and developments in corporate governance regulations, with timely notifications and Board meeting briefings. 3. The Corporate Governance Officer actively reviewed and updated internal governance policies and organizational structures to reinforce Board independence, transparency, legal compliance, and the effective operation of internal audit and control systems. 4. Training opportunities were regularly provided to Board members, including reminders of continuing education courses and accumulated training hours. 5. Annual reporting on the Directors and Officers (D&O) liability insurance coverage was conducted. 6. Meetings involving auditors, the CFO, the Chief Audit Executive, and	No difference.

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and the reasons
	Yes	No	Summary description	
			independent directors were convened as needed to enhance communication. 7. Prior to each Board meeting, director input was solicited for agenda planning. Directors received at least 7 days' notice and sufficient meeting materials in advance. For items involving related parties or conflicts of interest, affected individuals were reminded to recuse themselves. 8. In compliance with regulatory deadlines, the date of the shareholders' meeting was registered annually, and all required materials—including meeting notices, annual reports, agenda handbooks, and minutes—were submitted within the prescribed timeframe. Amendments to the Articles of Incorporation and board re-elections were registered accordingly. 9. Annual performance evaluations were conducted for the Board, individual directors, the Audit Committee, and the Compensation Committee. Internal assessments of overall governance practices were also performed. Additionally, an external independent institution or group of experts is to be engaged at least once every three years, as needed, to conduct evaluations. 10. On September 13, 2024, the Company was invited by Taishin Securities to hold an in-person institutional investor conference, during which the management team presented the Company's latest R&D and business development progress. As the world's first company to receive U.S. FDA approval for ultrasound-based computer-aided diagnosis (CAD) as an innovative medical device, the Company has integrated ultrasound AI technology with clinical expertise to develop four high-end medical devices certified by the FDA, CE, and TFDA. These include the "AmCAD-UT[®]" for thyroid ultrasound AI diagnostics and the "AmCAD-UO[®]" system for 10-minute sleep apnea screening. These technologies significantly improve diagnostic speed and accuracy. Through innovation in AI, the Company continues to empower healthcare with internationally patented and certified technologies, earning multiple accolades.	
5.Has the Company established channels for communicating with its stakeholders (including but not	✓		The Company has established a communication channel for stakeholders in the Stakeholder Relations section on its official website, with dedicated personnel responsible for responding to important corporate social responsibility issues of	

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies and the reasons
	Yes	No	Summary description	
limited to shareholders, employees, customers, suppliers, etc.) and created a stakeholders section on its company website? Does the Company appropriately respond to stakeholders' questions and concerns on important corporate social responsibility issues?			concern to stakeholders in an appropriate manner. The Company maintains open communication channels with its stakeholders, and respects and protects their legal rights and interests. The Company reports on its communication with stakeholders to the Board of Directors on a regular basis, with a report presented in the first quarter of each year. The Company submitted a report on its communication with stakeholders for 2024 to the Board of Directors on February 25, 2025, and details can be found on the Company's website.	
6.Has the Company appointed a professional shareholder services agent to handle matters related to its shareholder meetings?	✓		Our company has appointed the "Shareholder Services Department of Fubon Securities Co., Ltd." as our shareholder services agency to handle shareholder meetings and related matters.	No difference.
7. Information Disclosure (1)Has the Company established a corporate website to disclose information regarding its financials, business, and corporate governance status?	✓		Our company has established the website: www.amcad.com.tw and complies with relevant regulations to regularly disclose or update financial, business, and corporate governance information on the Taiwan Stock Exchange Market Observation Post website. The company website also provides a link to access the Taiwan Stock Exchange Market Observation Post for further information.	No difference.
(2)Does the Company use other information disclosure channels (e.g., maintaining an English-language website, designating staff to handle information collection and disclosure, appointing spokespersons, webcasting investors conference etc.)?	✓		Our company has established an English version of our official website and designated the head of the accounting department as responsible for collecting company information. We are committed to following the regulations on information disclosure set by the competent authorities and reporting information that should be disclosed. We have also implemented a spokesperson and proxy spokesperson system and made available the process of our investor relations conference on our company website.	No difference.
(3)Does the company publish and report its annual financial report within two months after the end	✓		The Company's 2024 individual and consolidated financial statements in Chinese were publicly announced and filed on February 27, 2025. The consolidated financial reports in Chinese for the first, second, and third quarters of 2024 were	No difference.

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies and the reasons
	Yes	No	Summary description	
of the fiscal year, and publish and report its financial reports for the first, second, and third quarters as well as its operating statements for each month before the specified deadlines?			announced and filed on May 8, August 9, and November 8, 2024, respectively. The English versions of the consolidated financial reports for the first, second, and third quarters were announced and filed on July 4, August 20, 2024, and January 2, 2025, respectively. All of the above financial reports and monthly operating results were announced and filed within the required deadlines.	
8. Has the Company disclosed other information to facilitate a better understanding of its corporate governance practices (including but not limited to employee rights, employee wellness, investor relations, supplier relations, rights of stakeholders, directors' and supervisors' continuing education, the implementation of risk management policies and risk evaluation standards, the implementation of customer relations policies, and purchasing liability insurance for directors and supervisors)?	✓		1. Employee benefits : The Company values employee rights and follows legal requirements. A labor-management conference is held to reach labor-management harmony, and the Employee Welfare Committee regularly organizes employee welfare activities and establishes various system measures to fulfill its social responsibilities. For example, the Company has established an employee retirement system, purchased group insurance for employees, and held educational training. The Company's management team, consisting of the General Manager and various department heads, plans the annual "Manager Inspirational Meeting" for manager training and development. The team also has a leisure activity committee, which plans various group activities and holiday gifts, and a care committee that cares for colleagues and their families. To facilitate employee complaints, the Company has set up an electronic mailbox for employees to submit their opinions. 2. Employee care : The Company respects the human rights of all colleagues, provides equal opportunities to job applicants and employees without discrimination based on their race, belief, religion, party affiliation, gender, marital status, disability, or other government-protected factors that are unrelated to work. This principle applies to recruitment, employment, training, promotion, salary, welfare, transfer, and the Company discloses its "Measures for the Prevention and Punishment of Workplace Sexual Harassment," ensuring a friendly workplace for women and establishing a safe and healthy working environment. 3. Investor relations : In order to enable investors to better understand the Company's business status, the Company has set up an "Investor Relations" section on its website, regularly updating various stock and financial	No difference.

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and the reasons
	Yes	No	Summary description	
			information. 4. Supplier relations : When the Company signs a contract with a supplier, it also signs a statement of integrity in business. The Company strictly requires its employees and cooperation partners not to provide, promise, request or receive bribes, commissions, hospitality, kickbacks, improper gifts, or other improper benefits directly or indirectly during business activities. In order to establish a good cooperative relationship, the Company also requests that its cooperation partners not engage in any form of promise, bribery, commission, kickback, gift, hospitality or other improper benefit to any employee of the Company. Payment to suppliers is also made on time within the agreed payment period to maintain good relationships. 5. Rights of Stakeholders : The Company reported its 2024 stakeholder communication status to the Board of Directors on February 25, 2025. A dedicated “Stakeholders” section has been established on the Company’s official website. The Company remains committed to fulfilling its responsibilities to stakeholders—including suppliers, customers, shareholders, and employees—by upholding quality and service standards. Designated personnel are responsible for maintaining communication with stakeholders and safeguarding their respective rights and interests. 6. Board of Directors training situation : Please refer to the detailed explanation on page 80-82 of this year's annual report for relevant information regarding further education or training. 7. Implementation of Risk Management Policy and Risk Assessment Standards : The Company has established a “Risk Management Procedure” in accordance with ISO and EU MDR standards, covering the management of various risks, including credit risk, market risk, interest rate risk, operational risk, legal risk, and climate change risk. This procedure is designed to analyze potential inherent risks associated with the development and production processes of medical devices. It applies to risk management throughout the lifecycle of a medical device, including during the design phase, procurement process, or post-market complaint handling. The objective is to minimize potential risks and ensure the	

Evaluation item	Implementation status			Deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEX Listed Companies and the reasons
	Yes	No	Summary description	
			delivery of safer products. The Company conducts annual risk assessments and formulates risk management policies accordingly. These policies outline management objectives, organizational structure, responsibility allocation, and procedural mechanisms. They are implemented to effectively identify, measure, and control various risks, ensuring that the risks arising from operations and activities remain within acceptable levels. 8. Implementation of Customer Policy : The Company has established relevant regulations for customer credit management. All products sold are duly approved by government authorities in accordance with applicable regulations. A customer service email and hotline (+886-2-2713-6227) are provided on the Company's official website to ensure consumer protection. 9. Directors' Liability Insurance : As stipulated in the Company's Articles of Incorporation, the Company may purchase liability insurance for its directors and managerial officers. The status of this coverage was reported to the Board of Directors on August 8, 2024, and the policy has been duly implemented.	
9. Please describe improvements that have already been made based on the Corporate Governance Evaluation results released for the most recent fiscal year by the Corporate Governance Center, Taiwan Stock Exchange, and specify the priority enhancement objectives and measures planned for any matters still awaiting improvement. Explanation of the 2024 Corporate Governance Evaluation Areas for Improvement and Planned Measures for 2025 : (1) In 2025, the Company will actively invite more than half of the directors, including the convener of the Audit Committee, to attend the Annual General Meeting of Shareholders in person. (2) All directors will be encouraged to complete continuing education hours as stipulated in the "Directions for the Implementation of Continuing Education for Directors and Supervisors of TWSE/TPEX Listed Companies." (3) The Company plans to hold at least two institutional investor conferences in 2025, disclosing complete video links for at least two meetings, with an interval of more than three months between the first and last conference. (4) In 2025, the Company will prepare its Sustainability Report in accordance with the Global Reporting Initiative (GRI) Standards, submit it to the Board of Directors for approval, and upload both Chinese and English versions to the Market Observation Post System (MOPS) and the Company's official website.				

2.3.4 If the company has a remuneration committee or nomination committee in place, the composition and operation of such committee shall be disclosed :

The remuneration committee is responsible for assisting the board of directors in implementing and evaluating the company's overall compensation and benefits policies, as well as the remuneration of executives.

1. The company established the Remuneration Committee on November 29, 2013, and the members of the fifth term of the Remuneration Committee were approved at the board of directors meeting on May 18 and July 27, 2023. Mr. Chang Ching-Tian serves as the convener of this term's committee, which consists of four members: Mr. Chang Ching-Tian, Mr. Huang Weng-Foung, Mr. Li Hsueh-Yu and Ms. Lin She-Yi, all of whom meet the qualifications stipulated by the Securities and Exchange Act and the Regulations Governing the Establishment and Exercise of Powers of Remuneration Committees of Public Companies Whose Stock is Listed on the Stock Exchange or Traded Over the Counter at Securities Firms.

Please refer to our company website for the organization regulations of the Compensation Committee.

(1) Information on Remuneration Committee Members

Qualifications		Professional qualifications and experience	Independence analysis	Number of other public companies at which the person concurrently serves as remuneration committee member
Capacity	Name			
Convener (Independent Director)	Chang Ching-Tian	Please refer to pages 14-16 of this annual report for information disclosure regarding the professional qualifications of directors and the independence of independent directors.		0
Committee member (Independent Director)	Huang Weng-Foung			2
Committee member (Independent Director)	Li Hsueh-Yu			0
Committee member (Independent Director)	Lin She-Yi			0

(2)Operation of the Remuneration Committee

A. The Company's remuneration committee has a total of 4 members.

B. The term of the current members is from May 18th, 2023 to May 17th, 2026. The Compensation Committee met twice (A2).. The attendance by the members was as follows :

Title	Name	No. of meetings attended in person (B)	No. of meetings attended by proxy	In-person attendance rate (%) (B / A2)	Remarks
Independent Director	Chang Ching-Tian	2	0	100%	—
Independent Director	Huang Weng-Foung	2	0	100%	—
Independent Director	Li Hsueh-Yu	1	0	50%	—
Independent Director	Lin She-Yi	2	0	100%	—

Other information required to be disclosed:

1.If the board of directors does not accept, or amends, any recommendation of the remuneration committee, specify the board meeting date, meeting session number, content of the recommendation(s), the outcome of the resolution(s) of the board of directors, and the measures taken by the Company with respect to the opinions given by of the remuneration committee (e.g., if the salary/compensation approved by the board is higher than the recommendation of the remuneration committee, specify the difference(s) and the reasons). : None.

2.With respect to any matter for resolution by the remuneration committee, if there is any dissenting or qualified opinion of a committee member that is on record or stated in writing, specify the remuneration committee meeting date, meeting session number, content of the motion, the opinions of all members, and the measures taken by the Company with respect to the members' opinion. : None.

3.The operation of the Remuneration Committee should be disclosed, including the date and term of the Board meeting, the agenda, the resolution of the Remuneration Committee, and the company's handling of the opinions of the Remuneration Committee regarding remuneration and compensation :

Board of Directors Date/Term	Compensation Committee Date/Term	Agenda items and follow-up actions
2024.06.24 6th 6th	2024.06.24 5th 3th	Discussion on the Participation of Managers and Directors with Employee Status in the Employee Stock Subscription Allotment for the 2024 Cash Capital Increase.
		Resolution of the Remuneration Committee: After the chairman consulted with all members of the Remuneration Committee and there were no objections, the proposals were approved and submitted to the Board of Directors for further discussion.
		Handling of the Company's opinions on the Remuneration Committee: The proposal was approved by all attending directors.
2024.10.31 6th 8nd	2024.10.31 5th 4st	Discussion on the allocation of year-end and performance bonuses for the fiscal year 2024 is proposed.
		Resolution of the Remuneration Committee: After the chairman consulted with all members of the Remuneration Committee and there were no objections, the proposals were approved and submitted to the Board of Directors for further discussion.

		Handling of the Company's opinions on the Remuneration Committee: The proposal was approved by all attending directors.
--	--	---

Other resolution items not approved by the Compensation Committee but have been approved by over two-thirds of the entire board of directors: None.

- 4.The implementation of recusal by the Compensation Committee for matters involving conflicts of interest should include the names of the committee members, the content of the resolution, the reasons for recusal, and their participation in the vote: None.
- 5.Communication between the Compensation Committee and the internal personnel manager and the board meeting unit should include :
 - (1)The personnel manager and the board meeting unit of the Company communicate with the Compensation Committee irregularly.
 - (2)The personnel manager and the board meeting unit of the Company communicate the content of the current agenda to the Remuneration Committee before each scheduled meeting. The execution situation and results of personnel affairs have been fully communicated.
 - (3) Regarding the agenda of the second Compensation Committee meeting in 2024, the HR officer and the Board Secretariat both provided prior reports and engaged in thorough communication with the committee members.
 - (4)The communication channels between the personnel manager and the board meeting unit and the Remuneration Committee are smooth and they can contact each other directly as needed.

2.3.5 Promotion of Sustainable Development – Implementation Status and Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons :

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
I 、 Has the Company established a governance framework for promoting sustainable development, and established an exclusively (or concurrently) dedicated unit to be in charge of promoting sustainable development? Has the board of directors authorized senior management to handle related matters under the supervision of the board?	✓		To strengthen sustainability management, the Company’s Board of Directors approved the revision of the “Corporate Social Responsibility Best Practice Principles” to the “Sustainable Development Best Practice Principles” on February 18, 2022. In accordance with the FSC’s Letter No. 1110381030 dated March 9, 2022, regarding the “Sustainability Roadmap for TWSE/TPEX Listed Companies,” the Company established a “Sustainable Development Committee” and set up a sustainability task force. The task force is responsible for identifying sustainability issues relevant to the Company’s operations and stakeholders, formulating corresponding strategies and action plans, allocating sustainability-related budgets across departments, and planning and executing annual initiatives. It also monitors the effectiveness of these actions to ensure the sustainability strategy is fully integrated into the Company’s daily operations. The Board of Directors regularly receives reports from the management team. The management is required to propose corporate strategies to the Board, which must evaluate the likelihood of success, regularly review progress, and urge adjustments by the management team as necessary. 1.The Company established the “Sustainable Development Committee” under the Board of Directors on October 31, 2024. In accordance with the “Sustainable Development Committee Charter,” the Committee shall convene at least once a year and report to the Board in the first quarter of each year on the execution results of the current year and the implementation plan for the following year. 2.The Sustainable Development Committee is composed of 33 members, including 2 directors and 3 individuals such as the Corporate Governance Officer. The main duties of the Committee include: (1)Formulating, promoting, and strengthening the Company’s sustainability policies, annual plans, and strategies. (2)Reviewing, tracking, and revising the implementation status and effectiveness of sustainability initiatives.	No difference.

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons																				
	Yes	No	Summary description																					
			(3)Supervising the disclosure of sustainability-related information and reviewing the sustainability report. (4)Overseeing the execution of tasks related to the Company’s Sustainable Development Best Practice Principles or other sustainability matters as resolved by the Board of Directors. 3.The term of the current Committee is from October 31, 2024 to May 17, 2026. The professional qualifications and experience of the Sustainable Development Committee members are as follows: <table><tr><th>Title</th><th>Name</th><th>Sustainability expertise and competencies</th></tr><tr><td>Chairperson and Convener (Chairman and President)</td><td>Lee Yi-L</td><td>Sustainability strategy, participation in social welfare activities, organization of relevant medical events and seminars, and management of related areas such as energy and supply chain.</td></tr><tr><td>Committee Member (Vice Chairman)</td><td>Lee I-Lin</td><td>Assisted in participating in social welfare activities and organizing relevant medical events and seminars.</td></tr><tr><td>Committee Member (Corporate Governance Officer)</td><td>Huang Chih-Yuan</td><td>Assisted with matters related to sustainable development.</td></tr></table> 4.The implementation status for 2024 was reported to the Board of Directors on February 25, 2025, with the following details: <table><tr><th>Item</th><th>Execution status</th></tr><tr><td>1</td><td>The Company has established a dedicated Sustainability section on its official website to disclose the actual implementation status of key sustainability initiatives.</td></tr><tr><td>2</td><td>The Company has formulated the Sustainability Development Best Practice Principles, which are available on the official website and in the internal network storage system (NAS) accessible to all employees, with enhanced preventive measures and educational outreach.</td></tr><tr><td>3</td><td>An employee grievance section has been established on the Company’s</td></tr></table>	Title	Name	Sustainability expertise and competencies	Chairperson and Convener (Chairman and President)	Lee Yi-L	Sustainability strategy, participation in social welfare activities, organization of relevant medical events and seminars, and management of related areas such as energy and supply chain.	Committee Member (Vice Chairman)	Lee I-Lin	Assisted in participating in social welfare activities and organizing relevant medical events and seminars.	Committee Member (Corporate Governance Officer)	Huang Chih-Yuan	Assisted with matters related to sustainable development.	Item	Execution status	1	The Company has established a dedicated Sustainability section on its official website to disclose the actual implementation status of key sustainability initiatives.	2	The Company has formulated the Sustainability Development Best Practice Principles, which are available on the official website and in the internal network storage system (NAS) accessible to all employees, with enhanced preventive measures and educational outreach.	3	An employee grievance section has been established on the Company’s	
Title	Name	Sustainability expertise and competencies																						
Chairperson and Convener (Chairman and President)	Lee Yi-L	Sustainability strategy, participation in social welfare activities, organization of relevant medical events and seminars, and management of related areas such as energy and supply chain.																						
Committee Member (Vice Chairman)	Lee I-Lin	Assisted in participating in social welfare activities and organizing relevant medical events and seminars.																						
Committee Member (Corporate Governance Officer)	Huang Chih-Yuan	Assisted with matters related to sustainable development.																						
Item	Execution status																							
1	The Company has established a dedicated Sustainability section on its official website to disclose the actual implementation status of key sustainability initiatives.																							
2	The Company has formulated the Sustainability Development Best Practice Principles, which are available on the official website and in the internal network storage system (NAS) accessible to all employees, with enhanced preventive measures and educational outreach.																							
3	An employee grievance section has been established on the Company’s																							

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies and the Reasons
	Yes	No	Summary description	
			website to ensure that employees have the right and channel to access information and express opinions regarding the Company's management activities and decision-making. 4 The Company has also established a customer complaint section via telephone, email, and its website, providing a transparent and effective complaint procedure for consumers to ensure fair and prompt resolution of product or service-related issues. 5 As a medical software development company, the industry's environmental impact is relatively low. 6 The Company practices waste sorting in daily operations and conducts annual paper recycling through cooperation with paper manufacturers. 7 All employees sign labor contracts that comply with regulations on human rights, gender equality, labor rights, and employee welfare. 8 The Company strictly implements its quality management system, complies with ISO 13485 standards issued by the International Organization for Standardization and Taiwan's PIC/S GMP regulations, and in November 2023 became the first company in Taiwan to obtain EU MDR certification for smart medical software. 9 Personal Data Protection Guidelines have been established in compliance with the Personal Data Protection Act and relevant regulations to fully respect consumer privacy and protect personal data provided by customers. 10 In March 2024, the Company held an interdisciplinary sleep symposium featuring a demonstration of the "AmCAD-UO" sleep apnea detection system, enhancing cross-specialty physician knowledge in the field of sleep medicine. 11 In May-June 2024, the Company sponsored the 25th Anniversary International Conference of the Chang Gung Sleep Center and the Taiwan Society of Sleep Medicine Summer Meeting, hosting a workshop on the "AmCAD-UO" system to engage in in-depth exchanges with local sleep experts and improve the quality of clinical care.	

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			12 In September–October 2024, the Company sponsored the Annual Meeting of the Taiwan Society of Sleep Medicine to enhance diagnostic quality in sleep apnea detection for medical professionals. 13 In September–October 2024, the Company sponsored the 40th Anniversary Annual Meeting of the Taiwan Society of Medical Ultrasound, showcasing the latest AI technology for differentiating benign and malignant thyroid nodules, improving diagnostic quality and efficiency in thyroid ultrasound. 14 In November–December 2024, the Company sponsored clinical research on dental treatments for sleep apnea in collaboration with Taipei Tzu Chi Hospital’s dental department, improving treatment accuracy. 15 In November–December 2024, during the Healthcare+ Expo Taiwan, the Company offered public access to sleep apnea screening experiences to promote sleep health awareness in the general public. In 2024, the Company actively participated in various social welfare activities. To enhance the quality of healthcare professionals and promote patient well-being, the Company collaborated with major medical societies and healthcare institutions to organize academic annual meetings, clinical education programs, and expert symposiums. These efforts engaged more than 5,000 healthcare professionals and beneficiaries. At the Board of Directors meeting on February 25, 2025, board members provided guidance and recommendations based on the sustainability performance report for 2024.	
2.Does the company conduct risk assessments of environmental, social and corporate governance (ESG) issues related to the company's operations in accordance with the materiality principle, and formulate relevant risk management policies or	✓		1. This disclosure covers the Company’s sustainability performance from January to December 2024 at its major operational sites. The scope of risk assessment focuses on the Company itself, including its existing operations in Taiwan. Due to operational relevance and the materiality of impact, the subsidiary SoundBite Medical Corp. is also included. 2. On October 31, 2024, the Board of Directors approved the Company’s “Risk Management Policy and Procedures.” The risk management framework includes	No difference.

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
strategies?			the Board of Directors, Audit Committee, senior management, internal audit, and various operational units—business, R&D, manufacturing, and administration. The risk management process includes risk identification, measurement, monitoring, reporting and disclosure, and response planning. These processes help define and control operational risks through appropriate measures. A report on the implementation of risk management for 2024 was submitted to the Board on February 25, 2025. Further details are available on the Company’s website. 3. In compliance with ISO standards, the Company has adopted a “Risk Management Procedure” as its highest guiding principle. The procedure is used to assess inherent risks in the development and production of medical devices, with the aim of minimizing potential risks and ensuring the safety of products. This procedure applies to the design phase, procurement process, and post-market complaint handling. Potential product failure modes are proactively analyzed using technical knowledge and experience to implement preventive measures in advance. The Company conducts annual risk assessments and formulates risk management policies for each type of risk, covering management objectives, organizational structure, defined responsibilities, and implementation mechanisms. The goal is to effectively identify, assess, and control all risks arising from business activities within an acceptable range. Risks managed include credit risk, market risk, interest rate risk, operational risk, legal risk, and climate change risk. 4. Based on the risk assessments, the Company has formulated the following policies and strategies: (1) Environmental Protection As a biotech company focused on the development of advanced medical devices, the Company collaborates with experts from NTU College of Medicine and College of Engineering to develop innovative “non-invasive” ultrasound computer-aided diagnostic (CAD) systems for detecting and	

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			diagnosing tumor malignancies. The Company's operations have minimal adverse environmental impact. (2)Product Responsibility Suppliers are required to obtain all necessary environmental permits (e.g., emission monitoring), approvals, and registration documents and are expected to regularly maintain and update these. Suppliers must identify and manage hazardous chemicals and substances released into the environment to ensure their safe handling, transport, storage, use, recycling, and disposal. The Company complies with the EU RoHS (Registration, Evaluation, Authorization, and Restriction of Chemicals) standards. (3)Labor Relations Employees are the Company's most valuable asset. The Company is committed to creating a workplace that values gender equality and adheres to a "merit-based hiring" philosophy. Mutual trust and respect are promoted between employees and the Company to foster a supportive environment in which all employees can thrive. (4)Anti-Corruption The Human Resources Department is responsible for revising, implementing, and overseeing the Company's anti-corruption regulations and maintains related records. An annual report on the previous year's performance is submitted to the Board in Q1. The Company has established the "Code of Ethical Conduct," "Ethical Corporate Management Best Practice Principles," "Operating Procedures and Guidelines for Ethical Conduct," internal control systems, and delegation of authority guidelines. Anti-corruption efforts are supported by internal audits, self-assessments, and a whistleblower hotline. Suppliers must sign a declaration of integrity when entering into contracts with the Company. Employees and business partners are strictly prohibited from offering, soliciting, or accepting bribes, commissions, entertainment, rebates, inappropriate gifts, or other improper benefits. Suppliers are asked not to provide any form of bribery or improper benefits to the Company's	

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			personnel. All major supplier contracts include clauses stating that if a supplier violates its corporate social responsibility obligations or has a significant negative impact on society or the environment, the Company reserves the right to terminate the contract at any time. (5)Intellectual Property Rights The Company has established “Intellectual Property Management Regulations” and “Patent Infringement Handling Procedures.” Trade secrets must be kept confidential, and employees are prohibited from accessing or collecting confidential information not related to their duties, including trademarks, patents, copyrights, or other IP, or disclosing such information to others. The Company enters into Non-Disclosure Agreements (NDAs) with suppliers and customers. Information security is managed through the “Network Usage and Confidential Document Management Policy” and “Business Intelligence Management Guidelines.” (6)Compliance with Socio-Economic Regulations The Company complies with local laws as well as those of its export markets. All products meet international safety standards, environmental regulations, and import/export laws. The Company conducts internal training sessions to raise awareness and ensure compliance with regulations and ethical business practices.	
3.Environmental Issues (1)Has the Company set an environmental management system designed to industry characteristics?	✓		The Company is a high-end medical device manufacturer and a biotechnology firm focused on the research and development of advanced medical devices. It complies with ISO 13485 and the EU Medical Device Regulation (MDR), obtaining certification annually. In collaboration with experts from the College of Medicine and College of Engineering at National Taiwan University, the Company develops innovative, non-invasive ultrasound computer-aided diagnostic (CAD) systems to assist physicians in the clinical detection and diagnosis of tumor malignancy. The Company's operations have minimal negative	No difference.

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			environmental impact. For hardware products outsourced for manufacturing, the Company requires suppliers to obtain all necessary environmental permits (e.g., emission monitoring), approvals, and registration documents, and to maintain and update them regularly. Suppliers are also required to identify and manage hazardous chemicals and other substances released into the environment to ensure safe handling, transportation, storage, usage, recycling, reuse, and disposal. All processes must comply with the EU RoHS directive (Registration, Evaluation, Authorization, and Restriction of Chemicals).	
(2)Does the Company endeavor to use energy more efficiently and to use renewable materials with low environmental impact?	✓		The Company actively promotes various energy reduction initiatives by selecting equipment with high energy efficiency and energy-saving designs to reduce both corporate and product energy consumption. Efforts are also made to increase the use of renewable energy, thereby optimizing overall energy efficiency. All raw materials used by the Company comply with EU regulations, including environmental permits (e.g., emission monitoring), approvals, and registration documents, which are regularly maintained and updated. Suppliers are required to identify and manage hazardous chemicals and other substances released into the environment to ensure their safe handling, transport, storage, usage, recycling, reuse, and disposal. Compliance with the EU RoHS directive (Registration, Evaluation, Authorization, and Restriction of Chemicals) is strictly enforced. In terms of green manufacturing, the Company aims to minimize unnecessary resource waste and pursue waste reduction and reuse technology development. Across the value chain, both upstream and downstream partners collaborate to share and recycle packaging materials. In product development, the Company is also actively testing the use of environmentally friendly and recycled materials to minimize environmental impact and maximize the benefits of a circular economy.	No difference.
(3)Has the Company evaluated the potential risks and opportunities posed by climate change for its business now and in the future	✓		Regarding the potential risks and opportunities associated with climate change and greenhouse gas emissions: 1. Risks to companies from climate change-related regulations As regulations and agreements related to climate change become more stringent	No difference.

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
and adopted relevant measures to address them?			globally, companies operating in the new drug development industry like ours are minimally affected by the impact of global climate change and greenhouse gas emissions. However, as responsible corporate citizens, we will continue to monitor relevant domestic and foreign regulations and strive to meet industry trends in social responsibility. 2. Real risks to companies from climate change In response to the dramatic effects of greenhouse gases on global climate change, companies may incur indirect or direct increases in operating costs. These real risks to our company include : (1)Water resource instability after typhoons causing decreased production or production shutdowns. (2)Heavy rainfall leading to road collapses or waterlogging, preventing the company's products from reaching customers. (3)Strong winds causing power outages, affecting the company's ability to operate fully. 3. Opportunities for companies from climate change In response to climate change, companies will have a greater demand for energy-saving or green products, which will encourage them to actively invest in the use and development of energy-saving or green products, contribute to sustainable environments, and enhance the competitiveness of their industry. To reduce the above-mentioned risk factors, our company is simultaneously identifying feasible opportunities and devising corresponding measures. In terms of mitigating climate change, we are developing green operations, energy management, carbon information disclosure, and green building projects. In terms of adapting to climate change, our company has implemented measures to strengthen basic infrastructure, build sustainable operation capabilities, and fully utilize green buildings.	
(4)Did the company collect data for the past two years on greenhouse gas emissions, volume of water			Strategies, methods, and targets for managing greenhouse gas emissions, water consumption, and total waste generation: 1. In accordance with the “Sustainability Roadmap for TWSE/TPEX Listed	No difference.

I t e m	I m p l e m e n t a t i o n s t a t u s					Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons																																			
	Yes	No	Summary description																																						
consumption, and the total weight of waste, and establish policies for greenhouse gas reduction, reduction of water consumption, or management of other wastes?			Companies” issued by the Financial Supervisory Commission, the Company (including the Taipei office and Neihu facility) completed inventories of greenhouse gas emissions, water consumption, and waste generation for 2023 and 2024. The details are as follows: Year 2023 <table><tr><th>Category Item</th><th>Scope 1 Direct emission sources</th><th>Scope 2 Energy indirect emission sources</th><th>Scope 3 Transportati on indirect emission sources</th><th>Scope 4 Raw materials/ser vices indirect emission sources</th><th>Total</th></tr><tr><td>Emission Equivalent (metric tons CO₂e/year)</td><td>0.0000</td><td>11.4900</td><td>—</td><td>—</td><td>11.4900</td></tr><tr><td>Proportion</td><td>0.00%</td><td>100.00%</td><td>0.00%</td><td>0.00%</td><td>100.00%</td></tr></table> Year 2024 <table><tr><th>Category Item</th><th>Scope 1 Direct emission sources</th><th>Scope 2 Energy indirect emission sources</th><th>Scope 3 Transportati on indirect emission sources</th><th>Scope 4 Raw materials/se rvices indirect emission sources</th><th>Total</th></tr><tr><td>Emission Equivalent (metric tons CO₂e/year)</td><td>0.0000</td><td>21.9512</td><td>0.4703</td><td>8.2074</td><td>30.6289</td></tr><tr><td>Proportion</td><td>0.00%</td><td>71.67%</td><td>1.54%</td><td>26.79%</td><td>100.00%</td></tr></table> Note: Scope 1 corresponds to Category 1, Scope 2 to Category 2, and Scope 3 includes Categories 3 and 4. The water consumption and waste inventory details for 2023 and 2024 are as follows:			Category Item	Scope 1 Direct emission sources	Scope 2 Energy indirect emission sources	Scope 3 Transportati on indirect emission sources	Scope 4 Raw materials/ser vices indirect emission sources	Total	Emission Equivalent (metric tons CO ₂ e/year)	0.0000	11.4900	—	—	11.4900	Proportion	0.00%	100.00%	0.00%	0.00%	100.00%	Category Item	Scope 1 Direct emission sources	Scope 2 Energy indirect emission sources	Scope 3 Transportati on indirect emission sources	Scope 4 Raw materials/se rvices indirect emission sources	Total	Emission Equivalent (metric tons CO ₂ e/year)	0.0000	21.9512	0.4703	8.2074	30.6289	Proportion	0.00%	71.67%	1.54%	26.79%	100.00%
Category Item	Scope 1 Direct emission sources	Scope 2 Energy indirect emission sources	Scope 3 Transportati on indirect emission sources	Scope 4 Raw materials/ser vices indirect emission sources	Total																																				
Emission Equivalent (metric tons CO ₂ e/year)	0.0000	11.4900	—	—	11.4900																																				
Proportion	0.00%	100.00%	0.00%	0.00%	100.00%																																				
Category Item	Scope 1 Direct emission sources	Scope 2 Energy indirect emission sources	Scope 3 Transportati on indirect emission sources	Scope 4 Raw materials/se rvices indirect emission sources	Total																																				
Emission Equivalent (metric tons CO ₂ e/year)	0.0000	21.9512	0.4703	8.2074	30.6289																																				
Proportion	0.00%	71.67%	1.54%	26.79%	100.00%																																				

I t e m	I m p l e m e n t a t i o n s t a t u s				Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons																	
	Yes	No	Summary description																			
			<table><tr><th rowspan="2">Year</th><th rowspan="2">Water Consumption (metric tons)</th><th colspan="3">Waste (metric tons)</th></tr><tr><th>Hazardous waste</th><th>Non-hazardous waste</th><th>Total</th></tr><tr><td>2023</td><td>417.89</td><td>0</td><td>0</td><td>0</td></tr><tr><td>2024</td><td>345.71</td><td>0</td><td>0</td><td>0</td></tr></table>	Year	Water Consumption (metric tons)	Waste (metric tons)			Hazardous waste	Non-hazardous waste	Total	2023	417.89	0	0	0	2024	345.71	0	0	0	
Year	Water Consumption (metric tons)	Waste (metric tons)																				
		Hazardous waste	Non-hazardous waste	Total																		
2023	417.89	0	0	0																		
2024	345.71	0	0	0																		
			2. Strategies for Responding to Climate Change and Greenhouse Gas Management: In response to the global trend of carbon reduction and to fulfill corporate social responsibility, the Company is committed to the following actions: (1)Accurately monitor the status of greenhouse gas emissions. (2)Propose greenhouse gas reduction plans. (3)Implement greenhouse gas reduction measures. (4)Actively increase the proportion of green energy usage. 3. Targets and Performance for Reducing Greenhouse Gas Emissions, Water Consumption, and Total Waste: In 2024, the Company’s greenhouse gas emissions increased by approximately 10.46 metric tons, representing a 91.04% rise; water consumption decreased by 72.18 metric tons, a 17.27% reduction; and there was no waste generated. Although the target of more than 3% annual reduction was not met, the Company is actively managing and controlling emission sources to gradually reduce greenhouse gas emissions, water consumption, and waste in the coming years. 4. Budget and Plans for Reducing Greenhouse Gas Emissions, Water Consumption, and Waste: The Company’s environmental expenditures account for approximately 1% of its output value. As the Company’s output value continues to grow annually, investments in environmental protection and energy-saving measures will be sustained, with the goal of achieving more than a 3% annual reduction in greenhouse gas emissions, water consumption, and waste generation.																			
4.Social Issues																						

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons												
	Yes	No	Summary description													
(1)Has the company formulated relevant management policies and procedures in accordance with relevant laws and regulations and international human rights conventions?	✓		In compliance with labor-related laws and regulations, our company ensures that all employees are covered by labor insurance, national health insurance, and contribute to a personal account for labor retirement pension. Additionally, we provide accident insurance for all employees to ensure protection in case of accidents occurring outside of work. Our company's regulations regarding work hours, rest, vacation, overtime, and retirement fully comply with labor laws and have been approved by the competent authorities. Furthermore, we have established a welfare committee to organize regular activities and advocate for the maximum benefits of our employees. Regarding retirement, whether under the old or new system, we fully comply with the Labor Standards Act and relevant regulations, ensuring that employees' rights and benefits are fully protected. During the financial crisis, we took into consideration the employees' families and did not implement measures such as layoffs or unpaid leave, thus fulfilling our corporate social responsibility. In terms of human rights, we refer to international human rights standards such as the United Nations Universal Declaration of Human Rights, the United Nations Global Compact, the United Nations Guiding Principles on Business and Human Rights, and the International Labor Organization. We aspire to be an international corporate citizen that advocates for human rights. Regarding diversity in the workplace, our company provides a safe and healthy work environment and respects and implements diversity. In the process of selection, employment, training, and promotion, we do not discriminate based on race, class, language, religion, political affiliation, place of origin, gender, sexual orientation, age, marital status, appearance, physical or mental disability, or past union membership. We protect our employees from discrimination, harassment, or unequal treatment based on applicable laws and regulations. <table><tr><th>Indicator</th><th>%</th></tr><tr><td>Percentage of female employees among total employees</td><td>50%</td></tr><tr><td>Percentage of female</td><td>50%</td></tr></table> <table><tr><th>Gender pay equity indicator</th><th>Gap</th></tr><tr><td>Gender pay gap in average salary</td><td>0.66</td></tr><tr><td>Gender pay gap in median salary</td><td>0.74</td></tr></table>	Indicator	%	Percentage of female employees among total employees	50%	Percentage of female	50%	Gender pay equity indicator	Gap	Gender pay gap in average salary	0.66	Gender pay gap in median salary	0.74	No difference.
Indicator	%															
Percentage of female employees among total employees	50%															
Percentage of female	50%															
Gender pay equity indicator	Gap															
Gender pay gap in average salary	0.66															
Gender pay gap in median salary	0.74															

Item	Implementation status					Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons										
	Yes	No	Summary description													
			<table><tr><td>supervisors among all supervisors</td><td></td></tr><tr><td>Percentage of female top executives among all top executives</td><td>100%</td></tr></table>	supervisors among all supervisors		Percentage of female top executives among all top executives	100%		<table><tr><td></td><td></td></tr><tr><td>Gender gap in average variable bonus</td><td>0.68</td></tr><tr><td>Gender gap in median variable bonus</td><td>0.90</td></tr></table>			Gender gap in average variable bonus	0.68	Gender gap in median variable bonus	0.90	
supervisors among all supervisors																
Percentage of female top executives among all top executives	100%															
Gender gap in average variable bonus	0.68															
Gender gap in median variable bonus	0.90															
			Our company, though not having a labor union organization, still adheres to government labor laws and holds regular labor-management meetings for two-way communication and negotiation. In addition, we occasionally hold labor-management meetings in accordance with Article 83 of the Labor Standards Act to discuss issues related to promoting labor-management cooperation, coordinating labor relations, improving labor conditions, and planning labor welfare. We also require our suppliers to comply with the same human rights policies and are committed to creating the best practices for human rights in the biopharmaceutical industry. The policy and specific management plan for safeguarding human rights that our company implemented in 2024 are summarized as follows: 1.No operational locations or suppliers violate or seriously endanger freedom of association and collective bargaining. 2.No operational locations or suppliers have significant risks of using child labor. 3.No operational locations or suppliers have significant risks of forced or compulsory labor. 4.No human rights issues have been filed, processed, and resolved through formal complaint mechanisms. 5.Our company and suppliers have not been involved in any events related to violating indigenous peoples' rights. 6.No human rights complaints have been filed. 7.No discrimination events have occurred. 8.No violations of regulations related to social categories have occurred, nor have any fines been imposed. 9.There are no significant actual or potential negative impacts on human rights in the supply chain.													

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			In addition, our company has established "Measures for Preventing and Dealing with Workplace Sexual Harassment Complaints and Disciplinary Actions," which have been posted on the company's website. In 2024, there were a total of 3 human rights protection-related training sessions for new employees, with a combined duration of 6 hours. These sessions were attended by a total of 7 individuals. In the future, we will continue to focus on human rights protection issues, promote relevant education and training, and raise awareness of human rights protection to reduce the likelihood of related risks occurring.	
(2)Has the Company established and implemented reasonable employee welfare measures (include salary/compensation, leave, and other benefits), and are business performance or results appropriately reflected in employee salary/compensation?	✓		1. Our company has established a Welfare Committee for employees in accordance with government regulations, and allocated welfare funds as required by law. Both labor and management jointly supervise the use and management of the welfare funds. We also comply with the Labor Standards Act and related laws to establish various salary standards, attendance and leave policies, and welfare measures for employees. We provide competitive benefits to motivate our employees, conduct regular evaluations, distribute performance bonuses, and share the profits with our colleagues. 2. In addition to the salaries set forth in the company's bylaws, our employees' compensation is estimated based on the company's annual profits and their performance, and adjustments and incentive rewards are made accordingly. We aim to improve employees' sense of belonging and loyalty to the company by providing appropriate compensation and benefits.	No difference.
(3)Does the Company provide employees with a safe and healthy working environment, and implement regular safety and health education for employees?	✓		1. Security and access control system : There are access control systems at all workplace entrances and exits, and security personnel coordinate access control operations. The facility is equipped with surveillance systems and 24-hour security personnel to conduct regular safety patrols and ensure the safety and protection of the plant. 2. Fire Safety Management : No fire incidents occurred in our company in 2024. To enhance fire safety management, our company conducts regular fire safety inspections every year, establishes a fire prevention management team, and holds fire safety training	No difference.

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			sessions with practical fire extinguisher drills every six months. All equipment, such as emergency lighting, evacuation signs, and fire extinguishers, undergo regular inspections. 3. Occupational safety and health : Before new employees start working, they are required to submit a physical examination report to identify their suitability for the job and assess whether they are fit for the work to avoid threats or injuries to their health caused by work. Regular health checks are also implemented for current employees. Outdoor smoking areas are planned in accordance with the government's smoke-free workplace policy, and lactation rooms are set up for postpartum female employees. Monthly overtime hours for employees do not exceed 46 hours. 4. Establishment of occupational safety and health management units : According to the Regulations for Occupational Safety and Health Management, an occupational safety and health supervisor is appointed to implement the relevant provisions of the Occupational Safety and Health Act and its enforcement regulations, prevent occupational accidents, protect employee safety and health, maintain the common rights and interests of labor and management, and promote sound business development. 5. Company Verification Status: As of the printing date of the 2024 annual report, the company has not obtained relevant labor safety verification. 6. Occupational Accident Situation: The company regards disaster prevention and disaster mitigation as core principles, utilizing appropriate management tools and available resources to integrate occupational safety and health issues. Effective measures are proposed and continuously improved to promote a culture of occupational safety. Additionally, protective management for operational personnel is strengthened to create a zero-accident environment. In 2024, there were no	

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			occupational accidents involving employees, with zero cases and zero individuals affected.	
(4)Has the Company established effective career development training programs for employees?	✓		We prioritize long-term talent development in our company, and plan various internal and external training programs based on the needs of our organization, departments, and individual employees. For example, we hold motivational meetings every month and invite well-known external figures to share new information with our employees, to enhance and update their knowledge and skills, and to establish effective career capabilities, please refer to page 93 of this year's annual report.	No difference.
(5)Does the company comply with the relevant laws and international standards with regards to customer health and safety, customer privacy, and marketing and labeling of products and services, and implement consumer protection and grievance policies?	✓		Our company has established "Personal Information Protection Guidelines" and "Internet Use and Confidential Document Management Measures" to protect consumer rights and establish complaint procedures. We have also created a stakeholder area on our official website, providing customers with a channel to voice their complaints. We continuously monitor product safety information and implement a sound personal information management mechanism to fulfill our commitment to manage and protect customer privacy. Through internal auditing, crisis prevention, and education and training, we safeguard our customers' personal information.	No difference.
(6)Has the company formulated supplier management policies requiring suppliers to comply with relevant regulations on issues such as environmental protection, occupational safety and health, or labor rights, and what is the status of their implementation?	✓		The Company, as a manufacturer of advanced medical devices, complies with ISO 13485 and the EU Medical Device Regulation (MDR), and has obtained the relevant certifications. Additionally, the Company has established a "Supplier Management Policy", which requires all suppliers to adhere to applicable standards related to environmental protection, occupational health and safety, and labor and human rights. The Company conducts annual assessments of suppliers' compliance with these requirements. If a supplier is found to be in violation of corporate social responsibility policies and such actions result in significant negative environmental or social impact, the Company reserves the right to reach a mutual agreement on contract termination or cancellation at any time. In cases where a supplier violates legal regulations	No difference.

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			and fails to make immediate improvements, the Company may terminate the contract accordingly.	
5.Does the company refer to international reporting standards or guidelines when preparing its sustainability report and other reports disclosing non-financial information? Does the company obtain third party assurance or certification for the reports above?		✓	Our company has not yet compiled a sustainability report. However, all employees are actively promoting energy conservation and carbon reduction to enhance the effectiveness of sustainable development. The company is also considering the compilation of a sustainability report in accordance with regulatory policies and operational conditions.	Not yet compiled.
6.If the Company has adopted its own sustainable development best practice principles based on the Sustainable Development Best Practice Principles for TWSE/TPEX Listed Companies, please describe any deviation from the principles in the Company's operations : On February 21, 2014, the Board of Directors approved the adoption of the Company's "Corporate Social Responsibility Best Practice Principles." Subsequently, partial amendments were approved on April 24, 2015, and on February 18, 2022, the Board resolved to rename the principles to the "Sustainability Development Best Practice Principles" to strengthen the Company's commitment to sustainable development. The Company regularly reviews its implementation based on these principles and makes improvements accordingly. The progress of sustainability implementation is reported to the Board in the first quarter of each year, with the most recent report presented on February 25, 2025. Under the Company's corporate culture of "Integrity, Reciprocity, and Courtesy," this philosophy has been deeply ingrained across the organization—from top management to all employees—fostering shared beliefs and behavioral standards. These values have been consistently reflected in the Company's concrete actions toward fulfilling its social and sustainability responsibilities, with no material deviations observed to date.				
7. Other important information to facilitate better understanding of the company's promotion of sustainable development : (1) In terms of promoting sustainable development, our company adheres to the corporate culture of "integrity, mutual benefit, and courtesy" as a code of conduct : ① Integrity - Conducting business with integrity and regularly reporting on the implementation of sustainable development to the board of directors. ② Mutual benefit - Adhering to the principle of mutual benefit in our relationships with stakeholders, including employees, shareholders, suppliers and customers upstream and downstream, consumers, communities, and banks, and sharing the economic value created by the company. ③ Courtesy - Placing importance on corporate ethics internally and following laws and moral standards externally. Our company has established a				

I t e m	I m p l e m e n t a t i o n s t a t u s			Deviations from the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies and the Reasons
	Yes	No	Summary description	
code of ethics for directors and supervisors and a code of ethical behavior for first-level managers to regulate their ethical standards. (2) In terms of environmental protection, the Company not only complies with relevant domestic regulations but also supports the government's resource recycling policies by implementing strict waste sorting practices. The use of single-use items such as paper cups and disposable utensils is actively reduced to prevent resource waste, promote conservation, and achieve effective resource utilization while preventing environmental pollution.Among the Company’s products, the “Computer-Aided Detection/Diagnosis System” is classified as computer application software, and its development process does not generate industrial waste. For all other hardware products, production is carried out in strict compliance with international environmental regulations and relevant certifications have been duly obtained.				

2.3.5.1 Implementation of Climate-Related Initiatives:

Item	Implementation status				
1. Describe the oversight and governance of climate-related risks and opportunities by the board of directors and management.	The Board of Directors of the company will report annually in the first quarter on the implementation status of sustainable development initiatives in the preceding year. Led by the Chairman, the company will assist in promoting corporate sustainability and climate change-related management actions. It will evaluate climate change issues, company characteristics, and relationships within the supply chain to identify significant risks and opportunities while addressing the substantial risks posed by global warming to the global economy. This proactive approach aims to mitigate the impact of climate change and maximize the company's benefits. In the future, the company will regularly report on the progress of ESG initiatives and ESG implementation goals to the Board of Directors.				
2. The identified climate risks and opportunities are explained below in terms of their impact on the business, strategy, and finances of the enterprise in the short, medium, and long term.	R: Risk / O: Opportunity	Type of Risk / Opportunity	Short Term (Within 3 Years)	Medium Term (3–5 Years)	Long Term (Over 5 Years)
	Risk	Transition Risk Risks arising from the transition to a low-carbon economy, including policy, legal, technological, market, and reputational risks.	Greenhouse gas emission caps	Changes in consumer demand and preferences. Transition to low-carbon technologies. Inadequate climate action may lead	Net-zero emission trends

				to reputational damage.	
		Physical Risk Extreme rainfall patterns in Taiwan may negatively affect water quality and disrupt production. Climate change may drive up the cost of key commodities, affecting operations.	Increased flooding due to extreme climate patterns, potentially damaging operational assets	Increased drought leading to supply chain disruptions	Rising average temperatures
	Opportunity	Opportunity Developing green products to reduce environmental impact; in response to the low-carbon transition, production equipment must gradually be replaced with energy-efficient or renewable-energy-powered systems. Production processes must also adopt new technologies to meet low-carbon standards.	Innovation and development of new low-carbon products and services	Improved resource use efficiency	Enhanced corporate reputation
The Company has conducted assessments of the aforementioned risks and identified climate-related risks and opportunities that may have a significant financial impact. The corresponding response strategies are outlined as follows:					
	R: Risk / O: Opportunity	Risk / Opportunity Description	Financial Impact	Response Strategy	
	R: Risk Extreme Changes in Rainfall Patterns	Extreme Changes in Rainfall Patterns Extreme rainfall in Taiwan may negatively affect water quality and disrupt production.	Decrease in revenue	Promote water resource management and water-saving initiatives to improve water use efficiency; implement preventive measures in advance upon heavy rainfall warnings.	
	R: Risk Policies and Regulations	Policies and Regulations The “Climate Change Response Act” is expected to introduce a carbon fee in	Increase in costs	Continuously assess the impact and challenges of carbon fee-related regulations on the Company.	

		the future.		
	R: Risk Increase in Raw Material Costs	Rising Raw Material Costs Climate change may drive up the cost of key commodities, affecting operations.	Increase in costs	Manage sourcing of raw materials to mitigate price volatility.
	O. Opportunities Development of medical diagnostic software	The development of medical diagnostic software is classified as a green product and is relatively environmentally friendly.	Increased revenue	The R&D team develops and updates medical diagnostic software.
	O. Opportunities Technology	In response to the low-carbon transition trend, outsourced manufacturers are required to ensure that their production processes comply with international low-carbon standards.	Increase in costs	Outsourced manufacturers are required to comply with international low-carbon product standards, thereby enhancing product quality and standards, which in turn helps boost sales performance.
3. Description of the financial impact of extreme weather events and transition actions.	Impact of Extreme Climate Events on Financial Performance Through internal discussions and assessments, the Company has identified potential risks associated with extreme weather events such as floods, droughts, changes in precipitation patterns, and other climate anomalies that may affect production or transportation. Heavy rainfall-induced flooding can lead to temporary shutdowns of operational sites and damage to equipment, resulting in disruptions to shipments. Droughts and water shortages may hinder the normal operation of production lines, requiring measures such as reduced water usage or transporting water across regions via water trucks, thereby increasing operating costs. To address the risks of flooding from typhoons and the impacts of changing precipitation and climate patterns, the Company analyzed the potential operational and financial impacts using data from the Taiwan Climate Change Projection Information and Adaptation Knowledge Platform. Under this scenario, the number of typhoons affecting Taiwan is expected to decrease by 15% by mid-century, while the proportion of severe typhoons is projected to increase by 100%, indicating an overall rise in climate-related risks. Impact of Transition Actions on Financial Performance Under the risk of transition, the shift toward a low-carbon economy may involve widespread changes in policies, regulations, technologies, and markets. Over the analyzed period, total greenhouse gas emission control, renewable energy regulations, and shifts in consumer preferences could increase operating costs or			

	reduce sales volumes. Given that the Company operates in the medical software sector—which has relatively low environmental impact—sales are not expected to be significantly affected under different scenarios. As a result, the Company’s primary focus is on analyzing operating costs. In a low-carbon transition scenario, carbon pricing may increase both operational and supply chain costs for the consolidated entity. To address these transition risks, the Company has launched energy-saving initiatives aimed at minimizing the impact of energy and water consumption as well as waste generation on the climate. By improving energy efficiency across operations and the supply chain, the Company seeks to mitigate these impacts. However, such projects are expected to lead to increased capital expenditures and operating costs for the consolidated entity.
4. Description of how the process of identifying, assessing, and managing climate risks is integrated into the overall risk management system.	On October 31, 2024, the Board of Directors approved the Company’s “Risk Management Policy and Procedures” as the highest guiding principles for the Company’s risk management. Each management unit conducts regular assessments and reviews of risk-related matters. Senior management is responsible for strategic planning, overseeing, and implementing risk-related decisions to enhance operational efficiency and reduce strategic and operational risks. Assessment results are reported to the Board of Directors. Climate change and environmental risk management have also been incorporated into the identification of risk and opportunity topics.
5. If using scenario analysis to assess resilience to climate change risks, the following should be explained: the scenarios, parameters, assumptions, analysis factors, and main financial impacts used in the analysis.	The company has not yet used scenario analysis to assess resilience to climate change risks. In the future, various scenarios will be analyzed to formulate response strategies to mitigate potential financial losses resulting from these risks, turning crises into opportunities.
6. If there is a transformation plan in response to managing climate-related risks, please explain the content of the plan, as well as the indicators and goals used to identify and manage physical risks and transition risks.	The company actively implements risk mitigation measures to reduce organizational carbon emissions, as follows: (1) Upgrading or replacing existing equipment with more energy-efficient alternatives. (2) Conducting greenhouse gas inventories for organizational carbon emissions in accordance with regulations in the future.
7. If internal carbon pricing is used as a planning tool, the basis for price determination should be explained.	Not applicable.
8. If climate-related targets are set, the covered activities, scope of greenhouse gas emissions, planned schedule, progress achieved each year, etc., should be explained. If	The company will continue to invest in various environmental expenditures and energy-saving measures to establish carbon reduction goals. It will continue to strive towards the annual reduction targets of over 3% for greenhouse gas emissions, water usage, and waste volume.

carbon offsets or Renewable Energy Certificates (RECs) are used to achieve related goals, the source and quantity of carbon offset credits exchanged or the quantity of RECs should be disclosed.	
9. Greenhouse gas inventory, verification status, reduction targets, strategies, and specific action plans (also filled in sections 1-1 and 1-2).	In accordance with the Financial Supervisory Commission's Order No. 11203852314 issued on November 13, 2023, companies, whose paid-in capital does not exceed NT\$5 billion, should complete information disclosure reviews starting from 2026, and full disclosure starting from 2028 for the parent company. Subsidiaries included in the consolidated financial statements should complete information disclosure reviews starting from 2027, and full disclosure starting from 2029. As the current regulations do not require disclosure, it is not applicable.

2.3.6 Ethical Corporate Management – Implementation Status and Deviations from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons :

Evaluation item	Implementation status			Deviations from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
1. Establishment of ethical corporate management policies and programs (1) Does the company have an ethical corporate management policy approved by its Board of Directors, and bylaws and publicly available documents addressing its corporate conduct and ethics policy and measures, and commitment regarding implementation of such policy from the Board of Directors and the top management team?	✓		The company has established a "Code of Ethics" which sets out the principles of fair, honest, trustworthy, and transparent business practices. In order to implement the policy of integrity management and prevent non-compliant behavior, all personnel (including subsidiaries) of the company must comply with the guidelines and principles when conducting business activities. The guidelines include upholding the spirit of honesty, rigor, and professionalism in performing duties, being loyal to their duties, and not engaging in any illegal or improper activities. They must also avoid any conflict of interest that may arise between personal interests and company interests, and must not engage in any behavior that would bring discredit to the company. The company follows the law and regulations, including the Company Act, Securities and Exchange Act, Commercial Accounting Act, Political Donations Act, Anti-Corruption Act, Government Procurement Act, Conflict of Interest Avoidance Act, and other relevant laws and regulations to ensure integrity in its business operations. The company's management team and board of directors are committed to promoting the implementation of the code of ethics. The board of directors practices self-discipline and refrains from participating in discussions and voting on proposals where they or their affiliated entities have a conflict of interest that could be harmful to the company. They may only provide opinions and answer questions related to the proposal. During discussions and voting, they must abstain from voting and recuse themselves from the matter. Directors are also not allowed to represent other directors in exercising their voting rights. The board of directors practices self-discipline and refrains from engaging in any improper mutual support.	No difference.

Evaluation item	Implementation status			Deviations from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
(2)Whether the company has established an assessment mechanism for the risk of unethical conduct; regularly analyzes and evaluates, within a business context, the business activities with a higher risk of unethical conduct; has formulated a program to prevent unethical conduct with a scope no less than the activities prescribed in Article 7, paragraph 2 of the Ethical Corporate Management Best Practice Principles for TWSE/TPE Listed Companies?	✓		Our company has established the "Integrity Operating Procedures and Code of Conduct" and has disclosed it on our official website. The code of conduct prohibits bribery, accepting or offering improper benefits, providing or accepting facilitation payments, engaging in unfair competition practices, improper charitable donations or sponsorships, disclosing business secrets, and harming the rights and interests of stakeholders. We have implemented measures to prevent these behaviors and conducted education and training to ensure the implementation of our integrity management policy.	No difference.
(3)Does the company clearly set out the operating procedures, behavior guidelines, and punishment and appeal system for violations in the unethical conduct prevention program, implement it, and regularly review and revise the plan?	✓		The Company conducts its business activities based on the principles of fairness, honesty, integrity, and transparency. To implement an ethical business policy and proactively prevent unethical conduct, the Company adopted the "Ethical Corporate Management Best Practice Principles" on February 21, 2014, in accordance with the "Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies" and applicable laws and regulations in the jurisdictions where the Company and its affiliates operate. Amendments to the principles were subsequently approved by the Board of Directors on April 24, 2015, and August 9, 2019. On August 14, 2015, the Company further established the "Procedures for Ethical Management and Guidelines for Conduct," which provide specific instructions for personnel to follow when conducting business. These include detailed operating procedures, codes of conduct, disciplinary measures for violations, and grievance mechanisms. These policies are applicable not only to the Company but also to its subsidiaries, foundations in which the Company directly or	No difference.

Evaluation item	Implementation status			Deviations from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
			indirectly contributes more than 50% of funds, and other entities or organizations under its substantial control.	
2.Ethical Management Practice (1)Does the company assess the ethics records of those it has business relationships with and include ethical conduct related clauses in the business contracts?	✓		Our company conducts business activities in a fair and transparent manner. Before engaging in any business transactions, we carefully consider the legality of agents, suppliers, customers, or other business partners and avoid conducting business with those who have a record of dishonest behavior. In the code of conduct agreement signed with our suppliers, we strictly prohibit our employees and cooperating factories from directly or indirectly providing, promising, requesting, or accepting bribes, commissions, entertainment, kickbacks, improper gifts, or any other illegitimate benefits during any business activity. To establish a good relationship, we also request that our cooperating factories do not engage in any form of bribery, commissions, kickbacks, gifts, entertainment, or other illegitimate benefits with any employee of our company. If any supplier violates the code of conduct agreement and is unable to improve their behavior in a timely manner, we reserve the right to terminate the contract.	No difference.

Evaluation item	Implementation status			Deviations from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons																								
	Yes	No	Summary description																									
(2)Has the company set up a dedicated unit to promote ethical corporate management under the board of directors, and does it regularly (at least once a year) report to the board of directors on its ethical corporate management policy and program to prevent unethical conduct and monitor their implementation?	✓		The company's "Code of Conduct" specifies that the personnel department is responsible for revising, implementing, interpreting, providing consultation services, and recording related operations and supervising the execution of this regulation. It also requires regular reporting to the board of directors on the implementation status. On February 25, 2025, the company reported to the board of directors on the implementation of the Code of Conduct in 2024 as follows : <table><tr><th>Item</th><th>Execution Status</th></tr><tr><td>1</td><td>The Company has established the “Ethical Corporate Management Best Practice Principles,” which are made available on the Company’s official website and the internal network storage system (NAS) accessible to all employees. Related preventive measures and educational initiatives have also been strengthened.</td></tr><tr><td>2</td><td>New employees of the Company are required to submit a “Commitment to Integrity and Ethics” and, during onboarding training, are instructed to comply with the “Labor Contract,” “Employee Regulations,” and “Ethical Corporate Management Best Practice Principles,” as well as to uphold confidentiality obligations regarding the Company’s trade secrets.</td></tr><tr><td>3</td><td>The Company’s official website includes a dedicated Stakeholders section, providing channels for stakeholders to communicate their reasonable expectations and needs. The Company responds appropriately to stakeholder concerns related to ethical business conduct.</td></tr><tr><td>4</td><td>To prevent improper gift acceptance, all employees are required to report and surrender any gifts received from vendors to the Chairperson’s Office for centralized handling.</td></tr><tr><td>5</td><td>The Company requires key suppliers to sign a Declaration of Ethical Business Conduct, and any violations may result in liability for damages.</td></tr><tr><td>6</td><td>The Company enforces its internal intellectual property rights (IPR) policies, and in 2024, no incidents of infringement or leakage were reported.</td></tr><tr><td>7</td><td>As of the end of 2024, the Company holds a total of 29 valid domestic and international patents, 34 international trademarks, and 31 domestic trademarks.</td></tr><tr><td>8</td><td>In 2024, the Company held five Board of Directors meetings. Only one agenda item, Proposal No. 2 at the meeting on June 24, 2024—“Allocation of Employee Stock Subscription Rights to Managerial Officers and Directors with Employee Status under the 2024 Cash Capital Increase”—involved conflict of interest, requiring three directors to recuse themselves. All other matters were handled in accordance with applicable legal requirements.</td></tr><tr><td>9</td><td>We have not had any off-book accounts or secret accounts, and our audit department has carried out annual audit plans thoroughly.</td></tr><tr><td>10</td><td>In 2024, we continued to use weekly meetings or monthly motivational meetings to periodically promote and cultivate a culture of integrity and ethical business practices among all employees.</td></tr><tr><td>11</td><td>We have established a chairman's mailbox and hotline for employee communication and whistleblowing on violations of ethical business practices.</td></tr></table>	Item	Execution Status	1	The Company has established the “Ethical Corporate Management Best Practice Principles,” which are made available on the Company’s official website and the internal network storage system (NAS) accessible to all employees. Related preventive measures and educational initiatives have also been strengthened.	2	New employees of the Company are required to submit a “Commitment to Integrity and Ethics” and, during onboarding training, are instructed to comply with the “Labor Contract,” “Employee Regulations,” and “Ethical Corporate Management Best Practice Principles,” as well as to uphold confidentiality obligations regarding the Company’s trade secrets.	3	The Company’s official website includes a dedicated Stakeholders section, providing channels for stakeholders to communicate their reasonable expectations and needs. The Company responds appropriately to stakeholder concerns related to ethical business conduct.	4	To prevent improper gift acceptance, all employees are required to report and surrender any gifts received from vendors to the Chairperson’s Office for centralized handling.	5	The Company requires key suppliers to sign a Declaration of Ethical Business Conduct, and any violations may result in liability for damages.	6	The Company enforces its internal intellectual property rights (IPR) policies, and in 2024, no incidents of infringement or leakage were reported.	7	As of the end of 2024, the Company holds a total of 29 valid domestic and international patents, 34 international trademarks, and 31 domestic trademarks.	8	In 2024, the Company held five Board of Directors meetings. Only one agenda item, Proposal No. 2 at the meeting on June 24, 2024—“Allocation of Employee Stock Subscription Rights to Managerial Officers and Directors with Employee Status under the 2024 Cash Capital Increase”—involved conflict of interest, requiring three directors to recuse themselves. All other matters were handled in accordance with applicable legal requirements.	9	We have not had any off-book accounts or secret accounts, and our audit department has carried out annual audit plans thoroughly.	10	In 2024, we continued to use weekly meetings or monthly motivational meetings to periodically promote and cultivate a culture of integrity and ethical business practices among all employees.	11	We have established a chairman's mailbox and hotline for employee communication and whistleblowing on violations of ethical business practices.	No difference.
Item	Execution Status																											
1	The Company has established the “Ethical Corporate Management Best Practice Principles,” which are made available on the Company’s official website and the internal network storage system (NAS) accessible to all employees. Related preventive measures and educational initiatives have also been strengthened.																											
2	New employees of the Company are required to submit a “Commitment to Integrity and Ethics” and, during onboarding training, are instructed to comply with the “Labor Contract,” “Employee Regulations,” and “Ethical Corporate Management Best Practice Principles,” as well as to uphold confidentiality obligations regarding the Company’s trade secrets.																											
3	The Company’s official website includes a dedicated Stakeholders section, providing channels for stakeholders to communicate their reasonable expectations and needs. The Company responds appropriately to stakeholder concerns related to ethical business conduct.																											
4	To prevent improper gift acceptance, all employees are required to report and surrender any gifts received from vendors to the Chairperson’s Office for centralized handling.																											
5	The Company requires key suppliers to sign a Declaration of Ethical Business Conduct, and any violations may result in liability for damages.																											
6	The Company enforces its internal intellectual property rights (IPR) policies, and in 2024, no incidents of infringement or leakage were reported.																											
7	As of the end of 2024, the Company holds a total of 29 valid domestic and international patents, 34 international trademarks, and 31 domestic trademarks.																											
8	In 2024, the Company held five Board of Directors meetings. Only one agenda item, Proposal No. 2 at the meeting on June 24, 2024—“Allocation of Employee Stock Subscription Rights to Managerial Officers and Directors with Employee Status under the 2024 Cash Capital Increase”—involved conflict of interest, requiring three directors to recuse themselves. All other matters were handled in accordance with applicable legal requirements.																											
9	We have not had any off-book accounts or secret accounts, and our audit department has carried out annual audit plans thoroughly.																											
10	In 2024, we continued to use weekly meetings or monthly motivational meetings to periodically promote and cultivate a culture of integrity and ethical business practices among all employees.																											
11	We have established a chairman's mailbox and hotline for employee communication and whistleblowing on violations of ethical business practices.																											

Evaluation item	Implementation status			Deviations from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
(3)Has the company established policies to prevent conflict of interests, provided appropriate communication and complaint channels, and properly implemented such policies?	✓		Our company's "Integrity Management Code of Conduct" also sets forth a policy for avoiding conflicts of interest. When our company personnel encounter situations in which there is a conflict of interest with themselves or the legal entities they represent, or which could result in improper benefits for themselves, their spouse, parents, children, or any other stakeholders, they must proactively disclose such situations and report them to their immediate supervisor and the responsible department of our company (i.e., the human resources department) for appropriate guidance. Our company personnel may not use company resources for business activities outside the company and may not let such activities affect their job performance.	No difference.
(4)Does the company have effective accounting and internal control systems in place to enforce ethical corporate management? Does the internal audit unit follow the results of unethical conduct risk assessments and devise audit plans to audit compliance with the systems to prevent unethical conduct or hire outside accountants to perform the audits?	✓		To implement effective accounting and internal control systems in accordance with the principles of ethical operation, our company has established effective accounting and internal control systems for business activities with higher risks of unethical behavior. These systems are regularly reviewed as part of the risk assessment process, and there is absolutely no allowance for off-the-books accounts or secret accounts. The design and execution of these systems are constantly reviewed to ensure their continued effectiveness. The internal audit unit also includes high-risk operating items in the annual audit plan based on risk assessments, regularly checks compliance with these systems, and reports to the Audit Committee and the Board of Directors.	No difference.
(5)Does the company provide internal and external ethical corporate management training programs on a regular basis?	✓		Our company arranges annual education and training sessions, as well as seminars, related to ethical business practices for our directors and employees. These sessions include the monthly motivational meetings and weekly team meetings. For more detailed information on the relevant education and training sessions, please refer to pages 79 、 80 、 124. of our annual report.	No difference.
3.Implementation of Complaint Procedures (1)Has the company established specific whistle-blowing and	✓		The company has established the "Code of Conduct and Guidelines for Ethical Business Operations," which includes a whistleblowing and rewards system, providing a normal reporting channel, and designating appropriate personnel to	No difference.

Evaluation item	Implementation status			Deviations from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
reward procedures, set up conveniently accessible whistle-blowing channels, and appointed appropriate personnel specifically responsible for handling complaints received from whistle-blowers?			handle reported cases. The company evaluates the effectiveness of the reported facts and provides appropriate rewards to the whistleblower.	
(2)Has the company established standard operation procedures for investigating the complaints received, follow-up measures taken after investigation, and mechanisms ensuring such complaints are handled in a confidential manner?	✓		Our company has established the "Integrity Operation Procedures and Code of Conduct," which provides detailed guidelines for the investigation of reported incidents and outlines the standard operating procedures, follow-up actions to be taken after the investigation, and the relevant confidentiality mechanism.	No difference.
(3)Has the company adopted proper measures to protect whistle-blowers from retaliation for filing complaints?	✓		Our company has established the "Code of Conduct for Ethical Business Operations," which includes a reporting and rewards system and provides normal reporting channels. Appropriate personnel are assigned to handle reported matters, and effective measures are taken in response to the facts reported.	No difference.
4.Strengthening Information Disclosure Does the company disclose its ethical corporate management policies and the results of their implementation on its website and the Market Observation Post System (MOPS)?	✓		Our company's website is www.amcad.com.tw . We regularly disclose or update information related to our code of conduct and the progress of our integrity initiatives on our company website and the Taiwan Stock Exchange Market Observation Post (MOPS).	No difference.
5.If the company has adopted its own ethical corporate management best practice principles based on the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies, please describe any deviations between the principles and their implementation :				

Evaluation item	Implementation status			Deviations from the Ethical Corporate Management Best Practice Principles for TWSE/TPEX Listed Companies and the Reasons
	Yes	No	Summary description	
Our company has established the "Code of Conduct for Ethical Management" and the "Operating Procedures and Behavior Guidelines for Ethical Management," and has implemented them without any violations. The content and related operations are not significantly different from the "Code of Conduct for Ethical Management" for listed and OTC companies.				
6.Other important information to facilitate a better understanding of the status of operation of the company’s ethical corporate management policies (e.g., the company’s reviewing and amending of its ethical corporate management best practice principles) :				
A. The company adheres to the corporate culture of "Integrity, Reciprocity, and Courtesy" as a code of conduct :				
① Integrity - uphold the principles of ethical corporate management and regularly report the implementation of ethical management to the board of directors.				
② Reciprocity - interact with stakeholders, including employees, shareholders, upstream and downstream suppliers and customers, consumers, communities, and banks, on the basis of reciprocity and share the economic value created by the company.				
③ Courtesy - place emphasis on corporate ethics internally and comply with laws and ethical standards externally.				
B. The company pays attention to the development of domestic and international ethical management regulations at all times and encourages directors, managers, and employees to provide suggestions for improving the company and enhancing the effectiveness of ethical management.				
C. All 13 directors have signed the Integrity Declaration, reaching a ratio of 100%.				
D. The company has signed the Integrity Management Statement with its suppliers and strictly requires its employees and all cooperation partners not to provide, promise, request or receive bribes, commissions, entertainment, kickbacks, improper gifts or any other illegitimate benefits, directly or indirectly, in any business activities. To establish a good cooperative relationship, the company also requests its cooperation partners not to engage in any form of direct or indirect form of contract, bribery, commission, kickback, gift, entertainment, or other improper benefits to any employee of the company. In case a supplier violates the ethical management policy and fails to make immediate improvement, the company may terminate the contract. As of 2024, all contracted suppliers have signed a declaration of integrity in business operations, representing 100% compliance for the entire year				
E. The company has established a stakeholder section on its official website, hoping that stakeholders can understand their reasonable expectations and needs through appropriate communication channels. The company will respond appropriately to important corporate social responsibility issues that stakeholders are concerned about.				
F. The company has implemented relevant measures regarding intellectual property rights and has not had any infringement or leakage incidents in 2024.				
G. The company does not have any secret external or secret accounts, and the audit unit executes the annual audit plan strictly.				
H. The company has signed the Anti-Money Laundering and Counter-Terrorism Financing Statement with Taiwan Depository & Clearing Corporation, Fubon Securities, and other banks with whom it has business transactions.				

2.3.7 Other significant information that will provide a better understanding of the state of the company's implementation of corporate governance :

1. The company follows the "Guidelines for Establishing Internal Control Systems for Public Companies to Handle Material Nonpublic Information," and has added the "Operating Procedures for Preventing Insider Trading Management." This system has been communicated to all employees, managers, and directors to prevent violations and occurrences of insider trading.
2. The company has established the "Corporate Governance Best Practice Guidelines," "Corporate Social Responsibility Guidelines," "Code of Ethics," "Integrity Management Guidelines," and "Operating Procedures and Conduct Guidelines for Integrity Management." These guidelines have been posted on the company's official website and communicated to all directors, managers, and employees to ensure compliance.
3. The courses attended by the managers of our company in 2024 are as follows :

(1) Financial Officer : Ann Chen

Appointed on October 31, 2024, Ms. Chen assumed the CFO role in the second half of the year. No relevant training programs were arranged in 2024, and participation will be scheduled in accordance with the company's training plan in 2025.

(2) Audit Manager : Lin Tung-Ku

Item	Institution of Continuing Education	Course title	Training hours
1	The Institute of Internal Auditors-Chinese Taiwan	Applying Digital Technology to Explore and Improve Operational Processes and Fraud Detection – A Practical Audit Perspective	6
2	Accounting Research and Development Foundation, R.O.C. (Taiwan)	"Practical Internal Control in Response to New Annual Report and ESG Disclosure Regulations" – Latest Legal Analysis and Internal Control Practices for Annual Report, Sustainability Information, and Financial Reporting Preparation	6

(3) Audit agent : Tung Yun-Ju

Item	Institution of Continuing Education	Course title	Training hours
1	The Institute of Internal Auditors-Chinese Taiwan	Interpretation of Financial Analysis Indicators and Prevention of Operational Risks	6
2	The Institute of Internal Auditors-Chinese Taiwan	Power BI – Risk Assessment and Visual Analytics	6

In the future, we will continue to arrange for our managers and supervisors to participate in relevant training courses.

4. The courses attended by the directors of our company in 2024 are as follows :

Title	Name	Training dates	Organizer	Training Course	Training hours
Chairman	Lee Yi-Li	2024.9.27	Chinese Corporate Governance Association (CCGA)	Construction Project Management and Practices	3
		2024.11.14	Chinese Finance and	Post-U.S. Presidential Election	3

			Economic Development Association	Global Political and Economic Analysis	
		2024.11.22	Chinese Finance and Economic Development Association	Circular Economy and Emerging Trends in Sustainable Management	3
Director	Chang King-Jen	2024.10.23	Business Sustainability Development Association	GHG Protocol Corporate Standard and Scope 3 Standard Awareness Course	7
Director	Sheu Jin-Chuan	2024.10.26	Accounting Research and Development Foundation	Legal Liabilities and Case Studies Related to Corporate Control Disputes	3
Director	Chiou Shu-Ti	2024.9.11	Business Sustainability Development Association	ACT-D Nature Disclosure Seminar & GRI 101 Biodiversity Standard Traditional Chinese Launch	4
Director	Tseng Gary T	2024.2.23	Chinese Association for Corporate Management and Sustainable Development	Corporate Governance Regulations – 1. Insider Trading Prevention from an Internal Control Perspective 2. Dividend Policy Regulations and Practical Issues	3
Director	Wang Tsay-Ping	2024.2.23	Chinese Association for Corporate Management and Sustainable Development	Corporate Governance Regulations – 1. Insider Trading Prevention from an Internal Control Perspective 2. Dividend Policy Regulations and Practical Issues	3
		2024.10.8	Taipei Exchange (TPEX)	The Interplay of Digital Finance and Sustainable Finance in the Era of AI – Special Lecture	3
Independent director	Chang Ching-Tian	2024.10.16	Chinese Corporate Governance Association (CCGA)	The 20th (2024) International Corporate Governance Summit – Focusing on Governance Priorities and Leveraging Talent Advantages	6
Independent director	Huang Weng-Foung	2024.8.13	Securities and Futures Institute (SFI)	Carbon Credit Trading Mechanisms and Applications in Carbon Management	3
		2024.12.2	Chinese Corporate Governance Association (CCGA)	AI and the Industrial Revolution: Generative AI Systems Based on the iFA Framework	3
		2024.12.2	Chinese Corporate Governance Association (CCGA)	New Perspectives on Corporate Strategic Management (New Nine Principles)	3
Independent director	Lin She-Yi	2024.2.23	Chinese Association for Corporate Management and Sustainable Development	Corporate Governance Regulations – 1. Insider Trading Prevention from an Internal Control Perspective 2. Dividend Policy Regulations and Practical Issues	3
		2024.11.16	Accounting Research	Latest ESG Sustainability Policies	3

			and Development Foundation	and Regulations Related to Annual Report Preparation	
--	--	--	-------------------------------	---	--

5. For other information, please refer to the execution status of corporate governance-related items of our company on the "Taiwan Stock Exchange and Taipei Exchange Market Observation Post System".

2.3.8 The implementation status of internal control system.

1. A Statement on Internal Control : Please visit the “Market Observation Post System (MOPS)” and navigate to : Corporate Governance → Internal Control Section → Internal Control Statement Announcements for further information.

<https://mops.twse.com.tw/mops/#/web/t06sg20> °

2. Where a CPA has been hired to carry out a special audit of the internal control system, furnish the CPA audit report : Not applicable.

2.3.9 Material resolutions of a shareholders meeting or a board of directors meeting during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report :

1. Important resolutions passed in the 2024 annual general meeting of our company are as follows :

(1) Agenda : To approve the individual financial statements, consolidated financial statements, and business report for the fiscal year 2023.

Resolution : The voting results of the shareholders present (including those exercising their voting rights electronically) show that the affirmative votes have exceeded the legally required threshold, and the proposal is passed accordingly.

The number of voting rights of attending shareholders	Number of votes in favor	Number of dissenting votes	Invalid votes	Abstain/Non-vote count
28,137,293	28,056,290	47,711	0	33,292
100.00%	99.71%	0.16%	0.00%	0.11%

(2) Agenda : Approval of the allocation of the 2023 deficit and the replenishment of accumulated deficit through capital surplus.

Resolution : The voting results of the shareholders present (including those exercising their voting rights electronically) show that the affirmative votes have exceeded the legally required threshold, and the proposal is passed accordingly.

The number of voting rights of attending shareholders	Number of votes in favor	Number of dissenting votes	Invalid votes	Abstain/Non-vote count
28,137,293	28,053,288	50,713	0	33,292
100.00%	99.70%	0.18%	0.00%	0.11%

(3) Agenda : Discussion on Conducting a Private Placement of Common Shares through Cash Capital Increase.

Resolution : The voting results of the shareholders present (including those exercising their voting rights electronically) show that the affirmative votes have exceeded the legally required threshold, and the proposal is passed accordingly.

The number of voting rights of attending shareholders	Number of votes in favor	Number of dissenting votes	Invalid votes	Abstain/Non-vote count
28,137,293	28,051,348	49,653	0	36,292
100.00%	99.69%	0.17%	0.00%	0.12%

(4) Agenda : Discussion on Lifting the Restriction on Directors from Engaging in Competitive Conduct.

Resolution : The voting results of the shareholders present (including those exercising their voting rights electronically) show that the affirmative votes have exceeded the legally required threshold, and the proposal is passed accordingly.

The number of voting rights of attending shareholders	Number of votes in favor	Number of dissenting votes	Invalid votes	Abstain/Non-vote count
28,137,293	28,045,287	58,716	0	33,290
100.00%	99.67%	0.20%	0.00%	0.11%

2.The important resolutions adopted by the Board of Directors during the period from the fiscal year 2024 to the date of publication of the annual report are as follows :

Date/session number	Important agenda items and decisions
2024.02.23 6th 4th	1. Proposal for approval of the 2023 financial statements and business report.
	2. Proposal for approval of the 2023 deficit compensation plan.
	3. Proposal for discussion on conducting a private placement of common shares through cash capital increase.
	4. Proposal for discussion on lifting the restriction on directors from engaging in competitive conduct.
	5. Proposal for approval of convening the 2024 physical Annual General Meeting of Shareholders.
	6. Proposal for approval of the 2023 assessment of the effectiveness of the internal control system and the internal control system statement.
	7. Proposal for discussion on amendments to the “Internal Control System” and the “Procedures for Self-Assessment of Internal Control.”
	8. Proposal for discussion on amendments to the “Board Meeting Rules of Procedure.”
	9. Proposal for discussion on amendments to the “Audit Committee Charter.”
	10. Proposal for discussion on the remuneration of the certifying CPA and evaluation of their independence.
	11. Proposal for discussion on reconfirming the procedures and general policy for prior approval of non-assurance services provided by Ernst & Young and its affiliates, as well as the list of such services.
	12. Proposal for approval of the conversion of employee stock option certificates into common shares in fulfillment of the employee stock subscription for the fourth quarter of 2023.
	13. Proposal for approval of establishing credit lines with financial institutions.
	The above resolutions were passed by the chairman after consulting all attending directors and receiving no objections.
2024.05.02 6th 5th	1. Proposal for approval of the consolidated financial statements for the first quarter of 2024.

	2. Proposal for discussion on the proposed cash capital increase through the issuance of common shares.
	3. Proposal for approval of the conversion of employee stock option certificates into common shares for the first quarter of 2024.
	The above resolutions were passed by the chairman after consulting all attending directors and receiving no objections.
2024.06.24 6th 6st	1. Proposal for discussion on determining the issuance price and related matters for the 2024 cash capital increase.
	Resolution : Upon inquiry by the Chairperson, all attending directors agreed without objection to adopt the simple arithmetic average of the closing prices of common shares over the previous five business days, which is NT\$27.78, as the reference price. Applying a minimum threshold of 70% of the reference price, the issuance price for this cash capital increase was set at NT\$23 per share (at a premium), and the proposal was approved unanimously.
	2. Proposal for discussion on the participation of managerial officers and directors with employee status in the employee stock subscription under the 2024 cash capital increase.
	Resolution : Except for three interested parties—Chairperson Lee Yi-Li, Vice Chairperson Lee I-Lin, and Director Lee Chen-Chia—who recused themselves from discussion and voting due to conflicts of interest, all other attending directors unanimously approved the proposal after inquiry by the Acting Chairperson.
2024.08.08 6th 7th	1. Proposal for approval of the consolidated financial statements for the second quarter of 2024.
	2. Proposal for approval of the appointment of the Corporate Governance Officer.
	3. Proposal for discussion on lifting the restriction on managerial officers from engaging in competitive conduct.
	The above resolutions were passed by the chairman after consulting all attending directors and receiving no objections.
2024.10.31 6th 8rd	1. Proposal for approval of the appointment of the Head of Finance and Accounting.
	2. Proposal for approval of the consolidated financial statements for the third quarter of 2024.
	3. Proposal for discussion on the 2025 business plan.
	4. Proposal for discussion on the establishment of the Sustainability Development Committee and the adoption of its organizational charter.
	5. Proposal for the appointment of the first-term members of the Sustainability Development Committee.
	6. Proposal for discussion on the formulation of the “Procedures for the Preparation and Assurance of the Sustainability Report.”
	7. Proposal for discussion on the formulation of the internal control system for “Sustainability Information Management Operations.”
	8. Proposal for discussion on the formulation of the “Risk Management Policy and Procedures.”
	9. Proposal for discussion on the 2025 internal audit plan.
	10. Proposal for discussion on the investment in domestic listed

	financial stocks.
	11. Proposal for discussion on the distribution of 2024 year-end and performance bonuses.
	12. Proposal for approval of the compensation package for the newly appointed Head of Finance and Accounting.
	13. Proposal for approval of the conversion of employee stock option certificates into common shares for the fourth quarter of 2024.
	The above resolutions were passed by the chairman after consulting all attending directors and receiving no objections.
2025.02.25 6th 9th	1. Proposal for approval of the 2024 financial statements and business report.
	2. Proposal for approval of the 2024 deficit compensation plan.
	3. Proposal for discussion on conducting a private placement of common shares through cash capital increase.
	4. Proposal for discussion on amendments to the Articles of Incorporation.
	5. Proposal for approval of convening the 2025 physical Annual General Meeting of Shareholders.
	6. Proposal for approval of the 2024 assessment of the effectiveness of the internal control system and the internal control system statement.
	7. Proposal for discussion on amendments to the Internal Control System.
	8. Proposal for discussion on the remuneration of the certifying CPA and evaluation of their independence.
	9. Proposal for discussion on reconfirming the procedures and general policy for prior approval of non-assurance services provided by Ernst & Young and its affiliates, as well as the list of such services.
	The above resolutions were passed by the chairman after consulting all attending directors and receiving no objections.

3. Review of the implementation of resolutions passed at the 2024 Annual Shareholders' Meeting :

Resolution items	Execution status
1. Approval of the 2023 financial statements and business report.	Disclosed on the date of the shareholders' meeting.
2. Approval of the 2023 deficit compensation plan.	Recorded in accordance with the resolution of the shareholders' meeting.
3. Discussion on conducting a private placement of common shares through cash capital increase.	Executed as resolved by the shareholders' meeting.
4. Discussion on lifting the restriction on directors from engaging in competitive conduct.	Disclosed on the date of the shareholders' meeting.

2.3.10 Where, during the most recent fiscal year or during the current fiscal year up to the date of publication of the annual report, a director or supervisor has expressed a dissenting opinion with respect to a material resolution passed by the board of directors, and said dissenting opinion has been recorded or prepared as a written declaration, disclose the principal content thereof : In the latest fiscal year and up until the date of printing of the annual

report, the directors of the Company have not expressed any dissenting opinions regarding the important resolutions passed by the Board of Directors.

2.4 Information on the public fees for certified public accountants for visa applications.:

2.4.1 Information on the public fees for certified public accountants for visa applications

Amount unit: NTD thousands

Accounting Firm Name	Auditor Name	Audit Period	Audit Fee	non-audit fee	Total Fee	Remarks
Ernst & Young	Yu Chien-ju	January 1, 2024 to December 31, 2024	700	269	969	1.Tax audit 50 thousands °
	Chang Chiao-Ying					2.Employee stock option certificate.107 thousands ° 3. Cash capital increase certification. 56 thousands ° 4. Other 56 thousands °

2.4.2 If the accounting firm is changed and the audit fees for the year of change are lower than the audit fees for the previous year, the amounts of audit fees before and after the change and the reasons for the change should be disclosed. However, there is no such situation.

2.4.3 If the reduction in audit fees compared to the previous year is more than 10%, the amount, percentage, and reason for the reduction should be disclosed. However, there is no such situation.

2.5 Information on changing the accounting firm :Not applicable. °

2.6 There is no information to be disclosed regarding the Chairman, General Manager, Manager responsible for finance or accounting affairs who have worked for the accounting firm or its related enterprises within the past year, including their names, titles, and periods of employment with the accounting firm or its related enterprises, as there is no such situation.

2.7 Transfer of Stock Options and Changes in Equity Pledge of Directors, Supervisors, Managers and Shareholders Holding More Than 10% of Shares in the Latest Year and as of the Date of Printing of Annual Report:

2.7.1 Changes in Shareholding of Directors, Supervisors, Managerial Officers, and Major Shareholders :

Job title	Name	2024		As of Mar. 31, 2025	
		Shareholding increase (or decrease)	Pledged shareholding increase (or decrease)	Shareholding increase (or decrease)	Pledged shareholding increase (or decrease)
Chairman / General Manager	Lee Yi-Li	172,455	0	0	0
Vice Chairman	Phytohealth Corp. Representative : Lee I-Lin	3,217,101	0	0	0
		100,000	0	0	0
Director	Phytohealth Corp. Representative : Lee Chen-Chia	3,217,101	0	0	0
		77,000	0	0	0
Director	Chang King-Jen	0	0	0	0
Director	Maywufa Company Limited. Representative : Sheu Jin-Chuan	521,213	0	0	0
		0	0	0	0
Director	Phytohealth Corp. Representative : Chen Wal-Ter	3,217,101	0	0	0
		0	0	0	0
Director	Jen Yu Ltd. Representative : Chiou Shu-Ti	0	0	0	0
		0	0	0	0
Director	Maywufa Company Limited. Representative : Wang Tsay-Ping	521,213	0	0	0
		0	0	0	0
Director	Jen Yu Ltd. Representative : Tseng Gary T	0	0	0	0
		24,150	0	0	0
Independent Director	Chang Ching-Tian	0	0	0	0
Independent Director	Huang Weng-Foung	0	0	0	0
Independent Director	Li Hsueh-Yu	0	0	0	0
Independent Director	Lin She-Yi	0	0	0	0
Vice President	Evelyn Ning	2,000	0	0	0
Financial Officer	Chang Wen-Lan (Note 1)	5,000	0	0	0
Financial Officer(Acting)	Tai Yu-Ju (Note 2)	0	0	0	0
Financial Officer	Ann Chen (Note 3)	0	0	0	0
Corporate Governance Officer	Huang Chih-Yuan (Note 4)	31,000	0	0	0
Major Shareholder	Phytohealth Corp.	0	0	0	0

- Note 1: Chang Wen-Lan, Head of Finance and Accounting and Corporate Governance Officer, was relieved of her duties on August 8, 2024, due to internal job reassignment.
- Note 2: Tai Yu-Ju served as Acting Head of Finance and Accounting, announced on August 8, 2024, and was relieved of the acting role on October 31, 2024.
- Note 3: Chen Chao-Ming was officially appointed as Head of Finance and Accounting by resolution of the Board of Directors on October 31, 2024.
- Note 4: Huang Chih-Yuan was officially appointed as Corporate Governance Officer by resolution of the Board of Directors on August 8, 2024.

2.7.2 The counterparty for the transfer or pledge of stock options is a related party: None.

2.8 Information of Relationship among Top 10 Shareholders Who Are Related, Spouses, or Relatives within the Second Degree of Kinship:

April 5, 2025 (Book Closure Date)

Name(Note1)	Shareholding		Shareholding of spouse and minor children		Total Shareholding by nominee arrangements		Specify the name of the entity or person and their relationship to any of the other top 10 shareholders with which the person is a related party or has a relationship of spouse or relative within the 2nd degree (Note 3)		Remark
	Shares	%	Shares	%	Shares	%	Shares	%	
PhytoHealth Corporation	22,155,049	34.98%	0	0.00%	0	0.00%	Maywufa Company Ltd.	Affiliated Company	None
Representative: Lee Yi-Li	582,327	0.92%	0	0.00%	0	0.00%	Maywufa Company Ltd. Lee Chen-Chia	Vice Chairperson of the company Father and daughter	None
Maywufa Company Ltd.	3,994,996	6.31%	0	0.00%	0	0.00%	PhytoHealth Corporation	Affiliated Company	None
Representative: Lee Chen-Chia	595,375	0.94%	0	0.00%	0	0.00%	Maywufa Company Ltd. PhytoHealth Corporation Lee Yi-Li	Chairperson of the company Director of the company Father and daughter	None
Chang Chin-Chien	2,902,000	4.58%	0	0.00%	0	0.00%	None	None	None
Foxsemicon Integrated Technology Inc.	1,300,000	2.05%	0	0.00%	0	0.00%	None	None	None
Representative: Kao Hsin-Ming	0	0.00%	0	0.00%	0	0.00%	None	None	None
Huang Jui-Tang	850,000	1.34%	0	0.00%	0	0.00%	None	None	None
Yao-Xin Biomedical Venture Capital Limited Partnership	600,000	0.95%	0	0.00%	0	0.00%	None	None	None
Lee Chen-Chia	595,375	0.94%	0	0.00%	0	0.00%	Maywufa Company Ltd. PhytoHealth Corporation Lee Yi-Li	Chairperson of the company Director of the company Father and daughter	None
Lee Yi-Li	582,327	0.92%	0	0.00%	0	0.00%	PhytoHealth Corporation Maywufa Company Ltd. Lee Chen-Chia	Chairperson of the company Vice Chairperson of the company Father and daughter	None
Lin Chiu-Chuan	553,500	0.87%	0	0.00%	0	0.00%	None	None	None
Chen Ming-Chang	478,667	0.76%	0	0.00%	0	0.00%	None	None	None

Note1 : All of the top 10 shareholders should be listed, and the names of corporate/juristic person shareholders and their representatives should be listed separately.

Note2 : The shareholding ratio (%) is calculated as the total numbers of shares respectively held by the shareholder, their spouse and minor children, or through nominees.

Note3 : Disclose the relationships among the above-listed shareholders, including corporate/juristic person shareholders and natural person shareholders, in accordance with the provisions of the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

2.9 Shares Held by Company, Directors, Managers of Company, and Businesses Controlled Directly or Indirectly by Company of Same Reinvestment Business and Consolidated Calculation of Comprehensive Shareholding Ratio:

March 31, 2025 Unit : Thousand shares

Investee enterprise (Note)	Investment by the Company		Investment by the Directors, Managerial Officers and Directly or Indirectly Controlled Entities of the Company		Total investment	
	Shares	%	Shares	%	Shares	%
Broadsound Corporation	8,073	40.00%	3,731	18.48%	11,804	58.48%

Note : This refers to investee enterprises in which the Company makes long-term investment calculated according to the equity method.

3. Capital Overview

3.1 Capital and shares

3.1.1 Source of Capital

1. Sources of Capital

Unit: Shares; NTD

Month/ year	Issued price	Authorized capital		Paid-in capital		Remarks		
		Shares	Amount (NTD)	Shares	Amount (NTD)	Sources of capital	Capital paid in by assets other than cash	Other
12/2008	10	30,000,000	300,000,000	5,000,000	50,000,000	Set up capital (Note1) 50,000,000	None	None
12/2009	10	30,000,000	300,000,000	7,650,000	76,500,000	None	Know-How Pricing (Note2) 26,500,000	None
10/2012	10	30,000,000	300,000,000	15,000,000	150,000,000	Cash capital increase (Note3) 73,500,000	None	None
12/2012	10	30,000,000	300,000,000	14,375,000	143,750,000	Capital Reduction (Note4) 6,250,000 (Shareholder Abandonment of Shares)	None	None
11/2013	10	50,000,000	500,000,000	36,000,000	360,000,000	Cash capital increase (Note5) 161,800,000	Know-How Pricing (Note5) 54,450,000	None
03/2015	38	100,000,000	1,000,000,000	40,800,000	408,000,000	Cash capital increase (Note6) 48,000,000	None	None
03/2016	10	100,000,000	1,000,000,000	40,870,000	408,700,000	Employee stock option shares (Note7) 700,000	None	None
07/2016	30	100,000,000	1,000,000,000	52,670,000	526,700,000	Cash capital increase (Note8) 118,000,000	None	None
03/2017	10	100,000,000	1,000,000,000	52,695,000	526,950,000	Employee stock option shares (Note9) 250,000	None	None
03/2018	10	100,000,000	1,000,000,000	52,747,000	527,470,000	Employee stock option shares (Note10) 520,000	None	None
05/2018	10	100,000,000	1,000,000,000	52,912,000	529,120,000	Employee stock option shares (Note11) 1,650,000	None	None
03/2019	10	100,000,000	1,000,000,000	52,990,400	529,904,000	Employee stock option shares (Note12) 784,000	None	None
03/2020	10	100,000,000	1,000,000,000	53,221,400	532,214,000	Employee stock option shares (Note13) 231,000	None	None
12/2023	10	100,000,000	1,000,000,000	53,256,400	532,564,000	Employee stock option shares (Note14) 35,000	None	None
03/2024	10	100,000,000	1,000,000,000	53,301,400	533,014,000	Employee stock option shares (Note15) 45,000	None	None
05/2024	10	100,000,000	1,000,000,000	53,318,400	533,184,000	Employee stock option shares (Note16) 17,000	None	None
08/2024	10	100,000,000	1,000,000,000	63,318,400	633,184,000	Cash capital increase (Note17) 17,000	None	None
12/2024	10	100,000,000	1,000,000,000	63,332,900	633,329,000	Employee stock option shares (Note 18) 17,000	None	None

Note1 : Approved by the Taipei City Government on December 26, 2008, with reference number 09792235310.

Note2 : Approved by the Taipei City Government on December 9, 2009, with reference number 09891463000.

Note3 : Approved by the Taipei City Government on October 26, 2012, with reference number 10189102400.

Note4 : Approved by the Taipei City Government on December 14, 2012, with reference number 10190611000.

Note5 : Approved by the Taipei City Government on November 22, 2013, with reference number 10289539520.

Note6 : Approved by the Taipei City Government on April 10, 2015, with reference number 10482737310.

Note7 : Approved by the Taipei City Government on March 24, 2016, with reference number 10582285910.

Note8 : Approved by the Ministry of Economic Affairs on July 26, 2016, with reference number 10501185040.
 Note9 : Approved by the Ministry of Economic Affairs on March 10, 2017, with reference number 10601030400.
 Note10 : Approved by the Ministry of Economic Affairs on March 21, 2018, with reference number 10701026170.
 Note11 : Approved by the Ministry of Economic Affairs on May 16, 2018, with reference number 10701049220.
 Note12 : Approved by the Ministry of Economic Affairs on March 13, 2019, with reference number 10801027600.
 Note13 : Approved by the Ministry of Economic Affairs on March 18, 2020, with reference number 10901039890.
 Note14 : Approved by the Ministry of Economic Affairs on December 19, 2023, with reference number 11230221950.
 Note15 : Approved by the Ministry of Economic Affairs on March 19, 2024, with reference number 11330039890.
 Note16 : Approved by the Ministry of Economic Affairs on May 28, 2024, with reference number 11330083290.
 Note17 : Approved by the Ministry of Economic Affairs on August 19, 2024, with reference number 11330145620.
 Note18 : Approved by the Ministry of Economic Affairs on December 10, 2024, with reference number 11330203560.

2. Type of stock

April 5, 2025 (Book Closure Date) Unit: share

Type of stock	Authorized capital			Remarks
	Outstanding shares (Note)	Unissued shares	Total	
Common stock	63,332,900	36,667,100	100,000,000	Our company is an over-the-counter (OTC) listed stock.

3. Related information of the general declaration system: Not applicable.

3.1.2 List of Major Shareholders:

April 5, 2025 (Book Closure Date) Unit: share

Name of major shareholder	Shareholding (shares)	Shareholding (%)
PhytoHealth Corporation	22,155,049	34.98%
Maywufa Company Ltd.	3,994,996	6.31%
Chang Chin-Chien	2,902,000	4.58%
Foxsemicon Integrated Technology Inc.	1,300,000	2.05%
Huang Jui-Tang	850,000	1.34%
Yao-Xin Biomedical Venture Capital Limited Partnership	600,000	0.95%
Lee Chen-Chia	595,375	0.94%
Lee Yi-Li	582,327	0.92%
Lin Chiu-Chuan	553,500	0.87%
Chen Ming-Chang	478,667	0.76%

3.1.3 Company Dividend Policy and Implementation Status

1. The dividend policy stipulated in the company's articles of association:

Article 31 of the Company's Articles of Incorporation stipulates that, upon the closing of the annual accounts, if there is any surplus, and after payment of all taxes and dues and offsetting prior years' losses, 10% shall first be allocated as legal reserve in accordance with the law, and any necessary special reserve shall be adjusted. The remaining balance, combined with undistributed earnings from previous years, shall be subject to an appropriation plan proposed by the Board of Directors, with at least 50% of the distributable earnings to be allocated and submitted to the shareholders' meeting for approval.

The Company's dividend policy is determined by the Board of Directors based on the business plan, investment projects, capital budget, and internal and external environmental changes, and is distributed upon resolution by the shareholders' meeting. In principle, the Company adopts a balanced dividend policy, allocating dividends in the form of approximately 50% cash and 50% stock. However, adjustments may be made depending on the Company's cash flow, profitability, and future expansion needs.

2. The proposed dividend distribution for this shareholder meeting is as follows: After the settlement of the fiscal year ending on 31 December 2024, there are no retained earnings, and there are no profits available for distribution.

3.1.4 The impact of proposed bonus shares on the company's business performance and earnings per share is not applicable.

3.1.5 The remuneration of the employee and director:

1. The percentage or range of employee and director remuneration as stated in the company's articles of association is as follows:

Article 30 of our company's articles of association stipulates:

In the event that the company has profits for the year (defined as profit before tax, after deducting employee and director remuneration), after reserving an amount to make up for any accumulated losses, if there is still a surplus, three to six percent shall be allocated for employee remuneration and no more than four percent for director remuneration. The resolution shall be passed by a two-thirds majority of the attending directors with more than half of the attending directors in favor, and shall be reported to the shareholders'

meeting.

Employee remuneration mentioned in the preceding paragraph may be paid in the form of stock or cash and may include employees of subsidiary companies who meet certain conditions.

2. Basis for estimation and accounting treatment: As the Company is still operating at a loss for fiscal year 2024, this provision is not applicable.

3. Board-approved proposed distribution of employee compensation and directors' remuneration: Not applicable due to continued loss in fiscal year 2024.

4. Actual distribution of employee bonuses and directors'/supervisors' remuneration for the previous fiscal year (including number of shares, amount, and stock price), and explanation of any differences with previously recognized amounts: The Company's 2024 Annual General Meeting approved the deficit compensation plan for fiscal year 2023. As there was no distributable profit, no employee bonuses or directors' remuneration were paid. There was no discrepancy between the actual distribution and the original resolution of the Board of Directors.

3.1.6 Buyback of Treasury Stock: None.

3.2 Corporate bonds: None.

3.3 Preferred shares: None.

3.4 Global depository receipts: None.

3.5 Employee share subscription warrants and new restricted employee shares :

3.5.1 Unexpired employee stock option certificates and their impact on shareholders' rights and interests

March 31, 2025

Type of employee share subscription warrants	Employee stock option certificate issued in 2019		Employee stock option certificate issued in 2021		Employee stock option certificate issued in 2023	
Issue (handling) date and total units	2019/4/17 , 500 units		2021/7/29 , 1000 units		2023/7/10 , 500 units	
Issue (processing) date	2019/8/2	2020/2/21	2021/8/5	2022/5/9	2023/8/2	2023/11/10
Number of units issued	290 units	140 units	260 units	90 units	80 units	70 units
Unissued Units Available	0 unit		0 unit		350 units	
The ratio of the number of issued subscription shares to the total number of issued shares (%)	0.46%	0.26%	0.41%	0.14%	0.13%	0.11%
Subscription Duration	7 years	7 years	5 years	5 years	5 years	5 years
Duration	2021/8/2 ~ 2026/8/1	2022/2/21 ~ 2027/2/20	2023/8/5 ~ 2026/8/4	2024/5/9 ~ 2027/5/8	2025/8/2 ~ 2028/8/1	2025/11/10 ~ 2028/11/9
Performance method	Issuance of new shares delivery	Issuance of new shares delivery	Issuance of new shares delivery	Issuance of new shares delivery	Issuance of new shares delivery	Issuance of new shares delivery
Vesting period and percentage (%)	(A) Two years after the expiry of the grant of the employee stock option certificate, the right to exercise the stock option is limited to 25% of the number of the employee stock option certificates granted. (B) Three years after the expiry of the grant of the employee stock option certificate, the right to exercise the stock option is limited to 35% of the number of the employee stock option certificates granted. (C) Four years after the expiry of the employee stock option certificate granted, the stock option right can be exercised for 55% of the number of employee stock option certificates granted. (D) Five years after the expiry of the employee		(A) Two years after the expiry of the grant of the employee stock option certificate, the right to exercise the stock option is limited to 50% of the number of the employee stock option certificates granted. (B) Three years after the expiry of the grant of the employee stock option certificate, the right to exercise the stock option is limited to 75% of the number of the employee stock option certificates granted. (C) Four years after the expiry of the employee stock option certificate granted, the stock option right can be exercised for 100% of the number of employee stock option certificates granted.		(A) Two years after the expiry of the grant of the employee stock option certificate, the right to exercise the stock option is limited to 50% of the number of the employee stock option certificates granted. (B) Three years after the expiry of the grant of the employee stock option certificate, the right to exercise the stock option is limited to 75% of the number of the employee stock option certificates granted. (C) Four years after the expiry of the employee stock option certificate granted, the stock option right can be exercised for 100% of the number of employee stock option certificates granted.	

Type of employee share subscription warrants	Employee stock option certificate issued in 2019		Employee stock option certificate issued in 2021		Employee stock option certificate issued in 2023	
	stock option certificate granted, the right to exercise the stock option is limited to 85% of the number of employee stock option certificates granted. (E) Six years after the expiry of the employee stock option certificate granted, the right to exercise the stock option is limited to 100% of the number of employee stock option certificates granted.					
Number of shares subscribed through exercise of the warrants	0 shares	17,000 shares	80,000 shares	0 shares	0 shares	0 shares
Amount of the shares subscribed through exercise of the warrants (NT\$)	0	391,000	1,440,825	116,550	0	0
Number of unexecuted subscriptions	40,000 shares	33,000 shares	57,500 shares	50,000 shares	40,000 shares	50,000 shares
Number of unexercised shares Subscription price per share of the unexercised shares(NT\$)	24.42	22.46	16.11	16.65	21.88	24.51
Ratio of the number of unexercised shares to the total number of issued shares (%)	0.06%	0.05%	0.09%	0.08%	0.06%	0.08%
The effect on shareholders' equity	If the number of shares increased by full implementation accounts for 0.06% of the current issued shares of 63,332,900 shares, it will have little impact on shareholders' equity.	If the number of shares increased by full implementation accounts for 0.05% of the current issued shares of 63,332,900 shares, it will have little impact on shareholders' equity.	If the number of shares increased by full implementation accounts for 0.09% of the current issued shares of 63,332,900 shares, it will have little impact on shareholders' equity.	If the number of shares increased by full implementation accounts for 0.08% of the current issued shares of 63,332,900 shares, it will have little impact on shareholders' equity.	If the number of shares increased by full implementation accounts for 0.06% of the current issued shares of 63,332,900 shares, it will have little impact on shareholders' equity.	If the number of shares increased by full implementation accounts for 0.08% of the current issued shares of 63,332,900 shares, it will have little impact on shareholders' equity.

3.5.2 Names and Acquisition and Subscription Status of Managerial Officers Who Have Acquired Employee Share Subscription Warrants and the Top Ten Employees (Ranked by the Number of Subscribable Shares) Who Have Acquired Share Subscription Warrants :

March 31, 2025

Identity	Job title	Name	Number of shares subscribable from exercise of warrants granted	Ratio of the number of shares subscribable from the exercise of warrants granted to the total number of issued shares	Exercised				Unexercised			
					Number of shares	Exercise price	Total exercise price	Ratio of the number of exercised shares to the total number of issued shares	Number of shares	Exercise price (Note2)	Total exercise price	Ratio of the number of unexercised shares to the total number of issued shares
Managerial officers	General Manager	Lee Yi-Li	80,000	0.13%	40,000	16.50	660,000	0.06%	40,000	16.11	644,000	0.06%
	Vice President,	Evelyn Ning	65,000	0.10%	7,000	16.65	117,000	0.01%	50,000	16.65	833,000	0.08%
	Financial Officer	Chang Wen-Lan (Note)										
Employee	Senior Sales Engineer	Liu Cheng-Hsien	40,000	0.06%	0	24.42	0	0.00%	40,000	24.42	977,000	0.06%
	Senior Engineer	Shen Yu-Han										
	Director of Marketing	Peng Chih-Feng	50,000	0.08%	17,000	23.00	391,000	0.03%	33,000	22.46	741,000	0.05%
	Senior Engineer	Chao Pei-Yu	70,000	0.11%	32,500	16.50 16.11	495,000 40,000	0.05%	37,500	16.11	604,000	0.06%
	Engineer	Chen Wei-Hao										
	Senior Specialist	Liu Nan-Fu										
	Engineer	Hsu Wei-Yu										
	Engineer	Lee Yi-Wei	40,000	0.06%	0	21.88	0	0.00%	40,000	21.88	0	0.06%
	Engineer	Su Hsin-Ya										
	Product Specialist	Wang Kuan-Chu										
	Senior Specialist	Tai Yu-Ju										
	Regulatory Project Manager	Ling Jung-Chuan	50,000	0.08%	0	24.51	0	0.00%	50,000	24.51	1,226,000	0.08%
	Project Manager	Fu Tsung-Yu										
	Business Manager	Tsai Hsing-Jung										

Note : Resigned on August 9, 2024

3.6 Restrictions on employee rights related to the issuance of new shares: Not applicable (no such restrictions exist).

3.7 Mergers or acquisitions involving the issuance of new shares to acquire or transfer the shares of other companies: Not applicable (no such transactions).

3.8 Capital Utilization Plan and Execution Status:

3.8.1 The second cash capital increase and new share issuance in 2015.

Amcad Biomed Corp (hereinafter referred to as " Amcad " or "the company") . The second cash capital increase and new share issuance in 2015 (hereinafter referred to as "the case") was approved and became effective by the Financial Supervisory Commission (FSC) on March 14, 2016, under document No. 1050004713. The funds raised from this case were used for product development (hereinafter referred to as "the plan"), with the total amount of the plan being NT\$267,001,000. Subsequently, on November 6, 2018, the Board of Directors approved the modification of the plan, and on August 9, 2022, the Board of Directors approved further amendments to the plan.

3.8.1.1 The original plan, its progress, and expected benefits

1. The original plan:

(1) Total funding required for this plan: NT\$267,001 thousand.

(2) Source of funds:

(i)The Company planned to raise capital through a cash capital increase by issuing 11,800 thousand common shares, each with a par value of NT\$10, at an issue price of NT\$30 per share. The total expected proceeds were NT\$354,000 thousand.

(ii) If the actual issue price per share was adjusted due to market price fluctuations, resulting in a higher fundraising amount, the excess would be allocated to working capital.

(3) Original Capital Deployment Plan:

Amount unit: NTD thousands

Item		Planned Completion Date	Total funding required.	Planned Fund Utilization Schedule									
				2016				2017				2018	
				Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Product Development	Cytology-Based Thyroid Tumor Identification System	2018Q2	61,475	3,140	5,471	2,261	9,107	6,286	6,627	4,629	8,806	6,490	8,658
	Smart Functional Ultrasound Device	2018Q2	205,526	2,842	31,596	2,342	11,956	29,340	6,378	32,409	23,170	35,248	30,245
	Reinforcement of Working Capital	2016Q2	86,999	-	86,999	-	-	-	-	-	-	-	-
	Total		354,000	5,982	124,066	4,603	21,063	35,626	13,005	37,038	31,976	41,738	38,903

2. Original Planned Schedule for Fund Utilization

Amount unit: NTD thousands

Item	Execution status		Cumulative as of Q3 2018
Cytology-Based Thyroid Tumor Identification System	Amount Utilized.	Planned	61,475
		Actual	27,290
	Execution progress. (%)	Planned	100.00
		Actual	44.39
Smart Functional Ultrasound Device	Amount Utilized	Planned	205,526
		Actual	28,335
	Execution progress. (%)	Planned	100.00
		Actual	13.79
Reinforcement of Working Capital	Amount Utilized	Planned	86,999
		Actual	86,999
	Execution progress. (%)	Planned	100.00
		Actual	100.00
Total	Amount Utilized	Planned	354,000
		Actual	142,624
	Execution progress. (%)	Planned	100.00
		Actual	40.29

The fund utilization progress of the company's second cash capital increase in 2015 fell behind schedule. This delay was primarily due to the fundraising being completed later than originally planned—on June 27, 2016—which resulted in postponed procurement of certain hardware equipment. In addition, discussions with academic institutions and partner manufacturers regarding technical development and integration details led to deferred payments. As of the third quarter of 2018, the accumulated amount utilized was NT\$142,624 thousand, representing 40.29% of the originally planned execution progress. Upon evaluation, no material irregularities were identified.

3. Status of Achievement of Originally Planned Expected Benefits

The total amount of this capital increase plan is NT\$354,000 thousand, of which NT\$267,001 thousand is allocated for product development. The main purpose is to develop two new products: a Cytology-based Thyroid Tumor Identification System and a Smart Functional Ultrasound Device, with planned investments of NT\$61,475 thousand and NT\$205,526 thousand, respectively.

The development of the Cytology-based Thyroid Tumor Identification System aims to assist physicians in improving the diagnostic accuracy of benign and malignant tumors in traditional fine-needle aspiration cytology by providing image-based markers through software. The development was scheduled for completion in the first half of 2018, with a subsequent application for U.S. FDA marketing approval. It is projected to generate revenue of NT\$7,300 thousand in the second quarter of 2020.

The Smart Functional Ultrasound Device is designed to address the limitations of current ultrasound systems, which lack real-time image analysis and anomaly alerts. This product integrates the company's medical imaging and CAD software development capabilities and is jointly developed with ultrasound hardware manufacturers. Development was also scheduled for completion in the first half of 2018, followed by an application for U.S. FDA approval. Revenue of NT\$100,800 thousand is expected to be generated in the second quarter of 2020.

The projected development timeline and the estimated benefits from future sales of the company's products are summarized as follows :

(1) Planned Product Development Timeline

Item	Design Planning	Design Input	Design Output	Design Verification	Preclinical Evaluation	Application for Market Approval
Cytology-Based Thyroid Tumor Identification System	2015Q2	2016Q1	2016Q4	2017Q2	2018Q2	Q3 2018: U.S. FDA Application Q4 2018: EU Application Q2 2019: Taiwan Registration Application Q3 2019: China Application
Smart Functional Ultrasound Device	2015Q2	2016Q2	2017Q1	2017Q3	2018Q2	Q3 2018: U.S. FDA Application Q4 2018: EU Application Q2 2019: Taiwan Registration Application Q3 2019: China Application

Source: Provided by the Company.

(2) Expected Potential Benefits of the Cytology-Based Thyroid Tumor Identification System

Unit: Units; NT\$ Thousands

Year	Sales volume		Unit Price		Sales value		Gross Profit	Operating Profit
	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System		
2020	19	7	200	500	3,800	3,500	6,644	(20,544)
2021	102	23	200	500	20,400	11,500	29,033	9,017
2022	127	37	200	500	25,400	18,500	39,955	24,583
2023	153	51	200	500	30,600	25,500	51,059	37,209
2024	178	66	200	500	35,600	33,000	62,435	49,161

(3) Expected Potential Benefits of the Smart Functional Ultrasound Device

Unit: Units; NT\$ Thousands

Year	Sales volume	Unit Price	Sales value	Gross Profit	Operating Profit
2020	42	2,400	100,800	60,726	(851)
2021	118	2,400	283,200	170,611	116,163
2022	186	2,400	446,400	268,929	216,746

As of the end of the third quarter of 2018, the product development projects had not yet been completed; therefore, it is not yet necessary to assess the achievement of the projected sales revenue for the Cytology-Based Thyroid Tumor Identification System and the Smart Functional Ultrasound Device.

3.8.1.2 Capital Plan, Execution Progress, and Expected Benefits Following the Project Amendment Approved by the Board of Directors on August 9, 2022.

1. Reason for the Project Amendment:

Revision of Product Development Items

As of July 2022 (Year 111), the development of the Cytology-Based Identification System had been completed. In order to efficiently utilize the remaining funds, the company proposed reallocating the unused portion originally designated for the Cytology-Based Identification System to support the ongoing product development of the Smart Functional Ultrasound Device.

- (1) Since the Cytology Identification System is designed to complement AmCAD-UT[®] to assist doctors in thyroid diagnosis, the market strategy is to bundle it with AmCAD-UT[®] and distribute it through laboratory channels, eliminating the need for FDA approval.
- (2) The product development of the Smart Functional Ultrasound Device aims to enhance its value by expanding its applications beyond its existing rapid diagnosis function for sleep apnea. The plan includes broader use in companion diagnostics, such as positive airway pressure (PAP) devices, dental appliances, and surgical excision procedures. Currently, the company is collaborating with major hospitals and research centers to conduct clinical validation studies for these applications.

2. Revised Project Items and Fund Utilization Progress:

Amount unit: NTD thousands

Project Item		Planned Completion Date	Total Required Capital	Actual Fund Utilization Progress								Planned Fund Utilization Progress										
				2016	2017	2018	2019	2020	2021	2022				2023				2024				
										Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
Product Development	Cytology-Based Thyroid Tumor Identification System	2018Q2	38,681	7,039	10,256	12,565	5,954	952	1,151	313	334	117 (Note 2)	-	-	-	-	-	-	-	-	-	-
	Smart Functional Ultrasound Device	2018Q2	158,562	13,756	13,158	1,421	-	12,596	21,680	4,414	4,764	7,826	10,710	8,007	9,454	9,956	9,816	8,030	9,515	7,956	5,503	
Reinforcement of Working Capital		2016Q2	86,999	86,999	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Office Building Purchase		2018Q4	61,083	-	-	61,083 (Note 1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Equity Investment in Subsidiaries		2018Q4	27,000	-	-	27,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Total			372,325	107,794	23,414	102,069	5,954	13,548	22,831	4,727	5,098	7,943	10,710	8,007	9,454	9,956	9,816	8,030	9,515	7,956	5,503	

Note 1: Of the total, NT\$18,325 thousand was funded with the company's own capital, while the remaining NT\$42,758 thousand was covered by the original budget allocated for the product development of the Smart Functional Ultrasound Device.

Note 2: The Cytology-Based Thyroid Tumor Identification System was completed in July 2022.

3. Fund Utilization Progress After Project Amendmen:

Amount unit: NTD thousands

Item	Execution status.		Accumulated until the end of Q1 2025.
Cytology-Based Thyroid Tumor Identification System	Amount Utilized	Planned	38,681
		Actual	38,681
	Execution progress. (%)	Planned	100.00
		Actual	100.00
Smart Functional Ultrasound Device	Amount Utilized	Planned	158,562
		Actual	148,398
	Execution progress. (%)	Planned	100.00
		Actual	93.59
Office Building Purchase	Amount Utilized	Planned	61,083
		Actual	61,083
	Execution progress. (%)	Planned	100.00
		Actual	100.00
Equity Investment in Subsidiaries	Amount Utilized	Planned	27,000
		Actual	27,000
	Execution progress. (%)	Planned	100.00
		Actual	100.00
Total	Amount Utilized	Planned	285,326
		Actual	275,162
	Execution progress. (%)	Planned	100.00
		Actual	96.44

Source: Provided by the company

The Company's second cash capital increase and new share issuance in 2015 has progressed in terms of fund utilization. The product development of the Cytology-Based Thyroid Tumor Identification System, Office Building Purchase, and Equity Investment in Subsidiaries have been fully executed. However, as of Q4 2024, the product development of the Smart Functional Ultrasound Device has experienced delays.

The primary reasons for the delay include intensifying market competition in end-product applications, leading hardware manufacturers to propose integrating various CAD software applications with hardware equipment. Additionally, during the COVID-19 pandemic, the FDA application process for certain CAD software encountered submission delays, further impacting the product development timeline.

As of the date of this evaluation report, the Smart Functional Ultrasound Device has completed development and secured sales orders. However, to further enhance the product's functionalities, the company will continue investing in related R&D efforts.

Overall, as of Q1 2025, the cumulative funds utilized for this project amounted to NT\$275,162 thousand, achieving an actual execution progress of 96.44%. The delays were mainly due to adjustments to external market conditions, but no significant abnormalities have been identified in the overall project assessment.

4. Expected Benefits After Modification:

(1) Product development

(i) Planned Product Development Timeline:.

Product	Design Verification	Clinical Enrollment	Publication	Marketing
Smart Functional Ultrasound Device	Ongoing Function Optimization	OSA Evaluation/Companion Therapy Case Enrollment in Progress	In Progress	FDA Application for Sleep Apnea Assessment Completed in 2024

Note: Due to the limited market for the MSK project, efforts were redirected to the OSA detection field, yielding positive results. Considering the business opportunities in companion therapy, relevant clinical case enrollment is ongoing.

(ii) Expected Potential Benefits of the Cytology-Based Thyroid Tumor Identification System:.

unit:set : Amount unit: NTD thousands

Year	Sales volume		Sales Price per Unit		Sales value		Gross Profit	Operating Profit
	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System	Computer-Aided Diagnostic System	Digital Microscope Integration System		
2023	8	3	100	250	800	750	1,488	37
2024	19	8	100	250	1,900	2,000	3,769	2,562
2025	31	11	100	250	3,100	2,750	5,687	3,981
2026	45	17	100	250	4,500	4,250	8,491	6,243
2027	47	19	100	250	4,700	4,750	9,159	6,353
2028	50	22	100	250	5,000	5,550	10,218	7,094

(iii) Expected Potential Benefits of the Smart Functional Ultrasound Device:.

unit:set : Amount unit: NTD thousands

Year	Sales volume	Unit Price	Sales value	Gross Profit	Operating Profit
2023	10	2,000	20,000	12,510	5,417
2024	23	2,400	55,200	38,788	26,096
2025	40	2,400	96,000	69,405	48,363
2026	48	2,400	115,200	84,093	58,491

(2) Office Building Purchase

After the Board of Directors approved the project modification on November 6, 2018, the Company purchased an office space on the third floor of the same building as the AmCad office on Fuxing North Road on December 6, 2018, for NT\$61,083 thousand. The purchased office space has a total area of 77.32 pings.

Based on the market rental rate of approximately NT\$1,800 per ping per month for the eighth-floor office space leased by PhytoHealth Corporation, the parent company of AmCad, the estimated annual rental savings is approximately NT\$1,670 thousand.

Furthermore, after deducting the annual depreciation expense of NT\$204 thousand associated with the office acquisition, the estimated net annual benefit from 2019 onward is NT\$1,466 thousand. The expected benefits align with initial projections.

Amount unit: NTD thousands

	2019 and beyond
Expected Annual Rental Savings (Note 1)	1,670
Building Depreciation Cost (Note 2)	(204)
Total	1,466

Source: Provided by the Company.

Note 1: Annual rental savings are calculated based on the market rental rates of the intended purchase area and the purchased floor space.

Note 2: The total purchase price of the building, including transfer and other acquisition costs, is estimated at NT\$8,142 thousand. Amortized over 40 years, the annual amortization amount is NT\$204 thousand (NT\$8,142 thousand / 40 years).

(3) Equity Investment in Subsidiaries

Amount unit: NTD thousands

	2018	2019	2020	2021	2022
Operating revenue	49,000	119,640	161,430	204,870	250,470
Gross profit	24,850	69,358	93,183	118,407	144,927
Operating gain	11,314	21,058	42,783	62,607	83,727
Net gain	11,314	21,058	34,226	50,086	66,982
Investment Ratio	40.54%	40.00%	40.00%	40.00%	40.00%
Investment Income Recognized in the Current Year	4,587	8,423	13,690	20,034	26,793
Cumulative Investment Income Recognized	4,587	13,010	26,700	46,734	73,527
Expected Payback Period	3.01 years				

Broadsound Corporation is a comprehensive ultrasound equipment company and the only manufacturer worldwide that has obtained certification for ultrasound-compatible alternative probes. With advanced and well-established ultrasound technology, Broadsound independently develops, designs, manufactures, markets globally, and provides after-sales services.

Its flagship product, the ultrasound probe, is the only high-end alternative probe globally to receive both U.S. FDA market approval and EU CE certification. According to Broadsound Corporation's projected income statement, the cumulative profit is estimated to reach NT\$46,734 thousand by 2021, with a payback period of approximately 3.01 years.

3.8.1.3 Assessment of Differences Between Expected Benefits and Actual Achievements:

1 .Product development

As of the end of December 2022, the Cytology-Based Thyroid Tumor Identification System had just been successfully developed. According to the company's initial revenue projections, sales were expected to commence in 2023. However, to better align with market demand and enhance product competitiveness, the company has planned to integrate the Cytology-Based Thyroid Tumor Identification System with the Thyroid Detection product for joint sales. The company has already engaged with leading domestic hospitals, and as of 2024, the system has generated NT\$180 thousand in revenue.

Additionally, the Smart Functional Ultrasound Device has signed a sales contract with an overseas distributor, generating NT\$1,580 thousand in revenue in 2024.

The primary reasons for the differences between expected and actual benefits are as follows:

The Cytology-Based Thyroid Tumor Identification System is an innovative medical device that requires substantial clinical data and research reports to influence physicians' adoption and usage habits.

The Smart Functional Ultrasound Device still needs to obtain approval from the Korea Food and Drug Administration (KFDA) before it can be fully marketed. As a result, sales and profitability have deviated from the initial projections. However, after evaluation, no significant abnormalities have been identified.

2. Office Building Purchase

In 2018, the Company purchased a 77.32-ping office space. Based on the market rental rate of approximately NT\$1,800 per ping per month for the eighth-floor office space leased by PhytoHealth Corporation, the parent company of AmCad, the estimated annual rental savings is approximately NT\$1,670 thousand.

Furthermore, after deducting the annual depreciation expense of NT\$204 thousand associated with the office acquisition, the estimated net annual benefit from 2019 onward is NT\$1,466 thousand.

Upon evaluation, this expected benefit is considered reasonable.

Amount unit: NTD thousands

	2019 and beyond
Expected Annual Rental Savings (Note 1)	1,670
Building Depreciation Cos (Note 2)	(204)
Total	1,466

Note 1: Annual rental savings are calculated based on the market rental rates of the intended purchase area and the purchased floor space.

Note 2: The total purchase price of the building, including transfer and other acquisition costs, is estimated at NT\$8,142 thousand. Amortized over 40 years, the annual amortization amount is NT\$204 thousand (NT\$8,142 thousand / 40 years).

3. Equity Investment in Subsidiaries

Broadsound Corporation is a comprehensive ultrasound equipment company and the only manufacturer worldwide that has obtained certification for ultrasound-compatible alternative probes. With advanced and well-established ultrasound technology, Broadsound independently develops, designs, manufactures, markets globally, and provides after-sales services.

Its flagship product, the ultrasound probe, is the only high-end alternative probe worldwide to receive both U.S. FDA market approval and EU CE certification.

According to Broadsound Corporation's self-prepared financial statements for Q1 2025, the net loss after tax amounted to NT\$5,666 thousand, primarily due to ongoing order negotiations with key customers.

3.8.1.4 Reasonableness of the Use of Unutilized Funds:

The Company's actual expenditures on product development have not yet been fully utilized. Upon reviewing the Company's bank passbook and time deposit certificates, as of the end of March 2025, the Company's cash and cash equivalents amounted to NT\$244,122 thousand. After deducting the unused amount from the 2024 cash capital increase, which is NT\$226,996 thousand, the remaining balance is NT\$17,126 thousand, which exceeds the unused balance of NT\$10,164 thousand for this project.

However, the Company will continue product development and improvements. Based on the assessment of the Company's fund execution progress and unutilized funds, no significant abnormalities were found. The evaluation conducted by this securities firm has deemed the situation reasonable, with no major irregularities identified.

3.8.1.5 Whether the Plan Involves Changes:

The second cash capital increase for the year 2015 was modified by the Board of Directors on August 9, 2022. The main content of the modification was that the Thyroid Cytology Identification System had been developed, and therefore, the unused funds amounting to NT\$22,794 thousand were reallocated to the product development of the Smart Functional Ultrasound Device.

Since the amount of the change represents only 6.44% of the total funds raised (NT\$354,000 thousand), which is less than the 20% threshold, it does not qualify as a project change. However, the revised fund execution progress, the use of unused funds, and the expected benefits were evaluated by this securities firm and were deemed reasonable, with no significant abnormalities identified.

3.8.2 Cash capital increase and new share issuance in 2024.

3.8.2.1 Purpose of Evaluation:

In accordance with Article 9, Paragraph 1, Item 7 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers and the provisions set forth in the Financial Supervisory Commission's official letter No. 1130343354 dated June 7, 2024, this underwriter provides an evaluation opinion on the implementation progress of the fundraising, the expected achievement of benefits, and the rationality of the intended use of unutilized funds for the 2024 cash capital increase and new share issuance of AmCad BioMed Corporation (hereinafter referred to as "the Company" or "AmCad").

3.8.2.2 Brief Description of the Evaluation Process:

The verification procedures conducted by this underwriter regarding the implementation progress of the funds, the expected benefits, and the rationality of the intended use of unutilized funds are as follows:

- 1 . Review the bank account balances and detailed statements provided by the Company.
- 2 . Obtain relevant certificates for the company's product development.
- 3 .Inquire with the company's management and responsible personnel, and compare the actual implementation of funds with the planned funding schedule to verify whether there are any irregularities.

3.8.2.3 Key Contents of the Issuance Plan for This Cash Capital Increase and New Share Issuance:

- 1 . Total Fundraising Amount: A cash capital increase will be conducted through the issuance of 10,000 thousand new shares, with a par value of NTD 10 per share. Each share will be issued at a premium price of NTD 23, resulting in a total fundraising amount of NTD 230,000 thousand.
- 2 . Use of Funds: Product Development.
- 3 . Planned Projects and Expected Implementation Schedule:

Amount unit: NTD thousands

Project Item	Planned Completion Date	Total Required Capital	Planned Fund Utilization Schedule											
			2024		2025				2026				2027	
			Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
Companion Diagnostic Hardware Development for Sleep Apnea	2026Q3	99,760	-	28,920	720	28,920	720	19,520	720	720	19,520	-	-	-

Breast Ultrasound Clinical Research	2027Q2	104,000	14,157	6,757	7,407	7,407	7,531	7,407	7,407	7,407	7,531	7,407	7,057	16,525
Handheld Ultrasound Device Development	2025Q3	37,920	2,400	17,880	1,680	480	15,480	-	-	-	-	-	-	-
Total		241,680	16,557	53,557	9,807	36,807	23,731	26,927	8,127	8,127	27,051	7,407	7,057	16,525

4 . Expected Potential Benefits:

(1) Companion Diagnostic Hardware Development for Sleep Apnea.

The company is developing the next-generation OSA companion diagnostic hardware based on the experience gained from the first-generation OSA detection device and software. The goal is to integrate AmCAD-UO with the new OSA companion diagnostic equipment by enhancing the laser positioning system, allowing for a wider scanning angle and more precise imaging of relevant oral structures. Additionally, the target market will be expanded to include pediatric patients, with the new diagnostic hardware being adjustable for children. The product design planning is expected to commence in Q4 2024, with the product design finalized by Q3 2026. The company plans to apply for U.S. FDA market approval in Q4 2026 and, upon obtaining approval in 2027, will commence sales. From 2027 to 2030, the projected total revenue is NTD 352,656 thousand, with an accumulated net operating profit of NTD 171,044 thousand.

Item	Design Planning	Design Input	Design Output	Design Verification	Application for Market Approval
Obstructive Sleep Apnea (OSA) Companion Diagnostic Hardware	2024Q4	2025Q2	2025Q4	2026Q3	2026Q4

unit:set : Amount unit: NTD thousands

Year	Sales volume	Sales Price per Unit	Sales value	Gross profit from operations	Net profit from operations
2027	8	2,232	17,856	12,736	8,660
2028	30	2,232	66,960	47,760	32,477
2029	50	2,232	111,600	79,600	54,128
2030	70	2,232	156,240	111,440	75,779
Total	158	2,232	352,656	251,536	171,044

(2) Breast Ultrasound Clinical Research

The Breast Ultrasound Software is an intelligent real-time diagnostic system for breast cancer ultrasound detection. When paired with ultrasound hardware, it can fully leverage its real-time detection capabilities. To expand the product's overseas market opportunities, clinical trials for market approval will be conducted both domestically and in the U.S.,

which has a large market. The clinical trials are expected to be completed by Q2 2027, with the FDA market approval application planned for Q3 2027.

As an international ultrasound industry leader is currently in discussions with the company regarding cooperation on Anchor Thyroid Detection, and has also expressed interest in the Breast Ultrasound Software, the company expects to obtain market approval in Q2 2028. Following this, the company plans to collaborate with the international ultrasound giant to integrate the breast cancer ultrasound software into their existing breast ultrasound equipment.

From 2028 to 2033, the projected sales revenue share is estimated to be NTD 119,700 thousand.

Item	The expected R&D progress after the capital increase plan funds are invested.	The expected clinical trials	The expected start time	The expected completion time for the use of these funds	Application for Market Approval
The Breast Ultrasound	Apply for breast ultrasound FDA approval	Breast ultrasound clinical trials (Note 1)	2024Q3	2027Q2	2027Q3

Note: The clinical trials for breast ultrasound will be conducted in the United States and Taiwan, with plans to recruit 400 participants in Taiwan and 800 participants in the United States. This fundraising plan is scheduled to be carried out until the second quarter of 2027. By then, the clinical trial reports will be submitted to Taiwan and the United States, and applications for market approval will be made.

unit:set : Amount unit: NTD thousands

Year	2028	2029	2030	2031	2032	2033	Total
Authorized quantity	24	27	30	30	30	30	171
Authorized unit price	700	700	700	700	700	700	700
Sales revenue sharing amount	16,800	18,900	21,000	21,000	21,000	21,000	119,700

(3) Handheld Ultrasound Device Development

The Handheld Ultrasound Device integrates artificial intelligence (AI) into a portable ultrasound system, enhancing user convenience while improving diagnostic accuracy and efficiency. This application is particularly beneficial for patients in remote areas by providing more accessible diagnostic solutions.

The project timeline includes product design planning in Q4 2024, with product design completion by Q3 2025. The company plans to apply for U.S. FDA market approval in Q4 2025 and, upon obtaining approval in 2026, will commence sales.

From 2026 to 2028, the projected total revenue is NTD 109,500 thousand, with an accumulated net operating profit of NTD 44,676 thousand.

Item	Design Planning	Design Input	Design Output	Design Verification	Application for Market Approval
Handheld Ultrasound Device	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4

unit:set : Amount unit: NTD thousands

Year	Sales volume	Sales Price per Unit	Sales value	Gross profit from operations	Net profit from operations
2026	230	150	34,500	20,700	14,076
2027	240	150	36,000	21,600	14,688
2028	260	150	39,000	23,400	15,912
Total	730	450	109,500	65,700	44,676

3.8.2.4 Progress of Fund Utilization and Achievement of Expected Benefits.

1 . Fund Utilization Progress as of Q1 2025:

Amount unit: NTD thousands

Item	Execution status		2025Q1	Accumulated until the end of Q1 2025	Reasons for Progress Lead or Delay and Improvement Plan
Companion Diagnostic Hardware Development for Sleep Apnea	Amount Utilized	Planned	720	29,640	Companion Diagnostic Hardware Development for Sleep Apnea: During actual testing, the device experienced equipment delays, and the company is actively troubleshooting the issue. Once the problem is resolved, the fund utilization progress will return to schedule. Additionally, since the next-generation product aims to expand its target users to the pediatric market, clinical trials must be conducted on pediatric patients, with sufficient case data collected. The hardware design planning is now expected to be completed by Q2 2025. Breast Ultrasound Clinical Research: The originally planned clinical trial institution quoted costs significantly higher than the company's expectations. Given the limited project budget, the
		Actual	841	1,201	
	Execution progress. (%)	Planned	0.72	29.71	
		Actual	0.84	1.20	
Breast Ultrasound Clinical Research	Amount Utilized	Planned	7,407	28,321	
		Actual	260	736	
	Execution progress. (%)	Planned	7.12	27.23	
		Actual	0.25	0.71	
Handheld Ultrasound Device Development	Amount Utilized	Planned	1,680	21,960	
		Actual	767	1,067	
	Execution progress. (%)	Planned	4.43	57.91	
		Actual	2.02	2.81	
Total	Amount Utilized	Planned	9,807	79,921	
		Actual	1,868	3,004	
	Execution	Planned	4.06	33.07	

	progress. (%)				company decided to engage an alternative, suitable clinical trial institution, leading to project delays. Since collaborating with a professional clinical trial institution requires consideration of multiple factors, the company expects to sign the contract and commence clinical trials in Q2 2025.
		Actual	0.77	1.24	Handheld Ultrasound Device Development: The company has studied the collaboration model between GE and PIUR Imaging, where their deep partnership not only enhanced technological capabilities but also elevated brand prestige. As a result, the company has adjusted its strategic approach, no longer limiting development collaborations to domestic equipment manufacturers (such as Qisda). Instead, it is now focusing on seeking in-depth collaboration opportunities with international industry leaders.

2 . Achievement of Expected Benefits:

As of the end of Q1 2025, the product development plans have not yet been completed. Therefore, it is not yet necessary to evaluate the projected sales revenue for the OSA companion diagnostic hardware and handheld ultrasound device, nor the achievement of breast ultrasound sales revenue sharing.

3.8.2.5 Brief description of the evaluation process

1 . Project execution progress

As of the end of Q1 2025, the company has executed a total amount of NT\$3,004 thousand , with an overall execution progress of 1.24%, which is behind the planned 33.07%. Regarding the development of the sleep apnea diagnostic hardware, there has been equipment delays during actual testing. The company is actively troubleshooting the equipment issues, and once resolved, the fund utilization progress will get back on track. Additionally, the next-generation product is planned to expand its target market to children, which requires conducting clinical trials on pediatric patients and collecting data. The design planning for the hardware is expected to be completed by Q2 2025.

In terms of the breast ultrasound clinical research, the originally planned clinical trial organization had costs far exceeding the company's expectations. Considering the limited project budget, the company intends to commission another appropriate clinical trial organization, resulting in a delay. As cooperation with a professional clinical trial organization requires careful consideration of various factors, the contract is expected to be signed in Q2 2025, and clinical trials will commence thereafter.

Regarding the handheld ultrasound device development, the company has referenced the collaboration model between GE and PIUR Imaging, where deep cooperation not only enhanced technical capabilities but also further boosted brand reputation. As a result, the company has adjusted its strategy and is no longer limited to collaborating with domestic equipment manufacturers (such as Qisda) for development, but is focusing on seeking deep cooperation opportunities with international industry leaders. No significant abnormalities have been identified upon evaluation.

2 . Expected achievement of benefits

The product development plans have not yet been completed. Therefore, it is not yet necessary to evaluate the projected sales revenue for the OSA companion diagnostic hardware and handheld ultrasound device, nor the achievement of breast ultrasound sales revenue sharing.

3 . Unutilized funds

The actual expenditures incurred by the Company for product development have not yet been fully utilized. Based on a review of the Company's bankbook and time deposit certificates, the cash and cash equivalents on hand amounted to NT\$244,122 thousand as of the end of March 2025. After deducting the unused portion of NT\$10,164 thousand from the 2015 cash capital increase, the remaining balance stands at NT\$233,958 thousand, which exceeds the total proceeds of NT\$230,000 thousand raised under the current plan. Upon assessing the Company's fund utilization progress and the amount of unutilized funds, no material irregularities were identified. This securities firm considers the situation to be reasonable, with no significant issues observed.

4 . Whether the Plan Involves Changes:

The company's 2024 cash capital increase and new share issuance was approved and became effective by the Financial Supervisory Commission on June 7, 2024, under Letter No. 1130343354. There have been no changes to the plan.

3.8.2.6 Evaluation opinion

The company's 2024 cash capital increase and new share issuance was approved and became effective by the Financial Supervisory Commission on June 7, 2024, under Letter No. 1130343354. As of the end of Q1 2025, there are no significant irregularities in the fund utilization progress or the rationality of unutilized funds.

4. Operational overview

4.1 Business activities

4.1.1 Business scope

1. Main Business Content

Our company is primarily engaged in the research, development, production, and manufacturing of advanced medical devices.

The registered business scope includes medical devices, biotechnology services, and electronic information services, among others.

2. Business Proportion

The company's primary business is the sales of advanced medical devices.

3. Current Product (Service) Items of the Company

(1) **AmCAD-UT[®]**

An AI-powered ultrasound imaging system for thyroid analysis, utilizing advanced image processing to detect and quantify key diagnostic features. It enables real-time image analysis, automated nodule segmentation, and integration with global thyroid nodule diagnostic guidelines.

(2) **AmCAD-UO[®]**

This product features a laser-based automatic positioning system that standardizes ultrasound scanning, combined with an AI algorithm for consistent imaging, enabling the detection of high-risk moderate to severe obstructive sleep apnea patients. It has obtained FDA 510(k) clearance, CE Mark certification, and market approval in Taiwan. Clinical research with the Stanford Sleep Center has been presented at multiple conferences and published in JAMA Otolaryngology and Sleep Medicine. To expand clinical applications and accelerate global adoption, we are collaborating with medical centers in the U.S., Europe, and Taiwan to gather diverse clinical data and develop new indications.

(3) **AmCAD-US**

A novel ultrasound-based tissue imaging platform that enhances the visualization of tissue structures. It expands ultrasound applications beyond conventional elasticity imaging, covering liver fibrosis, liver steatosis, MSK conditions, breast cancer, and sleep apnea.

(4) **AmCAD-UV**

An ultrasound Doppler image enhancement platform that separates primary and secondary pulsatile signals while filtering noise, providing clinicians with clear visualization for vascular assessment.

(5) **AmCAD-CA**

A digital cytology analysis system that utilizes AI to assess cellular morphology and chromatic features, aiding in medical research and cancer diagnostics.

4. Upcoming Product Development

Since its establishment, our company has been focused on the high-end medical device market with high added value. In addition to the aforementioned developed systems, we are continuously researching and developing new disease diagnostic methods. In the future, while solidifying our leading position in the thyroid field, we will also actively explore unmet clinical needs and expand applications of artificial intelligence technology. Our company will continue to invest in research and development to create innovative medical devices with high potential, thereby expanding our product portfolio. Below, we provide a detailed description of the newly planned products under development.

AmCAD-UB

There are already breast ultrasound computer-aided detection and diagnosis (CAD) products on the market that have received regulatory approval. Most of these products are applied to breast ultrasound images stored after physician-performed scans or images collected through automated 3D breast scanning. According to the current regulations of the U.S. FDA, computer-aided detection tools can only serve as a second reader and cannot address the clinical challenge of requiring medical personnel to manually perform scans or review large volumes of automated 3D images.

AmCAD-UB builds upon AmCAD-UT's patented technology for ultrasound feature quantification and visualization and incorporates real-time detection and intelligent diagnosis using edge deep learning. With this innovative approach, it aims to address unmet clinical needs and provide a significant technological breakthrough in the field of breast health.

4.1.2 Industry Overview:

1.Current Status and Development of the Industry

Industry Overview

In recent years, Ultrasound AI has experienced rapid growth in the medical imaging market, driven by technological advancements and increasing clinical demand. Traditional ultrasound diagnosis heavily relies on the physician's expertise, resulting in higher variability and dependency in diagnostic outcomes. AI-assisted technologies are enhancing diagnostic accuracy and efficiency through deep learning and automated image analysis. Particularly in the screening of thyroid, breast, liver, and cardiovascular diseases, AI can assist physicians in real-time lesion detection, abnormal structure annotation, and reducing the risk of misdiagnosis.

With the rising demand for handheld ultrasound devices (POCUS), real-time AI (Live AI) diagnostics have become a key focus in the market. Established medical imaging giants such as GE, Philips, and Siemens are accelerating the development of AI modules and their integration into devices. Meanwhile, innovative companies like Caption Health, Koios Medical, and Ultromics are focusing on specific clinical applications—such as cardiac, breast, and thyroid AI diagnostics—driving market innovation. Additionally, growing hospital demand for PACS system integration is prompting AI solutions to support DICOM format transmission, thereby enhancing the efficiency of clinical workflows.

However, Ultrasound AI still faces challenges in clinical validation, regulatory approval, and market adaptability. Some AI solutions remain dependent on specific hardware, limiting their scalability, while regulatory requirements for AI diagnostic software are becoming increasingly stringent across different countries, resulting in longer time-to-market cycles. Moving forward, improving the accuracy of AI algorithms and optimizing integration into clinical workflows will be critical to the continued development of the Ultrasound AI market.

Industry Development Trends

(1) Ultrasound AI Technology Innovation

With ongoing advancements in deep learning and machine learning, Ultrasound AI is evolving toward higher precision and real-time diagnostics. Traditional computer-aided diagnosis (CAD) primarily relies on post-processing image analysis, whereas modern real-time AI (Live AI) technologies can identify lesions during the scanning process, enhancing diagnostic accuracy and reducing the risk of misdiagnosis. AI can also automatically annotate pathological areas and provide risk assessments, further improving the efficiency of healthcare professionals—particularly in the

diagnosis of thyroid, breast, liver, and cardiovascular diseases.

(2) Growing Demand for Chronic Disease and Cancer Screening

The global rise in chronic diseases and cancer incidence has driven healthcare institutions to place greater emphasis on early diagnosis and precision medicine. Ultrasound AI can detect early signs of disease, making it particularly suitable for applications such as thyroid nodule assessment, breast cancer screening, fatty liver detection, and cardiovascular risk evaluation. Moreover, AI-powered ultrasound technology—being non-invasive, real-time, and reusable—offers a more cost-effective alternative to traditional diagnostic methods such as biopsies or CT/MRI, making it a preferred solution for healthcare providers.

(3) Advancements in Medical Imaging Technology and Market Integration

With advancements in medical imaging technology—such as higher-resolution probes and more refined image capture capabilities—the application scenarios for Ultrasound AI continue to expand. The growing adoption of handheld ultrasound devices (POCUS) allows AI diagnostic technologies to move beyond hospitals and into primary care clinics and telemedicine settings. Additionally, the increasing demand for PACS system integration in healthcare institutions is driving AI solutions to support DICOM format transmission, ensuring seamless diagnostic workflows and improved clinical efficiency. These trends are set to accelerate the rapid growth of Ultrasound AI in the global healthcare market.

2. Product Analysis:

The 2024 Biotech Industry White Paper by the Ministry of Economic Affairs Industrial Development Bureau indicates that in 2023, diagnostic imaging products accounted for the highest share, reaching 23.8%. As shown in the figure below:





圖2-4 2023年全球醫療器材市場產品別銷售比例分析

資料來源：BMi Research，2024年；財團法人工業技術研究院產業科技國際策略發展所，2024年5月。

The upstream, midstream, and downstream supply chain of the medical imaging analysis and diagnosis industry.



3. Product Development Trends and Competitive Landscape

(1) Development Trends of Ultrasound Computer-Aided Diagnosis (CAD) Software:

With advancements in AI technology and the deepening of clinical applications, the Ultrasound AI computer-aided diagnosis (CAD) market is rapidly expanding, becoming a key development area in medical imaging. These technologies play a critical role in automated detection, real-time diagnosis, and precise lesion localization, and are already widely applied in the diagnosis and monitoring of conditions such as thyroid nodules, breast cancer, liver fibrosis, and prostate cancer. To enhance the accuracy and clinical applicability of AI models, large-scale data training, clinical validation, and continuous technological innovation are essential drivers of market growth.

In recent years, the rise of handheld ultrasound (POCUS, Point-of-Care Ultrasound) has further accelerated the adoption of CAD technology. With the integration of AI, POCUS not only benefits specialists but also enables primary care providers, emergency departments, and telemedicine services to access low-cost, convenient AI diagnostic tools—reducing reliance on specialists and enhancing diagnostic efficiency. Although the market still faces technical challenges such as improving image quality, data processing efficiency, and computational resource demands, these limitations are gradually being addressed through algorithm optimization and hardware upgrades. Looking ahead, AI is expected to be increasingly applied in real-time ultrasound diagnostics (Live AI) and remote

healthcare settings.

(2) Competitive Analysis:

Competition in the Ultrasound AI CAD market is intensifying, involving both traditional medical imaging giants and emerging AI technology companies:

- Established players (such as GE Healthcare, Siemens Healthineers, and Philips) are actively integrating AI into their ultrasound systems to enhance diagnostic accuracy and automation capabilities.
- Startups (such as Koios Medical, MEDO AI, and Caption Health) are focusing on specific disease areas, leveraging AI-driven CAD software to improve diagnostic efficiency, creating both complementary and competitive dynamics with major device manufacturers.

Within this competitive landscape, AmCad's products hold significant advantages:

- AmCAD-UT[®]: The world's first thyroid ultrasound AI diagnostic system to receive FDA approval in the United States. It features automatic nodule detection and deep learning algorithms, assisting physicians in enhancing diagnostic standardization and accuracy, positioning the product as a technological leader in the market.
- AmCAD-UO[®]: Offers an innovative, non-invasive solution for diagnosing obstructive sleep apnea (OSA) while the patient is awake. Compared to traditional polysomnography (PSG), it significantly improves patient comfort and clinical convenience.

As the market continues to grow and technology advances, AmCad must continuously innovate and enhance its product performance to maintain its competitive advantage. In addition, applying CAD technology to POCUS will further expand AmCad's market potential in the field of rapid and portable ultrasound diagnostics, meeting a wider range of clinical and emergency care needs. With effective marketing strategies and increased product value, AmCad is well positioned to capture a larger share of the ultrasound CAD market in the future.

4.1.3 Technology and R&D Overview

1. R&D expenses incurred in the most recent fiscal year and up until the date of printing of the annual report.

Amount unit: NTD thousands.

Item \ Year	2024	As of March 31, 2025 (Note 1)
Revenue (A)	53,105	-
R&D Expenses (B)	43,783	-
R&D Expense Ratio B/A	82%	-

Note 1: As of the date of printing of the annual report, the financial statements for the first quarter of the fiscal year 2025 have not yet been reviewed by the CPA

2. Successful Technologies or Products Developed

(1) Key Technical Competencies

- A. AI-based clinical diagnostic algorithms
- B. Medical device regulatory expertise
- C. Clinical trial design and execution
- D. Medical device validation and efficacy testing
- E. Medical imaging software development
- F. Advanced medical equipment selection and evaluation
- G. Medical device development planning and technical integration

- H. Compliance with international clinical trial regulations
- I. Quality management for medical device R&D and manufacturing

(2) Main Products

Main products are AmCAD-UT, AmCAD-UO, AmCAD-US, AmCAD-UB, and AmCAD-CA. For further details, please refer to "Section V: Business Overview, 1. Current Products (Services) of the Company.

For further details, please refer to “4. Business Overview –3.Current Product (Service) Items of the Company”

4.1.4 Long-term and short-term business development plans.

1. Short-term business development plans:

(1)AmCAD-UT[®] application for TFDA Certification of New Functional Specifications.

(2) AmCAD-UO[®] obtaining Market Approval for Products in South Korea.

2. Long-term business development plans:

Completion of UT, UO, and US Integrated Handheld Ultrasound System and Application for Market Approval in the U.S., EU, and Taiwan.

4.2 Market and Sales Overview

4.2.1Market Analysis

1.Sales Regions of Main Products/Services

Amount unit: NTD thousands

Sales Area \ Year	2024	2023
	Sales Amount	Sales Amount
Domestic	16,732	19,034
Foreign	36,373	46,222
Total	53,105	65,256

2. Market share

AmCAD-UT[®] is widely used in numerous hospitals and health screening centers across Taiwan, with a steadily growing market share. By 2023, the product had expanded into international markets, including medical institutions in Dubai, where it has gained recognition and adoption. In response to increasing global market competition, AmCad is actively exploring new market strategies aimed at enhancing its international brand visibility through partnerships with more global partners and the development of innovative sales channels.

In addition, AmCAD-UT[®] is planned to expand into the POCUS field, a technology that demonstrates significant potential in rapid diagnosis and patient monitoring due to its portability and real-time capabilities. AmCad aims to broaden the clinical applications of AmCAD-UT[®] in POCUS through continued research and innovation, in order to better meet diverse clinical needs.

AmCAD-UO[®] unique non-invasive detection method has attracted increasing attention in both domestic and international markets, particularly following its adoption by several medical institutions in Taiwan, the United States, and Dubai. Significant revenue growth is expected by the end of 2024. AmCad is actively strengthening collaborations with international medical centers and participating in more global clinical trials and academic exchanges to enhance the global recognition and credibility of AmCAD-UO[®].

Looking ahead, AmCAD-UO[®] will focus on strengthening its applications in the

field of Companion Diagnostics, particularly in dentistry and alternative treatments for OSA beyond CPAP therapy. The goal is to further explore the potential of its non-invasive detection technology to provide more comprehensive diagnostic and therapeutic solutions for OSA. AmCad's R&D team possesses key core technologies, enabling the efficient development of groundbreaking and innovative products for the market.

3. Market supply and demand situation and growth prospects for the future.

With global demographic shifts, the demand for early diagnostic technologies is steadily increasing, creating stable market growth opportunities for AmCAD-UT[®] and AmCAD-UO[®]. Specifically, AmCAD-UT[®] has gained wide recognition among endocrinologists for its high efficiency and accurate analysis in thyroid disease screening. To further strengthen its market position, AmCad is developing targeted solutions tailored to the needs of different medical institutions and markets, aiming to enhance user-friendliness and diagnostic efficiency.

For AmCAD-UO[®], its non-invasive ultrasound imaging technology provides in-depth analysis of the upper airway for the diagnosis of obstructive sleep apnea (OSA), thereby improving diagnostic accuracy and identifying the root causes of OSA. AmCad is actively collaborating with leading international medical centers to strengthen the clinical evidence base of the product through clinical research, aiming to enhance its competitiveness and recognition in the global market.

In summary, AmCAD-UT[®] and AmCAD-UO[®] demonstrate strong market potential driven by steady growth in demand and ongoing technological innovation. Through continuous product optimization and clinical collaboration, AmCad is reinforcing its leadership in the global medical diagnostics field, aiming to meet the evolving needs of the market and enhance the quality of healthcare services.

4. Competitive Advantages

- (1) Professional Management Team: High-end medical device development is a highly knowledge-intensive industry. AmCad's management team possesses strong backgrounds in pharmaceutical sciences and biomedical engineering, along with extensive industry experience. Moreover, the majority of the R&D team holds a master's degree or higher.
- (2) Professional Clinical Advisory Team: The Company collaborates with a clinical advisory team composed of experienced physicians, clinical medicine experts, and academic leaders to ensure that its products align with market needs and the latest clinical standards. In addition, these clinical advisors provide valuable insights and feedback to help optimize existing products and support the development of new solutions that address the evolving demands of the healthcare industry.
- (3) Strategic Planning and Partnerships: Through strategic product development and close collaboration with both domestic and international partners, AmCad is able to respond swiftly to market changes and maintain its competitive edge.
- (4) Innovation and Quality: With innovation at its core, AmCad continuously develops new products and improves existing ones, while upholding strict quality management to ensure high standards and product reliability.

5. Positive and Negative Factors and Response Strategies for Development Vision

(1) Positive factors:

A. Technological Innovation

With the development of big data and artificial intelligence, ultrasound computer-aided diagnosis (CAD) technology has been continuously innovating and improving, including advancements in resolution, diagnostic accuracy, and image reconstruction. CAD products will enhance the efficiency and precision of

diagnosis and treatment, offering better diagnostic and therapeutic outcomes.

B. Increased healthcare demand

With the global aging population and increasing disease burden, the demand for ultrasound computer-aided diagnosis (CAD) technology will continue to grow. CAD technology has been widely applied in the diagnosis and treatment of various diseases, including cancer, cardiovascular diseases, and neurological disorders.

C. Government policy encouragement

Government support for biotechnology investment, along with regulatory easing and tax reductions, provides a favorable development environment.

(2) Adverse factors:

A. Long product time-to-market and high risk

Due to the longer development timeline for unique high-end medical devices, the company faces high risks before the product is launched.

Mitigation measures:

In the future, the company will adopt a strategy of intermediate market entry to shorten development time and reduce risks.

B. Medical insurance reimbursement policies not yet implemented

In many countries, the existing medical insurance reimbursement system has not yet clarified the payment standards and scope for CAD technology, hindering the promotion of digital healthcare innovation solutions. This will limit its application and adoption in medical practice.

Mitigation measures:

Encourage distributors, strategic partners, or key opinion leaders (KOLs) to leverage their influence in local markets to include AI and CAD payment coverage within medical insurance reimbursement policies, which will help drive product procurement, adoption, and usage.

C. Competition from international giants

Due to the ample financial resources, abundant R&D talent, and rich experience of international giants, they have established a strong presence in the global market, making them the company's biggest competitors.

Mitigation measures:

Utilize a resource integration strategy by collaborating with domestic and international partners for joint research and development, and further work with international giants on co-development projects.

D. Recruitment and development of skilled professionals is challenging

The biotechnology industry in our country has a smaller market size, making it less developed compared to markets in Europe, the U.S., and other regions. As a result, there is a shortage of skilled professionals in areas like biotech R&D, which will affect the speed of industry development.

Mitigation measures:

In line with government policies, actively recruit highly specialized overseas scholars to return and serve domestically. Additionally, launch industry-academia collaboration programs to cultivate professional talent starting from schools.

4.2.2 Important uses and production processes

Product	Purpose	Production Process
AmCAD-UT [®]	This technology extracts commonly used clinical diagnostic features and tumor morphological characteristics	All five products belong to the category of software-based medical devices. For

	from thyroid ultrasound images and visualizes them to assist physicians in observing ultrasound image features. Additionally, it integrates thyroid nodule diagnosis and treatment guidelines from various countries, consolidating the product into a Thyroid Ultrasound Computer-Aided Detection and Diagnosis System	such products, software verification and version control are the top priorities during the production process. These aspects have been rigorously managed within our company's quality management system. AmCAD-UT is a software-based medical device paired with hardware. The hardware development is outsourced to qualified manufacturers, ensuring full compliance with our country's medical device QMS (Quality Management System) regulations.
AmCAD-UO®	AI-assisted ultrasound system for detecting moderate-to-severe OSA within 10 minutes.	
AmCAD-US	This technology utilizes a virtual color mode to visualize structural changes in tissues, enabling clinicians to perform more intuitive analyses in clinical practice.	
AmCAD-UB	Real-time breast ultrasound detection and AI-assisted diagnostics. AI-powered imaging analysis integrated with clinical workflows.	
AmCAD-CA	Digital cytology analysis system for cellular feature quantification and visualization. AI-enhanced cytology assessment for research and diagnostics.	

4.2.3 Supply Status of Raw Materials

With the adjustment of the company's business strategy, our main products are currently AI software-oriented CAD systems, with a focus on developing and enhancing software functionality and applications. We no longer rely on physical devices for software licensing, providing customers with a more flexible and convenient user experience.

For the hardware portion of our products, we adopt an Original Design Manufacturing (ODM) model, collaborating with qualified medical device manufacturers to produce the necessary hardware equipment. This approach not only leverages the advanced technology and economies of scale of external professional manufacturers but also allows the company to focus more on software R&D and innovation.

In terms of supply chain management, we continue to strengthen our relationships with suppliers to ensure the stable supply and high quality of raw materials and hardware. Our quality management system remains stringent, and we conduct annual supplier evaluations to monitor and ensure compliance with quality standards. If any factors potentially affecting product quality are identified, we will require suppliers to make immediate improvements. If necessary, we will replace non-compliant suppliers to ensure the high quality and competitiveness of our products.

By implementing these strategies, we can more effectively manage the supply chain, while enhancing the company's product innovation capabilities and market responsiveness, ultimately providing customers with higher-quality and more innovative ultrasound AI solutions.

4.2.4 In either of the past two years, the names of customers whose purchase(s) or sale(s) accounted for more than 10% of the total sales or purchases, along with their respective amounts and ratios, and an explanation for the reasons for any changes in such amounts or ratios.

1. Information on the main suppliers for the past two years

Amount unit: NTD thousands

Item	2023				2024				As of the end of the first quarter of 2025 (Note2)			
	Name	Amount	The percentage of the amount in relation to the net sales for the entire year.	Relationship with the issuer	Name	Amount	The percentage of the amount in relation to the net sales for the entire year.	Relationship with the issuer	Name	Amount	The percentage of the amount in relation to the net sales for the entire year.	Relationship with the issuer
1	A Supplier	2,264	18%	None	A Supplier	3,068	19%	None	-	-	-	-
2	B Supplier	1,408	11%	None	C Supplier	2,880	18%	None	-	-	-	-
3	Other (Note 1)	8,957	71%	None	Other (Note 1)	9,801	63%	None	-	-	-	-
	Purchase net amount.	12,629	100%		Purchase net amount.	15,749	100%		-	-	-	-

Note 1: If the net purchases from a single customer is less than 10% of the total net purchases for the year, it will not be disclosed.

Note 2: As of the date of printing of the annual report, the financial statements for the first quarter of 2025 have not been reviewed by the CPA.

Reason for Change: Mainly due to an increase in inventory at the end of the period.

2. Information on the main customers for the past two years

Amount unit: NTD thousands

Item	2023				2024				As of the end of the first quarter of 2025 (Note2)			
	Name	Amount	The percentage of the amount in relation to the net sales for the entire year.	Relationship with the issuer	Name	Amount	The percentage of the amount in relation to the net sales for the entire year.	Relationship with the issuer	Name	Amount	Percentage of purchases net amount as of the end of the first quarter of the year.	Relationship with the issuer
1	A customer	6,667	10%	None	Others (Note1)	53,105	100%	None	-	-	-	-
2	Others (Note1)	58,589	90%	None					-	-	-	-
	Net sales	65,256	100%		Net sales	53,105	100%		-	-	-	-

Note 1: Sales to a single customer that does not exceed 10% of the annual net sales are not disclosed.

Note 2 As of the date of printing of the annual report, the financial statements for the first quarter of 2025 have not been reviewed by the CPA.

4.3 Information on employees for the past two years and up to the date of publication of the annual report.

Year		2023	2024	As at Mar.31, 2025
Number of employees	Technical staff	29	28	28
	R&D and technical staff.	37	36	37
	Marketing and sales staff.	11	10	10
	Total	76	74	76
Average age		45.87	46.7	47.3
Average length of service		8.81	9.97	10.16
Distribution ratio of educational background	PHD	11.84	12.2	12.2
	Master degree	39.48	35.1	37.8
	Bachelor's degree	39.48	43.2	41.9
	High school diploma	9.20	9.5	9.5
	Secondary Education or Lower	0	0	0

4.4 Environmental Expenditure Information

4.4.1 Amounts of losses and disposal due to environmental pollution in the current and previous fiscal year up to the date of printing this annual report: None.

4.4.2 Future strategies and potential expenditures: None.

4.5 Labor-Management Relations

4.5.1 The company's various employee welfare measures, education and training programs, retirement system, and the status of their implementation, as well as agreements between labor and management and measures to safeguard employee rights and benefits :

1.Employee welfare measures: :

(1) Gifts are provided to employees during the Dragon Boat Festival and Mid-Autumn Festival, and birthday bonuses are also given. Additionally, flower baskets or traditional gifts are presented to employees for personal events such as weddings, funerals, and celebrations according to local customs.

(2) Labor insurance, health insurance and group accident insurance:

The company provides labor and health insurance to employees in accordance with regulations. In addition, employees' parents, spouses, and children can also be insured under the company.

(3) Other benefits:

In addition, the company provides employees with wedding and funeral subsidies and emergency relief funds, which show our care for our colleagues.

In accordance with legal requirements, the company provides maternity leave, paternity leave, and parental leave, etc

Item	Male/Number	Female/Number	Total
Actual number of employees who applied for parental leave in 2024. (A)	0	0	0
Expected number of employees returning to work after parental leave in 2024. (B)	0	0	0
Actual number of employees who returned to work after taking parental leave in 2024. (C)	0	0	0
Actual number of employees who returned to work after taking parental leave in the	0	0	0

2023. (D)			
Number of employees who remained employed 12 months after returning to work from parental leave in the 2023. (E)	0	0	0
Return-to-work rate(C/B)	0%	0%	0%
Retention rate(E/D)	0%	0%	0%

2. Education and Training :

The company values employee education and training. We have established a "Education and Training Management Measures," and our Human Resources Department provides quarterly pre-employment training for new employees. Each business unit regularly holds internal training to enhance product knowledge and sales skills. We also hold monthly manager inspiration meetings to cultivate problem-solving skills. Additionally, we periodically send employees to relevant external seminars and conferences to enhance their professional and competitive abilities. In 2024, the total number of participants in both internal and external training was 129, totaling 633 hours of training with a total training cost of NTD57,700.

Type of course		Number of trainees	Training hours	Expenditure
Internal Training	Health and Safety professional training General Studies newcomer training	111	543	22,2000
External Training	professional training New knowledge of laws and regulations Health and Safety	18	90	35,500

3. Retirement system and implementation

- (1) Our company was established in 2008 (Republic of China Year 97) and has no employees with seniority under the old labor retirement system. The relevant pension payment regulations are stipulated in the Employee Management Rules, as detailed below.:

The company's employee pension contributions are made in accordance with Article 14 of the Labor Pension Act, with 6% of each employee's monthly salary allocated to their individual pension account. Employees who voluntarily contribute to their pension will have their selected contribution rate deducted from their monthly salary and remitted to their individual pension account at the Bureau of Labor Insurance.

- (2) The company's application of the Labor Pension Act provisions is as follows:

A. Voluntary Retirement:

An employee may apply for voluntary retirement under any of the following circumstances: (For those who have opted for the Labor Pension Act, the retirement process shall be handled in accordance with the provisions of the Act.)

- ①Where the worker attains the age of 55 and has worked for fifteen years.
- ②Where the worker has worked for more than 25 years.
- ③Where the worker attains the age of 60 and has worked for 10 years.

B. Mandatory Retirement:

The company shall not enforce mandatory retirement on an employee unless one of the following conditions applies:

- ①Where the worker attains the age of sixty-five.
- ②Where the worker is unable to perform his/ her duties due to disability

A business entity may request the central competent authority to adjust the age prescribed in Subparagraph 1 of the preceding paragraph if the specific job entails risk, requires substantial physical strength or otherwise of a special nature; provided, however, that the age shall not be reduced below fifty-five.

C. Pension Payment Standards:

- ①The length of service before and after the application of the Labor Standards Act, as well as the choice to continue applying the pension regulations under the Labor Standards Act or to retain the service years accrued before opting into the Labor Pension Act, shall be calculated in accordance with Article 84-2 and Article 55 of the Labor Standards Act.
- ②Employees with the aforementioned years of service who are subject to mandatory retirement under Article 35, Paragraph 1, Subparagraph 2, and whose mental impairment or physical disability is caused by the performance of their duties, shall receive an additional 20% of their pension in accordance with Article 55, Paragraph 1, Subparagraph 2 of the Labor Standards Act.
- ③For employees covered under the Labor Pension Act, the company shall contribute an amount equivalent to 6% of their monthly salary to their individual pension accounts.

(3) Pension Payment:

The retirement benefits shall be paid in full within 30 days from the date of retirement.

4. Labor-Management Agreement :

The company values employee feedback and has established a labor-management conference, which is represented by both labor and management. Through this channel, both parties can discuss labor-management issues. In addition, a chairman's mailbox has been set up, and employee opinions can also be communicated through email to maintain good labor-management relations and avoid disputes.

- 4.5.2 List any losses suffered by the company in the most recent fiscal year and up to the annual report publication date due to labor disputes (including any violations of the Labor Standards Act found in labor inspection, specifying the disposition dates, disposition reference numbers, the articles of law violated, the substance of the legal violations, and the content of the dispositions), and disclosing an estimate of possible expenses that could be incurred currently and in the future and measures being or to be taken. If a reasonable estimate cannot be made, an explanation of the facts of why it cannot be made shall be provided:

This company implements its management regulations in accordance with the Labor Standards Act, and maintains harmonious labor-management relations with no litigation events.

4.5.3 The Code of Ethics for Employee Conduct:

Integrity, mutual benefit, and courtesy have always been the core values of the company's corporate culture. The company has always pledged to conduct all business activities with integrity and to be vigilant at all times with a spirit of honesty, accuracy, and

transparency, in order to uphold the company's commitment.

To maintain the core values of the company's culture, we have established the "Code of Conduct for Business Integrity" and the "Code of Ethics," and clearly stipulated service standards in the "Employee Work Rules," requiring every colleague to bear the important responsibility of maintaining the company's moral values and reputation and complying with legal regulations.

Therefore, the company has the following regulations :

1. Establish a rigorous code of conduct and ethical standards that strictly prohibit internal personnel such as directors and employees from using company property, non-public information, or their job to gain illegal benefits, ensuring that employees engage in no misconduct, malpractice, leaking of confidential information, or false reporting, and require employees to refuse entertainment and gifts offered by vendors.
 2. Employees should strictly adhere to the code of conduct for avoiding conflicts of interest, proactively report ethical concerns related to conflicts of interest, and establish non-compete clauses to prevent conflicts of interest.
 3. Conduct integrity investigations on customers, suppliers, and other stakeholders to prevent dishonest behaviors that could harm the company's interests. The goal is to ensure that all stakeholders understand and respect the company's commitment to ethical behavior and integrity in business.
 4. Employees are prohibited from using company information or their position to obtain business secrets for personal gain. Whether the information obtained pertains to technology, finance, or business secrets, and regardless of the means of obtaining it, such illegal actions are strictly prohibited and employees are not allowed to engage in any behavior that is detrimental to the company, the environment, and society.
 5. Employees are prohibited from using threats, intimidation, coercion, inappropriate language, or disrespectful behavior towards colleagues, clients, or others while working on-site or performing job duties outside the company..
 6. Raw material procurement sources adhere to the spirit of social responsibility.
 7. The company is committed to providing a safe and healthy working environment for all employees, and colleagues are also responsible for the health and safety of the workplace.
 8. Protect privacy and personal information, and strictly adhere to the company's internal regulations when dealing with other people's personal data or privacy.
 9. Respect intellectual property rights and comply with confidentiality obligations, strictly follow intellectual property protection laws and regulations, company internal operating procedures, and related contracts, and not disclose company secrets.
- 4.5.4 Employee Work Environment and Personal Safety

1. Occupational Safety and Health (OSH) :

The company employs a qualified occupational safety and health manager in accordance with the law, who is responsible for drafting, planning, supervising, and promoting occupational safety and health management tasks. The occupational safety and health manager regularly participates in various refresher courses in accordance with regulations and regularly assigns personnel to participate in various occupational safety and health prevention and disaster relief training.

2. Fire safety management :

According to the fire safety regulations, a qualified fire safety manager shall be appointed to regularly report on fire safety inspections to the fire department. The

manager is also responsible for drafting workplace protection plans, organizing self-defense fire teams, conducting two fire drills annually, and inviting fire authorities to provide guidance.

3. Injury medical subsidies

In order to mitigate the financial burden of medical expenses on employees in the event of unforeseen accidents, the company has purchased group insurance coverage for all employees, with the entire premium being fully subsidized by the company.

4.6 Cyber security management

4.6.1 Cyber security management:

The IT department is responsible for coordinating the implementation of information security policies, risk management and ensuring compliance with internal information security guidelines, procedures, and regulations.

4.6.2 Security policies :

1. Purpose

To maintain the confidentiality, integrity, availability, and legality of information assets, the secure operation of information systems, equipment, and networks, and to prevent deliberate or accidental threats, destruction, and theft from internal and external sources, and to ensure that the company's data, systems, equipment, and other information services can support the company's operations.

2. Scope:

All employees, customers, outsourced or cooperative vendors, third-party personnel, and the security management of all related information assets in the company shall be handled in accordance with the information security policy.

3. Collection and Use of Personal Information:

Personal information will be handled in accordance with the Personal Information Protection Act and related regulations and will not be disclosed to other third parties without authorization.

4. Information Security Responsibilities and Education and Training

(1) Based on roles and functions, information security education and promotion will be conducted for different levels of staff as necessary to raise employees' awareness of information security, potential security risks, and compliance with information security regulations.

(2) For personnel who are separated (retired, suspended), the processing procedures for personnel separation (retirement, suspension) will be followed, and all system logins and access rights will be immediately cancelled.

5. Information Security Operations and Protection

(1) Establish operating procedures for handling information security incidents and assign relevant personnel with necessary responsibilities to quickly and effectively handle information security incidents.

(2) Establish a change management notification mechanism for information facilities and systems to avoid vulnerabilities in system security.

(3) Handle and protect personal information with prudence in accordance with the relevant provisions of the Computer-Processed Personal Data Protection Act.

(4) Establish system backup facilities and regularly perform necessary data and software backups and backup operations to quickly restore normal operations in the event of disasters or storage media failures.

6. Network Security Management

(1) Establish a firewall to control data transmission and resource access between external and internal networks at network points connected to the outside world, and perform rigorous identity verification operations.

- (2) Confidential and sensitive data or documents should not be stored in publicly accessible cloud systems, and highly confidential documents should not be sent via email.
- (3) Conduct regular audits of internal network information security facilities and antivirus measures, update virus codes for antivirus systems, and implement various security measures.

7. System Access Control Management

- (1) Password issuance and change procedures and records will be established based on operating system and security management requirements.
- (2) Logins to each operating system will be reviewed, and access rights will be granted based on job responsibilities and the principle of least privilege.

8. Improving the company's information security level:

Training of information security management personnel should be strengthened to enhance the company's information security management capability.

9. Management of Sustainable Business Operations Plan:

Evaluate the impact of various human and natural disasters on normal business operations, develop emergency response and recovery procedures for ERP, BI systems, and adjust and update plans as necessary.

4.6.3 Concrete management program and Resources invested for cyber security management :

1. Network Security :

Use network firewalls to control network connectivity security and stability, prevent and monitor malicious intrusion behavior.

2. Device Security :

Install antivirus software on all computers, continuously update virus codes, and use sandbox technology to prevent unknown viruses and ransomware from running.

3. Data Security :

Prevent data leakage of confidential information through document access control and encryption technology, and regularly review the appropriateness of access settings; regularly back up files, take snapshots, and store them offsite to ensure file availability.

4. Backup security and Remote Disaster Recovery :

Ensure system high availability and disaster recovery capability through remote system backup.

In the event of a failure, disaster, or other issues at the main office, it can quickly switch to the remote backup system in factory to ensure business continuity. Utilize measures such as regular file backup, snapshots, and offsite storage, combined with regular disaster recovery drills to ensure continuous system operation without interruption.

5. Information security education training and publicity :

Regularly organize information security awareness and case studies to enhance employees' awareness of preventive measures against files and website links from unknown sources.

6. Regularly review various information security vulnerability announcements :

For example, the National Communications Security Commission of the Executive Yuan assesses the scope of information security vulnerabilities, proposes and implements corresponding system correction measures based on the system change management mechanism.

7. Notification of information security incidents :

When a significant information security incident occurs, it should be reported to the Information Department of the General Administration Department immediately, and a

cross-departmental team composed of personnel assigned by the General Administration Department leader should be responsible for handling information security and antivirus emergency response teams and reporting according to regulations of the supervising authority.

4.6.4 Resources invested for cyber security management:

2024 Corporate Information Security Measures Implementation Results

1. Evaluate the impact of major information security vulnerability announcements and implement vulnerability patching.
2. Conduct information security awareness training once a quarter for all new employees
3. Conduct information security awareness training once a year for all employees.
4. Conduct a full company information system disaster recovery drill once a year.
5. Install antivirus software on all computers and keep virus code updates online at all times.
6. Continuously update firewalls and intrusion defense systems.

4.6.5 Major cyber security incidents:

Up to the date of the annual report printing in the latest year, the company has not had any significant information security incidents.

4.7 Important Contract

Nature	Party involved	Contract start and end date	Main content	Restrictive clauses
Technology Transfer Licensing Agreement and Appendices.	National Taiwan University	2009/1/23~ 2015/1/22 Automatic extension after the six-year term	Subject matter: Thyroid disease computer-aided diagnosis system.Licensing territory: Global	none
Technology Transfer Licensing Agreement	National Taiwan University	2014/7/1~ Patent expiration date.	Subject matter: Patents related to the ultrasound functional imaging system technology for tissue fibrosis owned and pending application by the organization. Licensing sales territory: Taiwan	none
Product sales agreement	Maywufa Company	2015/4/1~ Automatic extension	Target: AmCAD-UT® Licensing sales territory: Taiwan	none
Authorized distribution agreement	Medical T. Bei Jing	Starting from April 6, 2016, until the first day of the month following the receipt of the CFDA registration certificate, the agreement will last for five years. If the agreed sales targets are met, the term can be automatically extended, with a maximum duration of eleven years.	1.AmCAD-UT® grants Medical T. Bei Jing an exclusive and non-transferable right, making it the exclusive general distributor of this product in mainland China. 2. Medical T. Bei Jing ordering, shipping, payment, etc., shall comply with the minimum purchase quantity and amount specified in the contract. Amcad is required to provide necessary training and technical support.	none

5. Review and analysis of financial condition and financial performance, as well as risk factors.

5.1 Financial condition

Unit: NTD thousands

Item \ Year	2024	2023	Difference	
			Amount	%
Current assets	418,085	325,893	92,192	28.29
Property, plant, and equipment	72,181	68,429	3,752	5.48
Intangible assets	66,322	73,679	(7,357)	(9.99)
Other assets	138,285	44,645	93,640	209.74
Total assets	694,873	512,646	182,227	35.55
Current liabilities	25,143	24,419	724	2.96
Non-current liabilities	6,012	10,279	(4,267)	(41.51)
Total liabilities	31,155	34,698	(3,543)	(10.21)
Share capital	633,329	533,306	100,023	18.76
Capital surplus	141,523	8,016	133,507	1,665.51
Retained earnings	(199,320)	(148,743)	(50,577)	(34.00)
Other equity	(6,880)	(11,996)	5,116	42.65
Treasury stock	-	-	-	-
Non-controlling interests	95,066	97,365	(2,299)	(2.36)
Total shareholders' equity	663,718	477,948	185,770	38.87
Please explain the major changes in the Company's assets, liabilities, and shareholders' equity over the past two years (where the variation exceeds 20% and the amount of change is more than NT\$10 million), including the main reasons for such changes, their impact, and future response plans. (1) Main Reasons and Impact of Major Changes: 1. The increase in current assets, other assets, capital stock, and capital surplus is due to a cash capital increase. 2. The decrease in retained earnings is due to the loss for the current period. (2) Future response plans for significant changes : Our company is actively expanding its business to generate revenue and profits.				

5.2 Financial performance

5.2.1 Financial performance comparative analysis

Unit: NTD thousands

Item \ Year	2024	2023	Increase (Decrease) amount	Change %
Operating Revenue	53,105	65,256	(12,151)	(18.62)
Operating Costs	20,171	24,232	(4,061)	(16.76)
Gross Profit	32,934	41,024	(8,090)	(19.72)
Operating Expenses	97,598	95,009	2,589	2.73
Operating Loss	(64,664)	(53,985)	(10,679)	(19.78)
Non-Operating Income and Expenses	11,788	10,836	952	8.79
Profit Before Tax	(52,876)	(43,149)	(9,727)	(22.54)
Income Tax Expense	-	-	-	-
Net Loss for the Year	(52,876)	(43,149)	(9,727)	(22.54)
1. Revenue decreased, mainly due to the decrease in the subsidiary's revenue. 2. Operating expenses increased, mainly due to the costs associated with the cash capital increase.				

5.2.2 Expected sales volume and its basis, as well as their potential impacts on the company's future financial operations and response plan, are as follows :

1. AmCAD-UT[®]

AmCAD-UT[®], after years of promotion in the domestic market, has gained recognition from physicians for its accuracy and efficiency in thyroid detection. It has been successfully introduced into multiple hospitals and health screening channels, with market results gradually emerging. Additionally, the company is actively seeking collaborations with international industry leaders and qualified distributors in other regions.

2. AmCAD-UO[®]

AmCAD-UO[®] overcomes the uncertainty in ultrasound scanning caused by operator dependence. When integrated with Amcad proprietary ultrasound imaging detection software for sleep apnea, it enables rapid, large-scale screening to identify moderate-to-severe sleep apnea patients. By collaborating with major ventilator manufacturers, the screening efficiency is enhanced, and leveraging their existing customer base allows for market expansion and revenue growth.

5.3 Cash flow

5.3.1 Analysis and explanation of changes in cash flow over the past year are as follows

Unit: NTD thousands

Item \ Year	2024	2023	Change %
Net cash flow from operating activities	(51,850)	(41,599)	(24.64)
Net cash flow from investing activities	(185,428)	27,311	(778.95)
Net cash flow from financing activities	225,376	(3,098)	7,374.89
Total	(11,902)	(17,386)	31.54

1. Analysis of Changes in Cash Flows for the Current Year:

(a) Cash inflow from operating activities decreased, mainly due to year-end stocking, resulting in higher inventory at the end of the period.

(b) Cash inflow from investing activities decreased, mainly due to the investment in financial stocks.

(c) Cash inflow from financing activities increased, mainly due to the cash capital increase.

5.3.2 Liquidity improvement plan

Improvement plan for insufficient liquidity: It is expected to support the funding needs of operations by planning cash flows and disposing of financial assets.

5.3.3 Analysis of cash flow liquidity for the upcoming year

Unit: NTD thousands

Beginning cash balance	Net cash flow from operating activities for the full year	Net cash flow from investing activities for the full year	Net cash flow from financing activities for the full year	Total	Cash surplus deficit	Expected cash deficit	
①	②	③	④	②+③+④	①+②+③+④	Financing plan	Financial plan
17,756	(82,000)	70,000	0	(12,000)	5,756	N/A.	N/A.

1. Analysis of Changes in Cash Flows for the Current Year:

The net cash outflow from operating activities amounted to NT\$112,000 thousand, primarily due to the net loss for the period and investments in the capital increase project.

The net cash inflow from investing activities totaled NT\$100,000 thousand, mainly attributable to the disposal of financial assets.

2. Remedial Measures for Expected Cash Shortfall: No cash shortfall is anticipated.

3. Note: The above balances exclude time deposits with maturities exceeding three months.

5.4 Impact of significant capital expenditures on financial operations in the recent year:

None.

5.5 The investment policy of the latest year, the main reason of the operating result and the improvement plans and the investment plans for the coming year.

(a) Investment policy: NA

(b) Reasons for profit or loss and improvement plans: BROADSOUND CORP. reported a net loss of NT\$1,374 thousand after tax in 2024, mainly due to a decrease in revenue.

(c) Investment plan for the coming year: NA

5.6 Risk Analysis and Assessment During the Most Recent Fiscal Year and as they Stood on the Date of Publication of the Annual Report

5.6.1 Changes to interest rates, currency exchange fluctuations, and inflation and how these may impact The Company's gain or loss, as well as future response measures:

1. The impact of inflation on the company's profit:

Unit: NTD thousands

Year	2024		2023	
Item	Interest Revenue	(loss) gain from foreign exchange	Interest Revenue	(loss) gain from foreign exchange
Net A	5,282	15	4,303	94
Operating revenue B	53,105		65,256	
Percentage of Revenue (A/B)	9.95%	0.03%	6.59%	0.14%

2. Future response measures are as follows

- (a) Interest Rate: The company currently has sufficient operating capital and does not require any borrowings. Regarding bank interest income, we continue to maintain close communication with banks to monitor interest rate trends and secure the most favorable deposit rates.
- (b) Exchange Rate: The company closely monitors the trends of major international currencies and non-economic global changes to anticipate exchange rate fluctuations and respond promptly. This approach enables us to determine optimal foreign currency exchange timing when expanding international business and effectively manage foreign currency assets and liabilities, thereby minimizing risks associated with exchange rate fluctuations.
- (c) Inflation: Currently, the company does not engage in large-scale raw material purchases or bulk shipments of finished products; therefore, inflation has no significant impact on our profitability. Moving forward, we will continue to closely monitor changes in the price index and assess the impact of inflation on our business. If necessary, we will adjust product pricing and inventory levels in response to rising costs, thereby mitigating the pressure of inflation on the company.

5.6.2 Policies, main reasons for gains or losses, and future coping measures for engaging in high-risk, high-leverage investments, lending funds to others, endorsing guarantees, and trading in derivative products

1. Policy on High-Risk, High-Leverage Investments, Key Factors Affecting Profit or Loss, and Future Countermeasures:

The company does not engage in high-risk, high-leverage investments. All investments are carefully evaluated and executed in accordance with company regulations.

2. Policy on Lending Funds to Others, Endorsements and Guarantees, and Derivative Transactions, Key Factors Affecting Profit or Loss, and Future Countermeasures:

The company does not engage in lending funds to others, providing endorsements and guarantees, or conducting derivative transactions. In the future, if business needs require financial arrangements, endorsements, guarantees, or derivative transactions, such activities will be carried out in accordance with the company's established operational procedures.

5.6.3 Future R&D plans and expected R&D expenditures

1. Develop an AI Platform Integration System Environment.
2. Development of User Interface for Acoustic Scattering Imaging Platform Applications (e.g., Fatty Liver, Obstructive Sleep Apnea).
3. AmCAD-UO[®] : Initiate Clinical Case Enrollment for Dental Aligners and Hypoglossal Nerve Stimulation, and Conduct Hardware Redesign and Optimization.
4. AmCAD-UB[®] : Optimize the UB Live Real-Time Detection and Diagnosis System and Conduct Clinical Case Enrollment.
5. Complete the Integration of UT, UO, and UB into a Handheld Ultrasound System and Apply for Market Approval in the U.S., EU, and Taiwan.
6. Estimated R&D Investment: Approximately NTD 400 million for the improvement of existing products and commissioned clinical research expenses.

5.6.4 Impact of domestic and international policy and legal changes on the company's financial business and response measures.

The biotechnology industry has experienced rapid advancements and limitless business opportunities over the past decade. Leading nations worldwide regard it as the next star industry of the century, following the information and electronics industries. Both governments and private sectors have invested substantial capital and talent to drive the industry's growth, making biotechnology investment a prevailing trend.

Biotechnology is one of the emerging industries that the government is actively promoting. Leveraging its existing strengths and resources in precision medicine, the government is focusing on two key pillars: "Enhancing the Ecosystem" and "Fostering the Industry Chain" to drive the development of Taiwan's precision health industry.

For "Enhancing the Ecosystem," efforts will continue to strengthen the cultivation and recruitment of biotech and interdisciplinary talent while providing investment support, R&D funding, and tax incentives to encourage businesses to expand their involvement in the biotech sector. Additionally, improvements in health data governance and cybersecurity management will be implemented to enhance industry applications and establish a regulatory framework.

For "Fostering the Industry Chain," the government will continue to promote the development of precision medicine, regenerative medicine, and digital health, while utilizing smart technology to advance field testing mechanisms. The goal is to establish innovative products and service models in precision health and encourage Taiwanese biotech companies to actively engage in international collaboration and exchanges, positioning Taiwan as a global hub for biomedical innovation and R&D.

The company will continue to leverage various national incentive programs for product development to reduce R&D expenditure outflows. Additionally, the management team closely monitors key domestic and international policy and regulatory changes and formulates appropriate response strategies accordingly.

Internationally, the company will comply with U.S. FDA and EU MDR medical device regulations, adhering to these internationally recognized standards to expand into the global market.

5.6.5 Changes to technology (including cyber security risks) and industry that impact the Company's financial operations, and response measures:

The company places great importance on technology and industry trends, and is committed to the application of information technology to integrate group data and information. By actively and effectively utilizing manpower and information technology, the company strives to enhance its competitiveness.

The biotechnology industry is a key sector actively promoted by the government. It is characterized by high entry barriers, long research and development cycles, a strong demand for specialized expertise, and high added value. Due to these attributes, the industry is less susceptible to significant short-term changes. Moreover, the company holds intellectual property rights for its products and possesses strong research and development capabilities, enabling it to closely monitor technological advancements and industry shifts and take appropriate measures as needed.

Furthermore, the company follows the 3-2-1 backup principle for risk management of information security, ensuring that at least three backups are stored in two different ways, with one copy stored offline. For high-risk level data, the company also implements mechanisms for off-site storage to meet data security requirements. To ensure the safe operation of the information system, the company conducts weekly full backups and annual disaster recovery drills to minimize potential losses and risks in case of system damage. Access to the company's mainframe for management settings is restricted to specific computers to prevent hacking and reduce the risk of information security breaches.

As of the most recent fiscal year and up to the date of this prospectus, there have been no events that have had a material impact on the company's financial position or business operations.

5.6.6 The impact of corporate image changes on the company's crisis management and corresponding measures

The company has always operated in compliance with the law and maintains a strong corporate image. Since going public, we have been committed to strengthening corporate governance by establishing a Compensation Committee and an Audit Committee, continuously enhancing our corporate reputation. In the most recent fiscal year and up to the date of this prospectus, there have been no incidents where changes in corporate image have impacted the company's crisis management.

5.6.7 Expected benefits, potential risks, and response measures for the merger and acquisition:

There have been no mergers or acquisitions of other companies by our company in the recent years up to the date of printing this annual report. Therefore, there are no expected benefits, possible risks, or corresponding measures related to such mergers or acquisitions.

5.6.8 Expected benefits, possible risks, and response measures of expanding the factory: NA.

5.6.9 Risks and Countermeasures Related to Concentration of Purchasing or Sales: NA.

5.6.10 There has been no significant transfer or replacement of the shares of the directors, supervisors, or shareholders holding more than ten percent of the company's shares, and there are no associated risks or contingency measures.

5.6.11 Impact, risks, and response measures of changes in the management rights:

There have been no changes in the management rights of the Company in recent years and up to the date of printing of this annual report, so there are no impacts, risks, or

response measures to be addressed.

5.6.12 Litigation or Non-Litigation Events :

The company has no significant litigation, non-litigation, or administrative disputes that have been determined by judgment or are pending and may have a significant impact on shareholder equity or securities prices as of the date of the annual report.

5.6.13 Other significant risks and countermeasures : NA.

5.7 Other significant matters. : NA.

6.Special Notes

6.1 Information on affiliates:

6.1.1 Consolidated Business Report of Affiliates:

Please visit the new version of the Market Observation Post System and navigate to: “Single Company” > “Download Electronic Documents” > “Affiliated Enterprises Disclosure Section,” then enter the company code or abbreviation to search.

https://mopsov.twse.com.tw/mops/web/t57sb01_q10

6.1.2 Financial Statements for Related-Party Business Merger :

Please visit the new version of the Market Observation Post System and navigate to: “Single Company” > “Download Electronic Documents” > “Affiliated Enterprises Disclosure Section,” then enter the company code or abbreviation to search.

https://mopsov.twse.com.tw/mops/web/t57sb01_q10

6.1.3 Affiliation Report:

Please visit the new version of the Market Observation Post System and navigate to: “Single Company” > “Download Electronic Documents” > “Affiliated Enterprises Disclosure Section,” then enter the company code or abbreviation to search.

https://mopsov.twse.com.tw/mops/web/t57sb01_q10

6.2 The situation regarding private placement of securities up to and including the date of printing of the latest annual report: None.

6.3 Additional necessary explanatory items: None.

7 、 Any significant events as defined in Article 36, Paragraph 3, Subparagraph 2 of the Securities and Exchange Act that have had a significant impact on shareholder equity or securities prices, up to and including the date of printing of the latest annual report: None.